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Clinical effectiveness and cost-effectiveness of issuing longer
versus shorter duration (3-month vs. 28-day) prescriptions
in patients with chronic conditions: systematic review and
economic modelling
Céline Miani,1 Adam Martin,1,2 Josephine Exley,1* Brett Doble,3,4
Ed Wilson,3 Rupert Payne,5 Anthony Avery,6 Catherine Meads,1,7
Anne Kirtley,1,8 Molly Morgan Jones1 and Sarah King9
1Cambridge Centre for Health Services Research, RAND Europe, Cambridge, UK
2Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds,
Leeds, UK
3Cambridge Centre for Health Services Research, Cambridge Institute of Public Health, School of
Clinical Medicine, University of Cambridge, Cambridge, UK
4Health Economics Research Centre, Nuffield Department of Population Health, University of
Oxford, Oxford, UK
5Centre for Academic Primary Care, School of Social and Community Medicine, University of
Bristol, Bristol, UK
6School of Medicine, University of Nottingham, Nottingham, UK
7School of Nursing and Midwifery, Faculty of Health, Social Care and Education, Anglia Ruskin
University, Cambridge, UK
8Strategy Division, Wellcome Trust, London, UK
9Cambridge Institute of Public Health, School of Clinical Medicine, University of Cambridge,
Cambridge, UK
*Corresponding author jexley@rand.org
Background: To reduce expenditure on, and wastage of, drugs, some commissioners have encouraged
general practitioners to issue shorter prescriptions, typically 28 days in length; however, the evidence base
for this recommendation is uncertain.
Objective: To evaluate the evidence of the clinical effectiveness and cost-effectiveness of shorter versus
longer prescriptions for people with stable chronic conditions treated in primary care.
Design/data sources: The design of the study comprised three elements. First, a systematic review comparing
28-day prescriptions with longer prescriptions in patients with chronic conditions treated in primary care,
evaluating any relevant clinical outcomes, adherence to treatment, costs and cost-effectiveness. Databases
searched included MEDLINE (PubMed), EMBASE, Cumulative Index to Nursing and Allied Health Literature,
Web of Science and Cochrane Central Register of Controlled Trials. Searches were from database inception
to October 2015 (updated search to June 2016 in PubMed). Second, a cost analysis of medication wastage
associated with < 60-day and ≥ 60-day prescriptions for five patient cohorts over an 11-year period from
the Clinical Practice Research Datalink. Third, a decision model adapting three existing models to predict
costs and effects of differing adherence levels associated with 28-day versus 3-month prescriptions in three
clinical scenarios.
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Review methods: In the systematic review, from 15,257 unique citations, 54 full-text papers were
reviewed and 16 studies were included, five of which were abstracts and one of which was an extended
conference abstract. None was a randomised controlled trial: 11 were retrospective cohort studies, three
were cross-sectional surveys and two were cost studies. No information on health outcomes was available.
Results: An exploratory meta-analysis based on six retrospective cohort studies suggested that lower
adherence was associated with 28-day prescriptions (standardised mean difference –0.45, 95% confidence
interval –0.65 to –0.26). The cost analysis showed that a statistically significant increase in medication
waste was associated with longer prescription lengths. However, when accounting for dispensing fees and
prescriber time, longer prescriptions were found to be cost saving compared with shorter prescriptions.
Prescriber time was the largest component of the calculated cost savings to the NHS. The decision
modelling suggested that, in all three clinical scenarios, longer prescription lengths were associated with
lower costs and higher quality-adjusted life-years.
Limitations: The available evidence was found to be at a moderate to serious risk of bias. All of the
studies were conducted in the USA, which was a cause for concern in terms of generalisability to the UK.
No evidence of the direct impact of prescription length on health outcomes was found. The cost study
could investigate prescriptions issued only; it could not assess patient adherence to those prescriptions.
Additionally, the cost study was based on products issued only and did not account for underlying patient
diagnoses. A lack of good-quality evidence affected our decision modelling strategy.
Conclusions: Although the quality of the evidence was poor, this study found that longer prescriptions
may be less costly overall, and may be associated with better adherence than 28-day prescriptions in
patients with chronic conditions being treated in primary care.
Future work: There is a need to more reliably evaluate the impact of differing prescription lengths on
adherence, on patient health outcomes and on total costs to the NHS. The priority should be to identify
patients with particular conditions or characteristics who should receive shorter or longer prescriptions.
To determine the need for any further research, an expected value of perfect information analysis should
be performed.
Study registration: This study is registered as PROSPERO CRD42015027042.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
General practitioners (GPs) in the NHS are encouraged to prescribe medication for no longer than28 days to avoid dispensing drugs that patients may not use (drug waste). However, it is uncertain
what evidence there is to support this policy. This project looked at whether or not 28-day prescriptions
for patients with stable, long-standing health conditions would be better than longer prescriptions.
We wanted to see if prescription length affected patients’ health, how patients took their medication
(adherence), drug waste and NHS costs. This project was in three parts.
1. We combined results from 16 studies that compared 28-day prescriptions with longer prescriptions and
assessed how reliable the findings of these studies were.
2. We looked at prescription costs for five different patient groups in a large database of GP records.
3. We used mathematical equations (modelling) to work out the impact of 28-day versus 3-month
prescriptions on patients’ health over their lifetime in three different patient groups.
The quality of the 16 studies was poor; there was no evidence in any of the 16 studies as to whether or
not prescription length affects patient health. However, the studies showed that patients with longer
prescriptions were more likely to take their drugs as advised by their doctor. The GP records showed that
although patients with longer prescriptions wasted more drugs (which may occur, for example, when a GP
changes a medication midway through a prescription), overall, longer prescriptions were found to be cost
saving because less time was taken up by issuing prescriptions. The mathematical models suggested that
longer prescriptions may be associated with better health and lower costs in all three patient groups.
These findings suggest that 3-month prescriptions might be better than 28-day prescriptions for people
with long-standing health conditions. Further research is needed to determine the best prescription length
for patients with long-standing health conditions, and to determine whether or not this varies according to
patient groups and conditions.
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Scientific summary
Background
Patients with stable chronic conditions often require treatment with long-term medication. In England,
an increasing number of NHS patients receive prescriptions for chronic conditions without a consultation
in primary care. These repeat prescriptions are typically for 28 days’ supply. The evidence base for this
relatively short duration is uncertain.
Objective
The objective of this study was to assess whether 28-day versus 3-month prescription lengths, or shorter
versus longer prescription lengths, in people with stable chronic conditions treated by general practitioners
(GPs), have positive or negative impacts on a range of health outcomes, patient adherence, drug waste,
dispensing costs, other NHS costs, and cost-effectiveness. There were three parts to this project:
1. a systematic review of the evidence on 28-day versus 3-month prescriptions in patients with chronic
conditions treated in primary care, evaluating any relevant clinical outcomes as well as adherence to
treatment, costs and cost-effectiveness
2. a cost analysis of medication waste associated with longer and shorter prescription lengths for five
patient groups using the UK Clinical Practice Research Datalink (CPRD) over an 11-year period
3. the adaptation of three existing decision models to predict the costs and effects of differing adherence
levels associated with 28-day versus 3-month prescription lengths in three clinical scenarios.
Methods
For the systematic review, databases searched included MEDLINE (PubMed) from inception to June 2016, and
EMBASE, Cumulative Index to Nursing and Allied Health Literature, Web of Science and the Cochrane Central
Register of Controlled Trials from inception to October 2015. Any comparative studies in patients with
chronic conditions treated in primary care evaluating any relevant clinical outcomes as well as adherence to
treatment, costs and cost-effectiveness were included. Standard systematic review methods were used,
including duplicate screening for inclusion, data extraction and quality assessment. Risk of bias was assessed
using the Risk Of Bias in Non-Randomized Studies – of Interventions (ROBINS-I tool). A meta-analysis was
conducted in RevMan version 5.3. (RevMan, The Cochrane Collaboration, The Nordic Cochrane Centre,
Copenhagen, Denmark). Dichotomous results were converted to continuous outcomes where necessary using
methods recommended in the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0).
The CPRD is a large, longitudinal primary care data set representing approximately 7% of the UK population.
The cost analyses were based on five patient cohorts: (1) glucose control with oral therapy in type 2 diabetes
mellitus (T2DM), (2) treatment of hypertension in T2DM, (3) treatment with statins (lipid management) in
T2DM, (4) treatment for the secondary prevention of myocardial infarction and (5) treatment of depression.
The analyses were run over an 11-year period and incorporated prescriptions from 250,000 patients in total.
Treatment patterns were analysed in Stata® version 13.1 (Stata Corp LP, College Station, TX, USA).
The decision modelling took a NHS perspective. The three clinical scenarios were (1) medications for
primary prevention of cardiovascular events in T2DM, (2) treatment of depression with selective serotonin
reuptake inhibitors (SSRIs) and (3) medications for secondary prevention of cardiovascular events in people
with hypertension. The three models chosen were adapted from models in relevant guidance issued by the
DOI: 10.3310/hta21780 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 78
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Miani et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
xxiii
National Institute for Health and Care Excellence (NICE). Models were adapted using results from the
systematic review on adherence, along with estimated dispensing fees (from NHS Drug Tariffs), prescriber
time (from the CPRD analysis), costs of wastage (from the CPRD analysis) and data on the relationship
between treatment and no treatment (from the NICE models or reports associated with them). The results
were presented as costs per quality-adjusted life-year (QALY) and incremental cost-effectiveness ratios
(ICERs). Modelling was conducted in Microsoft Excel® version 20.10 (Microsoft Corporation, Redmond,
WA, USA).
Results
In the systematic review, from 15,257 unique citations, 54 full-text papers were reviewed and 16 studies
were included, most of which were rated as having a moderate to serious risk of bias. For five of the
16 studies, only an abstract was available, and for a sixth study only an extended conference abstract was
available. None was a randomised controlled trial (RCT); 11 were retrospective cohort studies, three were
cross-sectional surveys and two were cost studies. A variety of patient groups were included, all studies
were carried out in the USA and all were conducted in a variety of primary care settings. Adherence was
based on indirect estimates of pharmacy refill claims, and was reported in a variety of ways including the
proportion of days covered and the medication possession ratio. Drug waste was also reported in several
ways, including the proportion of days’ supply wasted and the mean number of days’ supply wasted.
No information on health outcomes was available. One study reported on achievement of target
cholesterol levels and found that longer prescription lengths were associated with statistically significantly
lower final mean serum cholesterol values {185.3 mg/dl [standard deviation (SD) 46.2] vs. 191.5 mg/dl
[SD 52.6]}. Nine studies reported on adherence, and all nine reported better adherence with longer
prescription lengths. An exploratory meta-analysis of adherence results from six retrospective cohort studies
suggested that adherence was lower with a 28-day supply (standardised mean difference –0.45, 95%
confidence interval –0.65 to –0.26). From the six studies reporting on drug wastage, the trend was for
more wastage with longer prescription lengths. Five studies gave some information on costs, and four of
these suggested that total costs were lower with longer prescription lengths.
The cost analysis of CPRD data corroborated the review findings that although longer prescription lengths
(≥ 60 days) were associated with greater medication waste per prescription than shorter prescription
lengths (< 60 days), once the additional dispensing fees and prescriber time required to issue a prescription
were taken into account, longer prescription lengths resulted in a net cost saving. This finding was
consistent across all five conditions studied, and savings ranged from £6.33 to £9.07 per prescription
when total unnecessary costs (TUCs) were standardised to a common 90-day time period. The biggest
impact on the cost savings was prescribers’ time costs. The largest differences in the mean cost of wastage
per prescription for the two prescription lengths were observed in the lipid management of the T2DM
cohort, and the smallest differences were observed in the depression cohort.
The decision modelling suggested that longer prescription lengths were associated with lower costs and
higher QALYs than shorter prescriptions for all three clinical scenarios (primary prevention of cardiovascular
events in T2DM, medications for secondary prevention of cardiovascular events in people with hypertension
and treatment of depression with SSRIs).
Limitations
The available evidence base is rated as being at a moderate to serious risk of bias, and there is no good
evidence on the impact of prescription length on patient outcomes. All of the studies identified were
conducted in the USA, which has a distinctly different health-care system from that in the UK, with very
different (and generally higher) costs. This raises concerns over the generalisability of this evidence to the
UK setting.
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The cost analyses study could investigate only prescriptions issued and not patient adherence. In addition,
the cost analyses were based on products issued only and did not account for underlying patient
diagnoses. Lack of good-quality evidence affected the decision modelling strategy. The modelling was
based on existing models, and no probabilistic sensitivity analysis was available.
Conclusions
The current evidence suggests that 90-day prescription lengths are associated with better adherence than
28-day prescription lengths in patients with stable chronic conditions being treated in primary care.
No evidence was found of a direct impact of prescription length on health outcomes. This study found
evidence suggesting that longer prescriptions resulted in net cost savings owing to reductions in costs
associated with dispensing fees and prescriber time, which outweighed wastage costs.
Future work
One potential research priority is a cluster RCT to establish much more robust evidence for the most
appropriate prescription length in patients with a variety of chronic conditions treated in general practice.
The priority for future research should be to identify patients with particular conditions or characteristics
who should receive shorter or longer prescriptions. Primary care patients with chronic conditions should be
randomised to several prescription lengths including 28-day and 3-month prescriptions, and followed up to
establish all relevant clinical outcomes including health status, adherence, quality of life, patient experience
and patient costs. Drug waste and NHS costs should also be collected to derive more robust estimates of
the cost-effectiveness of differing prescription lengths in different conditions.
Further decision modelling could run probabilistic sensitivity analyses, which would enable an expected
value of perfect information analysis. This would help to determine the value of carrying out a RCT.
Standard methods for reporting of adherence and drug waste need to be established so that future studies
with these outcomes can be compared more easily.
Study registration
This study is registered as PROSPERO CRD42015027042.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Volume and cost of repeat prescriptions in primary care
In England, the NHS spends > £9B on prescription medicines dispensed in the community each year.1
An increasing number of NHS patients receive prescriptions for chronic conditions, which can be generated
without the need for a consultation in primary care. These are known as repeat prescriptions.2 It is
estimated that repeat prescriptions account for two-thirds of prescriptions generated in primary care.3
Among the 20 most prescribed medicines dispensed in the community in England during 2015, all but
one (amoxicillin, an antibiotic) are commonly prescribed on a repeat basis for chronic conditions (Table 1).
Such conditions include diabetes, asthma and hypertension.
The majority of prescription costs in primary care are for chronic conditions. For the last 9 years, drugs used
in the treatment of diabetes [classified under section 6.1 of the British National Formulary (BNF)] have
accounted for the largest net ingredient costs (NICs) (i.e. the cost of the drug not including dispensing
costs, fees or discounts) of prescriptions dispensed in primary care in England. Costs increased for diabetes
drugs by £87.6M (10.3%) since 2014 to reach £936.7M in 2015.5
The total NIC of all prescriptions dispensed in the community has increased by 16.8% since 2005, despite
a fall in the average NIC per prescription.5 It has been estimated that between £100M and £300M is
wasted in the form of unused or partially used medications each year.6,7 Ensuring that prescriptions are
issued for a duration that minimises the waste of medicines is an important factor in reducing financial loss
to the NHS.
Guidance and policy on repeat prescription length
With regard to repeat prescriptions, there is some ambiguity in the Department of Health’s (DH’s) guidance
on prescription length. Guidance issued by commissioners (Primary Care Trusts until 2011 and now Clinical
Commissioning Groups) in some areas, as well as that from the Pharmaceutical Services Negotiating
Committee (PSNC),8 has encouraged general practitioners (GPs) to issue shorter prescriptions, typically of
28 days in length.9–11 This guidance was based on evidence that limiting prescription length to 28 days
reduces medicine waste and thus results in cost savings,12,13 and on the reported success of local
prescribing schemes, for example in Surrey and Grampian,13 and Brighton and Hove.14 This was stated to
be in line with the DH’s policy to strike a ‘balance between patient convenience, good medical practice
and drug wastage’.11 Shorter prescription lengths have also been shown to benefit patients by providing
better signalling to GPs for treatment discontinuations due to adverse events.15
The guidance issued by local commissioning organisations and by the PSNC8 encouraging shorter
prescriptions has tended to advocate a blanket 28-day prescribing policy. In contrast, the National Institute
for Health and Care Excellence (NICE), through the BNF, recommends blanket 28-day prescribing for
certain classes of controlled drugs only.16 In addition, recent evidence argues for a more informed use of
28-day intervals for repeat prescriptions,7,17,18 closer to the DH’s more general principle that prescription
duration should be consistent with medically appropriate patient needs while also considering NHS
resources, patient convenience and the dangers of having excess quantities of prescription medications in
the home.19 Similarly, the British Medical Association and the General Medical Council do not recommend
a specific prescription duration but instead encourage safe and appropriate repeat prescription intervals
adapted to the needs of individual patients.19,20
Indeed, evidence shows that there may be some disadvantages to shorter prescriptions. Shorter
prescriptions may (1) increase the costs to the health system through increased GP administrative workload
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and dispensing fees to pharmacists,21 (2) increase costs incurred by the patient,22 (3) have a negative
impact on patient satisfaction23 and (4) have a negative impact on adherence.24 Whether or not the most
commonly used prescription length should be changed was identified as a key area for research in the
DH’s 2011 roundtable, Making Best Use of Medicines.25
Aims and objectives
Given the substantial cost that wasted medication represents, disparities in the evidence, and the
ambiguity in national dispensing guidelines for GPs, the National Institute for Health Research (NIHR)
Health Technology Assessment (HTA) programme has commissioned research to synthesise and assess the
evidence on the clinical effectiveness and cost-effectiveness of shorter (28-day) versus longer (3-month)
duration prescriptions in terms of patients’ health outcomes and health system costs.
TABLE 1 The 20 most commonly prescribed medicines dispensed in the community in England (2015)
BNF chemical name
Items prescribed,
n (millions)
NIC, £
(millions)a Class of item/example(s) of conditions it can treat
Simvastatin 34.4 46.5 HMG CoA reductase inhibitor/hypercholesterolaemia,
primary prevention CVD
Omeprazole 30.1 64.8 PPI/gastro-oesophageal reflux, peptic ulceration
Levothyroxine sodium 29.7 104.5 Thyroid hormone therapy/hypothyroidism
Aspirin 28.0 27.3 Antiplatelet agent/secondary prevention of stroke,
myocardial infarction
Atorvastatin 27.2 53.8 HMG CoA reductase inhibitor/hypercholesterolaemia,
primary prevention of CVD
Ramipril 26.7 42.7 ACE/hypertension, heart failure
Amlodipine 25.4 31.9 Calcium channel blocker/hypertension, angina
Lansoprazole 22.9 41.6 PPI/gastro-oesophageal reflux, peptic ulceration
Paracetamol 22.9 87.6 Analgesic/mild to moderate pain
Salbutamol 21.9 62.4 Bronchodilator/asthma
Colecalciferol 19.9 90.6 Secosteroid/osteoporosis
Metformin hydrochloride 19.8 120.4 Antihyperglycaemic agent/diabetes mellitus
Bisoprolol fumarate 19.4 26.1 Beta blocker/angina, heart failure
Co-codamol 15.7 97.6 Analgesic/mild to moderate pain
Citalopram hydrobromide 14.4 17.8 SSRI/depression, panic disorder
Bendroflumethiazide 13.5 14.8 Thiazide diuretic/hypertension
Furosemide 12.5 13.9 Loop diuretic/oedema
Amitriptyline hydrochloride 12.4 23.1 Tricyclic antidepressant/neuropathic pain (unlicensed)
Amoxicillin 11.9 18.4 Antibiotic/infection
Warfarin sodium 11.6 23.1 Anticoagulant/prevention of stroke in atrial fibrillation
ACE, angiotensin-converting enzyme; BNF, British National Formulary; CVD, cardiovascular disease; HMG CoA, 3-hydroxy-3-
methylglutaryl coenzyme; NIC, net ingredient cost; PPI, proton pump inhibitor; SSRI, selective serotonin reuptake inhibitor.
a Net ingredient cost (NIC) refers to the cost of the drug before discounts and does not include any dispensing costs or
fees. It does not include any adjustment for income obtained where a prescription charge is paid at the time the
prescription is dispensed or where the patient has purchased a pre-payment certificate.
Source: Adapted from NHS Digital (2016).4 Copyright © 2016, Re-used with the permission of NHS Digital. All rights reserved.
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The aim of this study is to provide a high-quality reference on the clinical effectiveness and cost-effectiveness
of primary care physicians issuing longer duration versus shorter duration (3-month vs. 28-day) prescriptions
in patients with stable chronic diseases. This study is intended to help inform prescribing policy. In addition,
this study is directly relevant to patient groups with stable, chronic conditions who require regular repeat
prescriptions. In order to provide a comprehensive and transparent assessment of the impact of different
prescription lengths on a relevant set of outcomes, the following approaches have been used:
l a systematic review of the clinical effectiveness and cost-effectiveness evidence, incorporating any
relevant clinical and cost outcomes
l a cost analysis based on available secondary data
l disease-specific decision-analytic models.
Table 2 presents the full list of the potential outcomes of interest, as well as a brief description of each one
and an indication of which approach(es) was used to examine it.
TABLE 2 Outcomes of interest
Outcome Description Method
Disease-specific health
outcomes
Any health outcomes that measure the impact of a particular
disease or condition on an individual’s health and well-being, for
example disease management measures such as glycosylated
haemoglobin level or cholesterol measures
Systematic review
Generic health outcomes Any health outcome measures that can be applied across diseases
or conditions, and that could be used to estimate QALYs
Systematic review,
decision models
Adverse events Any outcome that measures untoward medical occurrence
in a patient, for example adverse drug reaction, unplanned
hospitalisation including A&E attendance as well as admission
for ambulatory care sensitive conditions, death
Systematic review
Errors Any outcome that measures preventable adverse effect of care,
for example prescription error, drug monitoring error
Systematic review
Adherence Any outcomes that measure the extent to which a patient is
dispensed the medication as prescribed and takes the prescribed
medication as intended; this broad definition includes measures of
compliancea
Systematic review
Costs associated with adherence
Drug wastage Any outcome used to measure medicines issued to a patient but
not consumeda
Systematic review,
cost analysis
Costs associated with wastage
Professional administration
time/costs
For example, time to write, renew or process the prescription and
costs associated with administration time
Systematic review,
cost analysis
Pharmacists’ time/costs For example, time to renew or process the prescription and costs
associated with pharmacists’ time
Systematic review,
cost analysis
Patient experience/satisfaction Any measure used to elicit feedback from patients on their views
of care and services
Systematic review
Patient costs Any measure of personal expenses incurred by patients during the
course of their care, for example out-of-pocket payments and
travel costs
Systematic review
Costs to the NHS Longer-term health service costs Decision model
A&E, accident and emergency; QALY, quality-adjusted life-year.
a Adherence and wastage are implicitly linked: when patients are dispensed a prescription but do not take the medication,
there is both non-adherence and wastage. Conversely, when patients are not dispensed a prescription, they will be
non-adherent but no wastage will be incurred. Note, however, that it is possible for a medication to be deliberately
stopped before the supply runs out, leading to wastage but not non-adherence. Similarly, a patient may take a medicine
less frequently than prescribed (non-adherence) but collect medicines less often (resulting in less wastage).
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Structure of the report
Following this introductory chapter, the report is structured by method: Chapter 2 presents the systematic
review, Chapter 3 reports on the cost analyses and Chapter 4 reports on the decision analyses. These
three chapters can each be read as standalone documents, as they each present the method, findings
and discussion of the approach indicated by their title. Chapter 5 draws overarching conclusions and
recommendations from the different methods.
Patient and public involvement
Patients and members of the public, consulted through the INsPIRE (patIeNt and Public Involvement in
REsearch) group based in Cambridgeshire, were involved in the drafting of the systematic review protocol
specifically to help identify outcomes that were directly relevant to them. Based on their suggestions, we
included three patient-centred outcomes: patient time, costs to the patient and synchronisation of
prescriptions. This was in addition to the initial list of outcomes that we had already considered, which
included adherence measures, disease-specific outcome measurements, drug wastage, adverse events,
patient experience and satisfaction, professional administration time/costs, pharmacist costs, health
outcomes and cost-effectiveness.
In addition, a copy of the draft report was sent to members of the INsPIRE group to obtain their feedback
on the plain English summary. The summary was amended in light of the comments made by five patient
and public involvement representatives.
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Chapter 2 Systematic review
Introduction
This systematic review was conducted using rigorous methods26 and is reported in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance.27 The protocol for
this systematic review is published on the PROSPERO database (registration number CRD42015027042).28
This chapter is structured as follows: first, the objectives of the review are outlined (see Objectives); second,
our methods are described (see Methods); third, our findings are presented (see Results); and, finally, these
findings are discussed (see Discussion).
Objectives
This systematic review addresses the following research question: how do longer duration (i.e. 3-month)
medication prescriptions compare with shorter duration (i.e. 28-day) medication prescriptions in terms of
clinical effectiveness and cost-effectiveness in patients with stable, chronic conditions requiring one or
more repeat prescriptions in primary care settings?
The objectives of this systematic review were:
1. to assess whether shorter or longer prescription lengths have positive or negative impacts on a range of
health outcomes and patient experiences in patients with chronic stable diseases
2. to assess whether or not shorter or longer prescription lengths have an impact on patient adherence,
wastage, GP time, dispensing costs, and costs to patients with chronic stable diseases
3. to evaluate the cost-effectiveness of different prescription lengths in patients with chronic stable
diseases based on previously published economic analyses.
Methods
Inclusion and exclusion criteria
To address the above research questions, the inclusion and exclusion criteria of the populations, interventions,
comparisons, outcomes and study types of interest are defined in the following sections and summarised in
Table 3.
Populations
Studies were eligible for inclusion if they involved patients being treated in a primary care setting with a
stable chronic disease or condition such as hypothyroidism, diabetes, cardiovascular disease (CVD) or
depression, requiring one or more repeat prescriptions.
Studies conducted in secondary/tertiary care settings, or in low-income countries as defined by the World
Bank (2016),29 were excluded from the review. When it was not clear whether or not a study was
exclusively conducted in a primary care setting, or if it was not stated what the study setting was, we took
an inclusive approach and considered the study to be eligible.
Interventions and comparisons
This systematic review focused on studies that had the objective of evaluating prescription lengths. Eligible
studies were those that evaluated 3-month (90-day) prescriptions (or prescriptions around 90 days) in
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comparison with 28-day prescriptions (or prescription lengths around 1 month). The prescriptions could be
for pharmaceutical medication but could also include other non-pharmaceutical prescriptions such as
urostomy bags. Studies were excluded that evaluated excessively long prescription lengths (e.g. > 12 months)
or evaluated prescriptions that did not require dispensing (e.g. physical activity prescriptions).
TABLE 3 Summary of inclusion/exclusion criteria
Inclusion Exclusion
Population and setting
Studies of patients being treated in a primary care setting with a
stable chronic disease or condition requiring one or more repeat
prescriptions (including, but not limited to, hypothyroidism, diabetes,
hypertension, CVD and depression), were eligible for inclusion
Studies of patients in low-income countries
Studies of patients in high- and middle-income countries were
eligible for inclusion
Studies conducted exclusively in secondary or
tertiary care settings
Interventions
Eligible studies were those that evaluated 3-month (90-day)
prescriptions, or prescription lengths of around 90 days. The
prescriptions could be for pharmaceutical medication, but could
also include other medical prescriptions such as urostomy bags
Excessively long prescription lengths (> 12 months)
and prescriptions that do not require dispensing
(e.g. physical activity prescriptions)
Comparisons
28-day (i.e. 1-month) prescription lengths, or prescriptions around
1 month
Prescription lengths < 28 days (i.e. 1 month)
Outcomes
Eligible studies had to report on at least one of the following
outcomes:
l Disease-specific health outcomes (any health outcomes)
l Generic health outcomes (e.g. QALYs)
l Adverse events
l Errors
l Adherence
l Drug wastage
l Professional administration time/costs
l Pharmacists’ time/costs
l Patient experience/satisfaction
l Patient costs
l Costs to the NHS
Studies were excluded if they:
l Only reported on prescribing patterns/trends
l Evaluated the incidence of undertreatment or
overtreatment of medicine
l Reported costs of generic vs. branded prescribing
l Evaluated adverse events without evaluating
this outcome in direct association with
prescription length
Economic outcomes of interest included all of the above as well as
costs, QALYs and ICERs
Study designs
RCTs, observational studies, cost comparison studies and economic
evaluations were eligible for inclusion
Letters, editorials and commentaries were not
eligible for inclusion unless they presented new
data
Studies published as abstracts or conference presentations were
included if enough data were presented, and if the abstract was not
associated with a full paper
CVD, cardiovascular disease; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; RCT, randomised
controlled trial.
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Outcomes
Eligible studies had to report on at least one of the following outcomes:
l disease-specific health outcomes (any health outcomes that measure the impact of a particular disease
or condition on an individual’s health and well-being, e.g. disease management measures such as
glycosylated haemoglobin level or cholesterol measures)
l generic health outcomes [any health outcome measures that can be applied across diseases or
conditions, and that could be used to estimate quality-adjusted life-years (QALYs)]
l adverse events [any outcome that measures untoward medical occurrence in a patient, e.g. adverse
drug reaction, unplanned hospitalisation including accident and emergency (A&E) attendance as well as
admission for ambulatory care sensitive conditions and death]
l errors (any outcome that measures preventable adverse effect of care, e.g. prescription error, drug
monitoring error)
l adherence (any outcomes that measure the extent to which a patient takes the prescribed medication
as intended by the prescriber; this broad definition includes established measures of compliance)
l drug wastage (any outcome used to measure medicines issued to a patient but not consumed)
l professional administration time/costs (e.g. time to write, renew or process the prescription and costs
associated with administration time)
l pharmacists’ time/costs (e.g. time to renew or process the prescription and costs associated with
pharmacists’ time)
l patient experience/satisfaction (any measure used to elicit feedback from patients on their views of care
and services)
l patient costs (any measure of personal expenses incurred by patients during the course of their care,
e.g. out-of-pocket payments and travel costs)
l costs to the NHS (longer-term health service costs).
Studies that reported only prescribing patterns or trends or reported on the costs of generic versus
branded prescribing were excluded. Studies that evaluated adverse events without evaluating this outcome
in direct association with prescription length were also excluded.
Study designs
Randomised controlled trials (RCTs), observational studies, cost analyses (e.g. cost description studies) and
economic evaluations [e.g. cost-effectiveness analyses and cost–utility analyses, which may have reported
incremental cost-effectiveness ratios (ICERs)] were eligible for inclusion.
Studies published as abstracts or conference presentations were included if enough outcome data were
presented to interpret the findings, and if the abstract was not associated with a full paper, which we
sought to confirm by contacting authors. Letters, editorials and commentaries were not eligible for
inclusion unless they presented new data.
Search strategy
To identify relevant primary studies, we searched a number of databases:
l MEDLINE (PubMed)
l EMBASE
l Cumulative Index to Nursing and Allied Health Literature (CINAHL)
l Web of Science
l Cochrane Central Register of Controlled Trials, which includes the Database of Abstracts of Reviews of
Effects (DARE), the HTA database and the NHS Economic Evaluation Database (NHS EED).
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We also performed searches in grey literature databases:
l Open Archives Initiative harvester (OAIster)
l OpenGrey
l The New York Academy of Medicine (NYAM)’s Grey Literature Report.
Searches were conducted in all of the databases between 13 October 2015 and 21 October 2015. The
search was rerun in PubMed in June 2016 to check that no additional relevant studies had been published
in the interim period. Given that no additional studies of relevance were identified, further searching of
other databases was deemed unnecessary.
All of the search terms used were in English, but the searches were not otherwise restricted by language.
Search terms included (but were not limited to) ‘prescription length’, ‘prescription duration’, ‘medication
duration’, ‘medication length’, ‘length of prescription’, ‘duration of prescription’, ‘prescribing pattern’,
‘prescription pattern’, ‘repeat dispensing’, ‘prescription interval’, ‘dispensing trends’, ‘prescription trends’,
‘prescribing trends’, ‘standardised prescribing’, ‘standardised prescription’, ‘one month prescription’, ‘one
month supply’, ‘three month prescription’, ‘three month supply’, ‘90 day supply’, ‘28 day supply’, ‘30 day
supply’, ‘long prescription’ and ‘short prescription’.
Details of the full search strategy are presented in Appendix 1.
Additional searching techniques to identify relevant studies were applied. These included:
l searching for systematic reviews and health technology assessments that could yield additional primary
studies. We searched the Cochrane Database of Systematic Reviews (CDSR), NIHR HTA, DARE and the
NICE website between 13 October 2015 and 21 October 2015
l checking the references within included papers and other reviews
l searching for additional studies carried out by the first authors of relevant studies
l carrying out citation searches of key publications to identify subsequent publications that have cited
those key publications [using the ‘cited by’ option in Google Scholar™ (Google Inc., Mountain View,
CA, USA)].
Study selection
The study selection involved four stages, shown in Table 4.
TABLE 4 Stages of study selection
Stage Study selection
1 Titles and abstracts of studies identified in the searches were entered into an EndNote (Thomson Reuters, CA, USA)
database, and references that were obviously not relevant (e.g. studies conducted in animals, low-income
countries) were screened and excluded by the information specialist (JL). More details about this screening stage
can be found in Appendix 2
2 A pilot screening of 400 references was undertaken to ensure consistent agreement among the reviewers
(AK, CMiani and JE) regarding the application of the inclusion/exclusion criteria. Any discrepancies were discussed
among all reviewers, including a senior systematic reviewer (SK)
3 Two reviewers independently screened the remaining titles and abstracts for inclusion. Given the large numbers of
references to screen, three reviewers (AK, CMiani and JE) were involved in the double screening process. Any
discrepancies were discussed among all three reviewers, and a fourth reviewer (SK) screened studies deemed ‘unsure’
4 Full papers of potentially relevant studies identified during stage 3 (and any subsequent papers identified through
backward and forward searching of relevant studies) were obtained and screened independently by two reviewers
(CMiani and JE), with any discrepancies discussed with a third reviewer (SK). At this stage, a table with excluded
studies was created, stating reasons for exclusion (see Appendix 3)
SYSTEMATIC REVIEW
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Data extraction
To facilitate data extraction, a form was developed in Microsoft Excel® (Microsoft Corporation, Redmond,
WA, USA) and piloted using several studies. Eligible studies were extracted twice, once each by two reviewers
working independently (two of AK, AM, CMiani, JE and SK). When the data were incomplete [e.g. sample
sizes not reported, standard deviations (SDs) not reported], we attempted to contact the study authors.
In some cases, studies were found to be ineligible during this process. These studies were discussed among
the wider research team to ensure that there was agreement regarding their ineligibility before they were
added to the table of excluded studies. The two data extraction forms were then combined and compared
by a third reviewer. Any discrepancies were resolved through discussion among all of the reviewers.
Risk-of-bias assessment
As no RCTs were included, to assess risk of bias in observational cohort and cross-sectional studies we
used the Risk Of Bias in Non-Randomized Studies – of Interventions (ROBINS-I) assessment tool.30 The tool
assesses seven domains of bias (see Table 24, Appendix 4, for an overview of the tool). For each domain,
the ‘signalling questions’ were completed by three reviewers independently (two of CMiani, JE and SK in
each case) to determine the domain-level risk of bias, with any discrepancies resolved through discussion
or by consulting a fourth reviewer (CMeads). The overall risk of bias was determined by all four reviewers
based on the domain-level risk of bias and reviewers’ judgement of both the severity of the bias in a
particular domain and the relative consequences of bias in different domains.30 Studies were considered to
be at a ‘serious risk’ of bias if one or more of the domains assessed was at serious risk of bias. When
insufficient data were reported to allow a judgement, the risk of bias was classified as ‘no information’.
Grading of Recommendations Assessment, Development and Evaluation assessment
We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria31 to
assess the quality of the body of evidence for each outcome. As no RCTs were eligible for inclusion, only
GRADE methodology applicable to non-RCTs is presented here. Using the standard four GRADE levels of
quality (high, moderate, low and very low), non-RCTs were considered to have an initial rating of low.
This rating was then up- or downgraded using the criteria (1) risk of bias, (2) imprecision, (3) inconsistency,
(4) indirectness and (5) publication bias.
Synthesising the evidence
The evidence included in this review was largely summarised using a narrative synthesis, with data
presented in tables, in the text, and in forest plots for visual purposes.
For each eligible outcome presented within a study, we calculated effect sizes [odds ratios (ORs) with
95% confidence intervals (CIs) for dichotomous outcomes, and mean difference (MD) with 95% CIs for
continuous outcomes]. In some of the studies, SDs were imputed based on p-values (in cases where we
could not obtain SDs from the study authors). We have noted when this was done in the tables.
The studies classified data by general therapeutic area (e.g. lipid-lowering drugs, antidiabetics) and by
more specific chemical classification [e.g. angiotensin-converting enzyme inhibitors (ACEIs), statins]. We
refer to these henceforth as the therapeutic class and the chemical class, respectively. We presented data
for both the therapeutic class and the chemical class when these were available. When a study reported
data by chemical class only,32 we combined these data using a meta-analysis in order to derive data for
one of the corresponding broader therapeutic classes as evaluated in other studies (i.e. lipid-lowering
agents, antidiabetics, etc.). We did not compare any effect size differences between the different
therapeutic classes, as this review was not designed to consider these differences.
Exploratory meta-analyses were conducted for medication adherence and wastage. In each of these
meta-analyses, we combined continuous and dichotomous data. The first step of this process was to
calculate the standardised mean differences (SMDs) with 95% CIs for each dichotomous or continuous
outcome as presented within each study. Dichotomous outcomes were converted to continuous data using
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the methods recommended in the Cochrane Handbook section 9.4.6.33 We then calculated a standard error
from these CIs. The last step was to pool the SMD and standard errors using a random-effects model in
RevMan version 5.3 (RevMan, The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen,
Denmark). Evidence of the extent of statistical heterogeneity was assessed by visually examining the extent
to which the CIs overlapped. Additionally, the I2 value, automatically calculated by the RevMan software,
was reported, and an interpretation of the levels of heterogeneity was made based on the recommendations
of Deeks et al.34
Results
Studies identified
Our search identified a total of 24,876 records across the databases searched. After the removal of
duplicates and the initial screening of titles and abstracts, we considered 47 references for full-text
evaluation. Of these, nine studies were identified as eligible for inclusion in the review, along with seven
additional studies retrieved through backwards and forwards citation checking (Figure 1). Appendix 3
provides reference details of excluded studies and reasons for their exclusion based on our full-text review.
Included studies
Overview
The information presented on study populations was limited. Some study populations included those who
were new to treatment,35–38 while others included those receiving ongoing care,32,39–41 and another included
Additional records identified
through other sources
(n = 7)
Records identified through
database searching
(n = 24,876)
Records after 
duplicates removed
(n = 15,250)
Records screened
(n = 15,250)
Records excluded
(n = 15,203)
Id
en
ti
fi
ca
ti
o
n
Sc
re
en
in
g
El
ig
ib
ili
ty
In
cl
u
d
ed
Full-text articles 
assessed for eligibility
(n = 47)
Full-text articles 
excluded, with reasons
(n = 38)
• Article type, n = 8
• Availability, n = 10
• Duplicate, n = 2
• Quality, n = 1
• Relevance, n = 16
• Study type, n = 1
Studies included in the review
(n = 9 + 7 = 16)
Studies included in the
quantitative analyses on
adherence and/or wastage
(n = 13)
FIGURE 1 The PRISMA flow chart.
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both those who were new to treatment and those receiving ongoing care.42 Half of the studies specified the
insurance scheme that patients were enrolled in: two (US) studies included predominantly indigent populations
(adults who do not have health insurance and are not eligible for Medicaid, Medicare or private health
insurance),39,43 two studies were conducted among Medicaid patients,44,45 four studies were set in Veterans
Health Administrations37,40,42,46 and one study used data from Kaiser Permanente health-care delivery sites.47
All of the studies were conducted in the USA. In the majority of studies, there was insufficient information
presented to determine whether or not patients were being treated exclusively in primary care settings. For
the three studies that provided details of the setting, one was conducted in a primary care clinic,39 one was
conducted among patients seen in primary care, mental health clinics, inpatient services and integrated
mental health primary care,37 and one was conducted in an internal medicine practice.43 Faris et al.48
investigated patients in four specialty therapeutic categories (multiple sclerosis, rheumatoid arthritis,
oncology and growth hormone) that are not typically primarily managed in primary care in England, but
insufficient information is presented to determine in which setting these patients were being treated.
Nine of the 16 studies compared a 30-day medication supply with a 90-day supply32,35,36,41,42,45,46,48,49 and
three studies compared three lengths of supply: 30 days, 31–89 days and ≥ 90 days.38,40,47 The remaining
four studies considered (1) 30 days’ versus 60 days’ supply,39 (2) 100 days’ versus 34 days’ supply,44
(3) 90 days versus < 90 days’ supply37 and (4) prescription lengths of ≤ 90 days.43
The number of medications examined in a single study ranged from one40 to ‘any medication for a chronic
condition’.49 The most common clinical classes evaluated were lipid-lowering agents,32,35,36,38,39,41–45,47,49
antihypertensives,32,35,36,38,41–45,47,49 antidiabetics32,35,41–45,47 and antidepressants.32,36,37,42,44,45
The study periods ranged from 3 months46 to 7 years;37 only one study was conducted over a period of less
than 1 year,46 six studies were conducted over a 12-month period 32,36,42,43,45,47 and eight studies were
conducted over a period of more than 1 year.35,37,39–41,44,48,49 Ryvkin et al.38 did not report the length of their
study. The most common outcomes measured were adherence,35,36,39,40,43–45,47 wastage32,36,38,41,42,45,46,48
and costs.42,44–46,49
When the study design was not reported35,36,38,43,46 or was unclear,41,49 the design was classified by three
reviewers (JE, SK and CMiani) based on the information presented, and guided by the NICE algorithm for
classifying quantitative study designs.50 No RCTs were identified. Of the 16 included studies, nine were
retrospective cohorts (six described as such by the study authors32,37,39,40,45,48 and three classified as such
by the reviewers35,36,38), two were retrospective pre–post studies (one so described by the authors,44 the
other defined as such by the reviewers41), three were cross-sectional studies (two described as such by
the authors,42,47 the other so defined by the reviewers43) and two were cost analyses (both defined as such
by the reviewers).46,49 In addition, the authors of one of the retrospective cohort studies45 and of one
of the retrospective pre–post studies44 undertook a cost–consequences analysis. In the vast majority of the
studies, the authors undertook a secondary data analysis of pharmacy claims data.32,36–38,40–47,49
For five of the included studies, only an abstract was available,35,36,38,41,48 and a sixth included article was an
extended conference abstract.46 Although we attempted to contact the authors of these reports, the full
papers corresponding to these abstracts could not be obtained. Given the paucity of high-quality studies
identified, and in discussion with expert advisors, the decision was taken to include all six identified
abstracts. An overview of the characteristics of all 16 studies is presented in Table 5. The key findings are
presented by outcome measures (health, adherence, wastage, costs and other) in the Outcomes section of
this chapter.
Risk-of-bias assessment
Risk of bias was assessed in all 16 included studies based on the criteria presented in the ROBINS-I
assessment tool (see Table 24, Appendix 4).30 In addition, for the three cost analysis studies42,46,49 and the
two studies with cost–consequence analysis44,45 the quality was appraised using Drummond et al.51
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TABLE 5 Overview of included studies
Reference, country,
study design Setting Aim Participants Medication evaluated Comparison
Total sample
size (number of
patients unless
otherwise
stated)
Outcomes
measured Study length
Batal et al. 2007,39
USA, retrospective
cohort
Primary care clinic
serving a
predominantly minority
and indigent
population
To determine the effect of
prescription size on
patients’ adherence to
hyperlipidaemia therapy
Patients receiving
ongoing care and
medication for
hyperlipidaemia
Lipid-lowering agents
(statins)
60-day supply of
medication (based
on modal supply of
> 45 days) compared
with a 30-day supply
(based on modal supply
of < 45 days)
3386 Adherence,
health
3 years
Domino et al. 2011,44
USA, retrospective
pre–post controlled
study with a
cost–consequences
analysis
Not explicitly reported;
claims data from two
centres for Medicare
and Medicaid services
To estimate the effect of
two separate policy
changes in the North
Carolina Medicaid
programme: (1) reduced
prescription lengths from
100 to 34 days’ supply
and (2) increased co-
payments for brand name
medications
Adult Medicaid
recipients who use
medications for
chronic conditions
Antidepressants,
antihypertensives,
antipsychotics,
antidiabetics
(sulfonylureas), seizure
disorder medications, lipid-
lowering agents (statins)
Reduced prescription
length from 100 days to
34 days
268,050 Adherence,
costs
18 months
Faris et al. 2010,48
USA, retrospective
cohorta
Not explicitly reported To determine the impact
of days’ supply on waste.
To compare medication
waste rates between
patients with a 90-day
supply and those with a
30-day supply in four
specialty therapeutic
categories
Patients in one of four
specialty therapeutic
categories: multiple
sclerosis, rheumatoid
arthritis, oncology and
growth hormone
Medications for multiple
sclerosis, rheumatoid
arthritis, oncology and
growth hormone
90-day supply compared
with 30-day supply
Not reported Wastage 21 months
(360-day study
period and
270-day
washout period
to determine
drop off)
Hermes et al. 2010,35
USA, retrospective
cohorta
Not explicitly reported To compare adherence
within three chronic
medication classes by
days’ supply and evaluate
potential adherence
predictors
Members with a first
claim
Antihypertensives,
antidiabetics, lipid-
lowering agents
90-day supply compared
with 30-day supply
At 270 days:
183,666; at
540 days:
112,220
Adherence 540 days
Jiang et al. 2007,36
USA, retrospective
cohorta
Not explicitly reported;
pharmacy claims data
(Walgreens)
To compare adherence
and wastage of 30-day
retail programme,
mandatory 90-day retail
programme and voluntary
90-day retail programme
Patients who were
new to ACEI, statins
or SSRIs
Antidepressants (SSRIs),
antihypertensives (ACEIs),
lipid-lowering agents
(statins)
90-day supply, either
mandatory or
voluntarily, compared
with 30-day supply
1685 Adherence,
wastage
1 year
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Reference, country,
study design Setting Aim Participants Medication evaluated Comparison
Total sample
size (number of
patients unless
otherwise
stated)
Outcomes
measured Study length
Murphy et al. 2012,32
USA, retrospective
cohort
Not explicitly reported;
pharmacy claims data
(Walgreens)
To examine medication
wastage for patients filling
90-day supplies of
medication compared with
those filling 30-day
prescriptions
Adults with repeat
prescriptions for
ongoing care
Antidepressants (SSRIs,
tricyclics), antidiabetics
(biguanides, insulin),
antihypertensives
(alpha-beta blockers,
ACEIs, angiotensin II
receptor antagonists,
calcium channel blockers,
cardioselective beta-
blockers, loop diuretics,
thiazides), lipid-lowering
agents (statins, fibric acid
derivatives), thyroid
hormones
90-day supply
compared with 30-day
supply; 90-day supply
stratified in two
prescription fulfilment
groups: mail and retail
60,358 Wastage 1 year
Parikh et al. 2001,46
USA, cost analysis
Not explicitly reported;
hospital records from
Veterans Affairs San
Diego Healthcare
System
To determine whether or
not the cost of dispensing
90-day quantities offsets
the expense of potential
waste because of patients’
oversupply
Patients with a chronic
disease receiving a
90-day supply of
medication
Not reported 90-day supply compared
with 30-day supply
(NB hypothetical
comparator as all
participants received a
90-day supply)
178 Costs 3 months
Pfeiffer et al. 2012,37
USA, retrospective
cohortb
Not explicitly reported;
pharmacy claims from
Veterans Affairs
National Registry for
Depression. Variety of
settings including
primary care, mental
health clinics and
inpatient services
To examine whether or
not receipt of an initial
90-day supply of an
antidepressant was
associated with better or
worse longer-term
antidepressant coverage
compared with patients
who initially received a
< 90-day supply
Adult patients newly
diagnosed with major
depression
Antidepressants 90-day supply
compared with
< 90-day supply
383,634 Adherence,
other (clinical
encounters)
7 years
Rabbani and
Alexander 2009,49
USA, cost analysis
Not explicitly reported;
nationally
representative medical
expenditure panel
survey data
To measure the difference
in out-of-pocket and total
costs among patients
receiving different
quantities of the same
prescription drug used to
treat a chronic condition,
and to examine patient
and health system
characteristics associated
with the use of a 3-month
supply
Non-institutionalised
patients who were
observed to have filled
both a 3-month and a
1-month supply of a
given medicine during
a 12-month period
395 medications for
chronic conditions. Most
commonly prescribed
were antihypertensives
(atenolol,
hydrochlorothiazide,
furosemide, amlodipine),
oestrogen hormone
(conjugated oestrogens),
lipid-lowering agents
(atorvastatin), thyroid
hormones (levothyroxine)
3-month supply
compared with 1-month
supply
2971 Costs 2 years
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TABLE 5 Overview of included studies (continued )
Reference, country,
study design Setting Aim Participants Medication evaluated Comparison
Total sample
size (number of
patients unless
otherwise
stated)
Outcomes
measured Study length
Ryvkin and Garavaglia
2009,38 USA,
retrospective cohorta
Not explicitly reported;
pharmacy claims data
(Medco Health
Solutions)
To quantify medication
wastage for lipid-lowering
agents, antihypertensive
therapy and PPIs
Patients new to
therapy
Antihypertensives,
lipid-lowering agents,
antiulcers (PPIs)
30- to 90-day supply
and > 90-day supply
compared with 30-day
supply
43,318 Wastage Not reported
Schectman et al.
2002,43 USA,
cross-sectional study
Academic internal
medicine practice
To evaluate the
association between
multiple demographic and
prescription factors with
the adherence behaviour
of an indigent rural
population to determine
whether or not such
factors could assist in
targeting interventions
Low-income patients
without prescription
insurance coverage
on hypertension,
hypercholesterolemia
or oral diabetes
medication
42 medications:
antihypertensives,
antidiabetics,
lipid-lowering agents
NA; looking at factors
associated with
adherence among a
population receiving
standard care.
Prescription length
varied, maximum supply
was 90 days
1984 Adherence 9 months
Schmittdiel et al.
2015,47 USA,
cross-sectional study
Not explicitly reported;
electronic health data
from the three largest
Kaiser Permanente
health-care delivery
sites
To examine the
relationship between
Medicare STAR medication
adherence metrics and
modifiable health system-
level characteristics in a
cohort of Medicare-aged
diabetes patients
Adults aged
≥ 65 years with
diabetes
Antihypertensives (ACEIs,
ARBs), antidiabetics (oral
antihyperglycaemics),
lipid-lowering agents
(statins)
NA; looking at four
health system level
factors associated with
adherence. Days’ supply
was derived from
pharmacy electronic
medication dispensing
records. Categorised as:
< 30-day, 31- to
60-day, 61- to 90-day
and > 90-day supply
236,025 Adherence ≤ 1 year
Steiner et al. 1993,40
USA, retrospective
cohort
Not explicitly reported;
pharmacy records from
10 Veteran Affairs
Medical centres
To determine whether
large prescriptions
(≥ 90 days’ supplies)
enhance the acquisition of
maintenance medications
by patients
Patients who had
received digoxin
prescriptions in
the previous year
(ongoing care)
Digoxin 31- to 89-day supply
and ≥ 90-day supply
compared with 30-day
supply
120 Adherence 14 months
Taitel et al. 2012,45
USA, retrospective
cohort with a
cost-consequence
analysis
Not explicitly reported;
pharmacy claims data
(Walgreens)
To determine whether or
not 90-day refills at
community pharmacies
could improve adherence,
minimise wastage and
control costs
Medicaid patients Antidepressants (SSRIs),
antidiabetics (oral
hypoglycaemics),
antihypertensives,
lipid-lowering agents
(statins)
90-day prescription
(day supply ≥ 84 days)
compared with 30-day
prescription (day supply
< 84 days)
52,898 Adherence,
cost, wastage,
other
(persistency)
1 year
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Reference, country,
study design Setting Aim Participants Medication evaluated Comparison
Total sample
size (number of
patients unless
otherwise
stated)
Outcomes
measured Study length
Thiebaud and Patel
2006,41 USA,
retrospective pre–post
controlled studya
Not explicitly reported;
managed care
organisation
To evaluate the effect of a
new programme that
allowed patients to fill
90-day prescriptions in
retail pharmacies
Patients insured in a
single managed care
organisation receiving
ongoing care
Antidiabetics,
antihypertensives,
lipid-lowering agents
Increased from 30-day
supply to 90-day supply
88,590 Other (number
of prescriptions,
duration of
supply)
18 months
Walton 2001,42 USA,
cross-sectional study
and cost analysis
Outpatient prescription
data from the Veteran
Administration’s
Chicago Health Care
System
To investigate the relative
roles that fill quantity,
dispensing costs and
wasted medication play
in the total cost of
outpatient prescriptions
Outpatients who are
receiving ongoing
care and who are
new to treatment
through Veteran
Administration’s
Chicago Health Care
System
Lipid-lowering agents
(statins)
90-day supply
compared with 30-day
supply
16,990
prescriptions
Cost, wastage 1 year
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; NA, not applicable; PPI, proton pump inhibitor; SSRI, selective serotonin reuptake inhibitor.
a Abstract.
b Extended conference abstract.
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The ROBINS-I is a recently published tool which, following careful consideration and pilot testing by reviewers,
was considered more appropriate to this review and the nature of the studies included therein than other
pre-existing tools (e.g. the Newcastle–Ottawa scale52). Not all of the signalling questions within each domain
of bias presented in the ROBINS-I tool were found to be applicable to the studies included in this review. For
example, signalling questions relating to participant selection bias were not well suited to retrospective cohort
studies, and strictly following the users’ guidance did not appear to appropriately distinguish between the
higher and lower quality studies for this criterion. Therefore, we followed the general principles of the
ROBINS-I and used the accompanying guidance to critically appraise the risk of bias in each domain, but we
did not always apply the full list of questions. We present a summary of the quality appraisal (Table 6) based
on the ROBINS-I tool; full details of the double assessment for each study are available on request.
Of the 16 studies, an overall assessment of risk of bias could not be made for the five studies presented as
abstracts, as insufficient information was reported on the study methodology used.35,36,38,41,48 Three studies
were considered to be at a serious risk of bias,40,45,46 and the remaining eight studies were considered to
be at a moderate risk of bias.32,37,39,42–44,47,49 In general, these eight studies were found to be sound for a
non-randomised study (according to the ROBINS-I assessment tool) but cannot be considered comparable
with a well performed randomised trial, so they were considered to be at a moderate risk of bias.
For the majority of studies, potential bias was observed in the selection and classification of participants into
the study. For example, in all of the retrospective cohort studies, assignment to the intervention was based
on the prescription length that they had received. When studies did not explicitly restrict the inclusion criteria
to those patients who were new to treatment, the start of the follow-up period and the start of the
intervention did not coincide, so that bias could have been introduced if the length of time that an individual
had previously been on treatment varied. It is possible that patients who have been receiving treatment for a
longer period of time are more likely to receive longer prescription lengths than those new to treatment.
Given that patients were not randomly allocated to intervention or control there was also the potential for
bias as a result of additional underlying differences in patients who received longer or shorter prescriptions.
For example, in the retrospective cohort studies, patients who had received longer prescriptions might have
been those who were considered by the prescriber to be more adherent. In the majority of cases, the study
authors did not explicitly report that they took measures to control for selection bias. In contrast, however,
Domino et al.44 examined the ways in which individuals with longer prescriptions differed from individuals
with shorter prescriptions. They found that women, the continuously enrolled, and disabled, older and
individuals with more comorbid diseases were more likely to receive longer prescriptions, while minorities
and those with greater hospital use during the study period were less likely to fill a longer prescription.
The authors used person-specific fixed effects to control for differences.
Two studies were classified as being at a serious risk of bias owing to a small sample size (a criterion that
is not considered in the ROBINS-I tool).40,46 In the study by Parikh et al.,46 750 patients were randomly
selected for inclusion, of whom only 178 agreed to participate. Steiner et al.40 included only 120 patients,
of whom only 27 received shorter prescriptions. The small sample sizes result in uncertainty about the
reliability of findings. A third study was classified as being at a serious risk of bias based on the way in
which the lengths of prescriptions were classified. Taitel et al.45 used a cut-off point of 84 days but
provided no justification for this choice. This raises concerns that the assignment of the intervention status
might have been determined in a way that could have been affected by knowledge of the outcome.
For the five studies that included a cost assessment,42,44–46,49 we assessed the quality using selected aspects of
the Drummond assessment criteria that were appropriate to cost analyses or cost–consequences analyses
(Table 7). We concluded that, overall, the quality of evidence was low. This was primarily because most
studies did not account for uncertainty in the estimates of costs using a sensitivity analysis. Although none
of the studies used discounting to adjust for differential timings of costs (to reflect savings rates and the
positive rate of time preference), this was justified by the short follow-up. Similarly, no study performed an
incremental analysis of costs and consequences of alternative treatment, as no study was a cost-effectiveness
analysis. In addition, three of the studies did not allow for uncertainty in the estimates of costs and
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TABLE 6 Risk-of-bias assessments based on ROBINS-I
Reference
Bias as a result
of confounding
Bias in
selection of
participants
into the study
Bias in
classification of
interventions
Bias as a result
of departures
from intended
interventions
Bias as a
result of
missing data
Bias in
measurement
of outcomes
Bias in
selection of
the reported
result Overall bias
Batal et al. 200739 Low Moderate Low Low Low Low Low Moderate
Domino et al. 201144 Low Low Low Moderate Moderate Low Low Moderate
aFaris et al. 201048 No information No information Low No information No information Low No information No information
aHermes et al. 201035 Moderate Moderate Low No information No information Low No information No information
aJiang et al. 200736 No information Moderate Low No information No information Low No information No information
Murphy et al. 201232 Low Moderate Low Low Moderate Low Low Moderate
bParikh et al. 200146 No information Serious Low Moderate Serious Low No information Serious
Pfeiffer et al. 201237 Low Moderate Low Low Low Low Low Moderate
Rabbani and Alexander 200949 Low Moderate Low Low Low Low Low Moderate
aRyvkin and Garavaglia 200938 No information No information Low No information No information Low No information No information
Schectman et al. 200243 Moderate No information No information Moderate No information Low Low Moderate/serious
Schmittdiel et al. 201547 Low Moderate Low Moderate Low Low Low Moderate
Steiner et al. 199340 Serious Moderate Low Low No information Low Low Serious
Taitel et al. 201245 Moderate/serious Moderate Serious Moderate Low Low Low Serious
aThiebaud and Patel 200641 No information Low Low No information No information Low No information No information
Walton 200142 Moderate/serious Moderate/serious Low Low Low Low Low Moderate
a Abstract.
b Extended conference abstract.
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TABLE 7 Risk-of-bias assessment for cost analyses and cost–consequences analyses based on Drummond et al.51
Reference
Was a
well-defined
question
posed in an
answerable
form?
Was a
comprehensive
description of
the competing
alternatives
given (i.e. can
you tell who did
what to whom,
where and how
often)?
Was the
effectiveness
of the
programmes
or services
established?
Were all of
the important
and relevant
costs and
consequences
for each
alternative
identified?
Were costs and
consequences
measured accurately
in appropriate
physical units (e.g.
hours of nursing
time, number of
physician visits, lost
work-days, gained
life-years)?
Were
costs and
consequences
valued
credibly?
Were costs and
consequences
adjusted for
differential
timing?
Was an
incremental
analysis of
costs and
consequences
of alternatives
performed?
Was
allowance
made for
uncertainty in
the estimates
of costs and
consequences?
Did the
presentation
and discussion
of study
results include
all issues of
concern to
users?
Domino et al.
201144
Yes NA NA Yes Yes Yes No No No Yes
Parikh et al.
200146
Yes No NA Yes Yes No No No No No
Rabbani and
Alexander
200949
Yes NA NA Yes Yes NA No No No (sensitivity
analysis looked
at patient
subgroups)
Yes
Taitel et al.
201245
Yes Yes NA Yes Yes Yes No No Yes Yes
Walton 200142 Yes No NA Yes Yes Yes No No No (sensitivity
analysis looked
at patient
subgroups)
Yes
NA, not applicable.
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consequences,44–46 and two others42,49 relied on limited sensitivity analyses to allow for uncertainty. Finally,
the limitations of the Parikh et al.46 study raised by the ROBINS-I tool were confirmed, as it was one of two
studies42,46 that did not provide a comprehensive description of the competing alternatives, and the only
study in which costs and consequences were not valued credibly and the presentation and discussion of
study results did not include all issues of concern to users.
Outcomes
One study presented findings of a risk factor for health outcomes,39 nine studies presented data on
medication adherence,35–37,39,40,43–45,47 medication wastage was reported in six studies,32,36,38,42,45,48 costs were
reported in five studies42,44–46,49 and three studies reported on ‘other’ outcomes. These ‘other’ outcomes
were medication persistency,45 number of clinical encounters,37 and number of prescriptions and
prescription duration.41 No evidence was found related to other outcomes of interest. Findings for each
outcome are presented in turn below.
Health outcomes and health risk factors
No studies measured health outcomes. Only one of the included studies explicitly measured a risk factor
for health outcomes.39 This retrospective cohort study compared achievement of target cholesterol levels
between patients with 60-day prescriptions and those with 30-day prescriptions (overall sample size
analysed 3292; sample sizes by group were not reported). Patients in the 60-day group had significantly
lower mean final serum cholesterol values than those in the 30-day group [185.3 mg/dl (SD 46.2 mg/dl) vs.
191.5 mg/dl (SD 52.6 mg/dl); p = 0.003]. An attempt was made to contact the study authors to obtain
sample sizes, but no data were forthcoming. As a result, we could not calculate an effect size.
Quality assessment
Based on a GRADE assessment, the overall quality of the evidence for risk factors of health outcomes
(i.e. cholesterol levels) is low.
Adherence
Medication adherence was reported in nine of the included studies (six retrospective cohort
studies,35–37,39,40,45 one pre–post controlled study44 and two cross-sectional studies).43,47 All measures used
to assess adherence were indirect estimates based on pharmacy claims refill data. The most common
measures of adherence were the proportion of days covered (PDC) or the medication possession ratio
(MPR) (Box 1). When the MPR is used, patients who routinely refill their medications early can have a MPR
of > 100% (i.e. the numerator can be greater than the denominator).
Measures of adherence were presented as dichotomous (i.e. the number of patients with ≥ 80% or
< 80% PDC or MPR) or continuous outcomes (i.e. mean PDC or MPR). One study reported both
dichotomous and continuous outcomes.44 It was possible to calculate effect sizes for six cohort studies
based on the information reported in the papers (see Table 8 and Figures 2 and 3).35–37,39,40,45 The findings
are presented for dichotomous and continuous outcomes in turn below and summarised in Table 8.
BOX 1 Definitions of PDC and MPR
PDC is calculated as:
number of days in a given time period ‘covered’ by prescription claims for a particular drug × 100
number of days in the time period
. (1)
MPR is calculated as:
the sum of days’ supply for all fills of a particular drug in a given time period × 100
number of days in the time period
. (2)
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TABLE 8 Studies that evaluated claims-based medication adherence
Reference, study
type
Condition(s)/
medication(s)
evaluated
Adherence measurement
(as reported by the study
authors)
Duration
of study
90-day supply
(unless otherwise stated)
30-day supply
(unless otherwise stated) Effect size
Dichotomous outcomes (≥ 80% adherence)
Batal et al. 2007,39
retrospective cohort
Lipid-lowering agents
(statins)
Pharmacy refills; each patient’s
adherence score was calculated
as their days of drug acquired
divided by their days in the
study (days from first
prescription fill to last
prescription fill). The primary
outcome was proportion with
≥ 80% adherence
3 years 60-day supply: 1307 out of
2553 (51%)
303 out of 833 (36%) OR 0.53 (95% CI 0.45 to
0.62)a
bDomino et al.
2011,44 pre–post
controlled study with
a cost–consequences
analysis
Antidepressants,
antipsychotics,
antihypertensives,
antidiabetics, seizure
disorder medications,
lipid-lowering agents
(statins)
PDC measure; calculates daily
indicators of medication used
divided by the number of days
in the quarter. The outcome
was reported as difference-in-
difference-in-differencesc in the
percentage of quarters in
which individuals had PDC
≥ 80%
18 months NR NR Statins: –0.132 (0.025),
p < 0.01; diabetes: –0.053
(0.017), p< 0.01;
antihypertensives: –0.083
(0.006), p< 0.01; seizure
disorder: –0.022 (0.014),
p = ns; antidepressants:
–0.027 (0.021), p= ns;
antipsychotics 0.004
(0.018), p= ns
Hermes et al. 2010,35
retrospective cohortd
Antihypertensives,
antidiabetics,
cholesterol-lowering
agents
PDC (no further details
reported). The primary
outcome was the proportion
with a PDC ≥ 80%
540 days Cholesterol-lowering:
5414e out of 7219
(74.9%); antihypertensives:
7928 out of 9405 (84.3%);
antidiabetics: 1221 out of
1578 (77.4%)
Cholesterol-lowering:
20,820 out of 31,982
(65.1%); antihypertensives:
41,064 out of 53,192
(77.2%); antidiabetics:
6094 out of 8844 (68.9%)
Cholesterol-lowering:f
OR 0.62 (95% CI 0.59 to
0.66); antihypertensives:
OR 0.63 (95% CI 0.59 to
0.67); antidiabetics: OR
0.65 (95% CI 0.57 to 0.74)
Pfeiffer et al. 2012,37
retrospective cohort
Antidepressants Proportion of patients who
received ≥ 180 days of an
antidepressant treatment
during the 231-day period
following the index
prescription. The primary
outcome was the proportion
with > 80% adherence
7 years 67,077
g
out of 87,000
(77.1%)
‘Less than a 90-day supply’:
123,993 out of 296,634
(41.8%)
OR 0.21 (95% CI 0.21 to
0.22)
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Reference, study
type
Condition(s)/
medication(s)
evaluated
Adherence measurement
(as reported by the study
authors)
Duration
of study
90-day supply
(unless otherwise stated)
30-day supply
(unless otherwise stated) Effect size
Schmittdiel et al.
2015,47 cross-
sectional study
Antihypertensives
(ACEIs; ARBs),
antidiabetics (oral
antihyperglycaemics),
lipid-lowering agents
(statins)
PDC: the percentage of days in
the measurement period
‘covered’ by prescription fills for
the same medication or
medications in the same
therapeutic category. The
primary outcome was predictors
of adherence modelled as a
dichotomous outcome in a
Poisson regression model
Up to
1 year
NR NR Estimated risk ratio of being
adherent (PDC ≥ 0.8)
(reference group with
< 31 days’ supply):h
ACEI/ARB: 61–90 days 1.35;
> 90 days 1.61; oral
diabetes medications:
61–90 days 1.48; > 90 days
1.61; statins: 61–90 days
1.47; > 90 days 1.61
(p< 0.001 for all)
Continuous (mean PDC or MPR)
bDomino et al.
2011,44 pre–post
controlled study with
a cost–consequences
analysis
Antidepressants,
antipsychotics,
antihypertensives,
antidiabetics, seizure
disorder medications,
lipid-lowering agents
(statins)
PDC measure; as above 18 months NR NR Statins: –0.080 (0.012),
p < 0.01; diabetes:
–0.034 (0.008), p< 0.01;
antihypertensives: –0.045
(0.002), p< 0.01; seizure
disorder: –0.009 (0.006),
p = ns; antidepressants:
–0.030 (0.010), p< 0.01;
antipsychotics: –0.010
(0.008), p= ns
Jiang et al. 2007,36
retrospective cohortd
Antidepressants (SSRIs),
antihypertensives
(ACEIs), lipid-lowering
agents (statins)
MPR (no further details
reported)
1 year Mandatory 90 days: 0.7543
(SD not reported)i (n= 148),
voluntary 90 days: 0.6895
(SD not reported) (n= 582)
0.3999 (SD not reported)
(n= 955)
MD –0.30 (95% CI –0.58
to –0.03)j
Schectman et al.
2002,43 cross-
sectional study
42 medications:
antihypertensives,
antidiabetics,
lipid-lowering agents
Number of days of therapy
dispensed between first and
last refills divided by interval
between first and last refills. The
primary outcome was predictors
of adherence modelled in a
multivariable linear regression
model. No details were reported
as to whether or not MPR was
capped at 100%
9 months NR NR Based on multivariate
analysis, each 30-day
increment in prescription
drug supply (maximum
supply was 90 days) was
associated with a 5.7%
increase in mean
adherence (p < 0.0001)k
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TABLE 8 Studies that evaluated claims-based medication adherence (continued )
Reference, study
type
Condition(s)/
medication(s)
evaluated
Adherence measurement
(as reported by the study
authors)
Duration
of study
90-day supply
(unless otherwise stated)
30-day supply
(unless otherwise stated) Effect size
Steiner et al. 1993,40
retrospective cohort
Digoxin The proportion of prescribed
dose of maintenance
medication obtained.
Calculated as the total days’
supply divided by the number
of days between the first and
last fills
14 months 31 to 89 days: 103.6%l
(SD 26.6) (n= 41)
≥ 90 days: 113.0%l
(SD 21.4) (n= 46)
89.7% (SD 34.9) (n= 27) ≥ 90 days vs. ≤ 30 days:
MD –0.23 (95% CI –0.38
to –0.09)
Taitel et al. 2012,45
retrospective
cohort with a
cost–consequences
analysis
Antidepressants (SSRIs),
antidiabetics (oral
hypoglycaemics),
antihypertensives,
lipid-lowering agents
(statins)
MPR: sum of the days’ supply
for each therapeutic class
divided by 365, the number of
days in the follow-up period
1 year Antihypertensives: 0.910
(SD 0.174)m (n= 5835);
statins: 0.819 (SD 0.194)
(n= 2162); SSRIs: 0.817
(SD 0.196) (n= 266);
hypoglycaemics: 0.875
(SD 0.190) (n= 1511)
Antihypertensives: 0.774
(SD 0.292) (n= 33,009);
statins: 0.671 (SD 0.278)
(n= 12,136); SSRIs: 0.611
(SD 0.295) (n= 7017);
hypoglycaemics: 0.775
(SD 0.289) (n= 11,842)
Antihypertensives: MD
–0.14 (95% CI –0.14 to
–0.13); statins: MD –0.15
(95% CI –0.16 to –0.14);
SSRIs: MD –0.21 (95% CI
–0.23 to –0.18);
hypoglycaemics: MD –0.12
(95% CI –0.13 to –0.11)
ARB, angiotensin II receptor blocker; MD, mean difference; NR, not reported; ns, not significant; SSRI, selective serotonin reuptake inhibitor.
a The authors reported an adjusted risk ratio of 1.41 (95% CI 1.28 to 1.55), p < 0.01, controlling for age, gender, race, co-payment, comorbidities and insurance status. Given that this is a
retrospective cohort study, we have presented the effect size as an OR.
b The Domino 2011 study is included twice in this table because this study reports outcomes in two ways.
c Difference-in-difference-in-differences measures = differences from baseline to follow-up between two states (North Carolina and Georgia).
d Abstract.
e Numerators were calculated from data presented in the abstract.
f The authors reported the following effect sizes: cholesterol OR 0.60 (95% CI 0.57 to 0.64), p < 0.001; hypertension OR 0.60 (95% CI 0.56 to 0.63), p< 0.001; diabetes OR 0.61 (95% CI
0.53 to 0.70), p < 0.001. Our calculated ORs, as presented in Figure 2, are similar.
g Numerators were calculated from data presented in the text.
h Regression models were adjusted for site and for whether or not the patient was enrolled in a health plan.
i The authors were contacted, but SDs were not available.
j We combined the means from the mandatory and voluntary 90-day groups. SDs were imputed in order to calculate an effect size (based on p< 0.01).
k In the multivariate model for mean adherence, each day supply had a parameter estimate of 0.19, so that for 30 days, adherence was estimated to be 5.7%.
l Presented as rate in Figure 3.
m Means and SDs were obtained from the study authors.
Note
All information in this table is taken directly from the studies indicated in column 1.
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0.55 (0.46 to 0.64)
0.62 (0.59 to 0.66)
Study or subgroup Events Total
30 days
Events Total
90 days Odds ratio
M–H, fixed, 95% CI
Odds ratio
M–H, fixed, 95% CI
Lipid-lowering agents
Batal et al. 200739
Hermes et al. 201035
303
20,820
833
31,982
1307
5414
2553
7219
0.63 (0.59 to 0.67)
Antihypertensives
Hermes et al. 201035 41,064 53,192 7928 9405
0.65 (0.57 to 0.74)
Antidiabetics
Hermes et al. 201035 6094 8844 1221 1578
0.21 (0.21 to 0.22)
0.2 0.5 1 2 5
Antidepressants
Pfeiffer et al. 201237 123,993 296,634 67,077 87,000
Adherence with 
30 days’ supply
Adherence with
90 days’ supply
FIGURE 2 Studies that assessed the percentage of patients with ≥ 80% medication adherence. An ‘event’ is defined as ≥ 80% adherent. Batal et al.39 compared 30-day medication
supply with 60-day supply, and Pfeiffer et al.37 compared 90-days’ supply with < 90 days’ supply. M–H, Mantel–Haenszel.
–0.15 (–0.16 to –0.14)
Study or subgroup
Mean difference
IV, fixed, 95% CI
Mean difference
IV, fixed, 95% CI
Lipid-lowering agents
Taitel et al. 201245 0.278 12,136 0.194 2162
–0.14 (–0.14 to –0.13)
Antihypertensives
Taitel et al. 201245 0.292 33,009 0.174 5835
–0.12 (–0.13 to –0.11)
Antidiabetics
Taitel et al. 201245 0.289 11,842 0.190 1511
–0.21 (–0.23 to –0.18)
–0.50 –0.25 0.0 0.25 0.50
Antidepressants
Taitel et al. 201245 0.295 7017 0.196 266
Adherence with 
30 days’ supply
Adherence with
90 days’ supply
–0.23 (–0.38 to –0.09)
Digoxin
aSteiner et al. 199340 0.349 27 0.214 46
–0.30 (–0.58 to –0.03)
Mixed classes
Jiang et al. 200736 0.399
30 days
SD TotalMean
0.671
0.774
0.755
0.611
0.897
2.868 955 0.703
90 days
SD TotalMean
0.819
0.910
0.875
0.817
1.130
2.868 730
FIGURE 3 Studies that assessed mean adherence using the MPR or the PDC. a, Steiner et al.40 compared a 30-day medication supply with a ≥ 90-day supply.
IV, instrumental variable.
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Proportion of days covered and medication possession ratio measured as a
dichotomous outcome
Five studies (three cohort studies, one pre–post study and one cross-sectional study) compared the
proportion of patients with ≥ 80% or < 80% medication adherence using PDC35,37,44,47 or MPR.39
Effect sizes (ORs) could be calculated for three of the cohort studies because they reported adherence rates
of individuals who received longer prescription lengths and those who received shorter prescription lengths
(see Table 8).35,37,39 These studies presented data for lipid-lowering agents, antihypertensives, antidiabetics
and antidepressants. The effect sizes consistently show that longer prescriptions increase medication
adherence compared with shorter prescriptions for all four clinical classes (see Figure 2).
Domino et al.44 compared changes in adherence both before and after the introduction of a policy in one
US state (North Carolina) to reduce prescription length from 100 days to 34 days, and another state
(Georgia) where the maximum duration of supply remained constant at 31 days. Adherence was expressed
as the proportion of quarters per year in which individuals were at least 80% adherent to their target
medications. This study found that shortening the prescription length was associated with a reduction in
adherence for five of the six clinical classes studied, but the difference was statistically significant only
for statins, diabetes and antihypertensive medications (see Table 8). The policy change in North Carolina
was stated to have increased the rate at which chronic medication users were non-adherent to their
prescribed medication.44
In a cross-sectional study by Schmittdiel et al.,47 associations between adherence and health system
characteristics, including mean days’ supply of medication (as categorical variables 31–60 days, 61–90 days and
> 90 days), were analysed using regression analysis. The authors considered various cardiovascular medications
including ACEIs and angiotensin II receptor blockers (ARBs), statins and oral diabetes medications.47 Across all
medications, the strongest health system predictor of achieving greater medication adherence was a longer
prescription length (a mean supply of > 90 days) [the relative risk (RR) was 1.61 for each of these medications;
p< 0.001] (see Table 8).47
Proportion of days covered and medication possession ratio measured as a
continuous outcome
Five studies (three cohort studies,36,40,45 one pre–post controlled study44 and one cross-sectional study43)
evaluated medication adherence using mean values of PDC44 or MPR.36,40,43,45
Effect sizes (mean differences) could be calculated for the three cohort studies that reported the mean
adherence rates of individuals who received longer prescription lengths and of those who received
shorter prescription lengths (see Table 8).36,40,45 These studies presented data for lipid-lowering agents,
antihypertensives, antidiabetics, antidepressants and digoxin. The effect sizes consistently show that longer
prescriptions increase medication adherence compared with shorter prescriptions for all four clinical classes,
and for digoxin (see Figure 3).
The pre–post controlled study by Domino et al.3 found that shortening the supply of medication from
100 days to 34 days was associated with decreased adherence by 1.5–4.6 percentage points across the
six therapeutic classes studied. However, the results for seizure medication and antipsychotics were not
statistically significant (see Table 8).
Finally, a cross-sectional study by Schectman et al.43 examined associations between demographics and
prescription factors, including length of medication supply and adherence to medications for diabetes,
hypertension and hypercholesterolaemia. Based on a multivariate regression model, the authors reported
that each 30-day increment in prescription length (the maximum supply was 90 days) was associated with
a 5.7% increase in mean adherence (p < 0.0001) (see Table 8).43
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Pooled meta-analysis
As an exploratory analysis, we combined dichotomous and continuous measures of adherence from six
retrospective cohort studies35–37,39,40,45 by pooling SMDs for each therapeutic class and all classifications
combined (Figure 4). As ORs or mean differences with 95% CIs (and thus SMDs) could not be calculated
for three of the nine studies reporting on adherence, their results are not included in this analysis.43,44,47
The overall effect size shows that medication adherence was significantly increased in patients who
received a 90-day medication supply compared with patients who received a 30-day supply (SMD –0.45,
95% CI –0.65 to –0.26; p < 0.00001), but there was significant statistical heterogeneity between the
different studies/comparisons [τ2 = 0.10; χ2 = 2611.51, degrees of freedom (df) = 10; p < 0.00001;
I2 = 100%]. Given this heterogeneity, the effect size estimate may not be meaningful, and should, as
intended, be considered exploratory.
Quality assessment
Based on a GRADE assessment, the overall quality of the evidence for adherence is moderate. This
assessment was made because most of the studies that evaluated this outcome were considered to be at
only a moderate risk of bias, there was consistency in the direction of effect, the CIs were generally narrow
and we did not find any evidence (such as small study effects) that could indicate publication bias.
However, there was concern regarding the extent to which the evidence presented is applicable to the UK
setting, as all of the studies were conducted in the USA, which has a very different health service structure
from that of the UK.
–0.35 (–0.44 to –0.26)
–0.26 (–0.29 to –0.23)
–0.55 (–0.59 to –0.51)
–0.39 (–0.59 to –0.18)
Study or subgroup
Standard mean 
difference SE Weight (%)
Standard mean difference
IV, random, 95% CI
Standard mean difference
IV, random, 95% CI
Lipid-lowering agents
Batal et al. 200739
Hermes et al. 201035
Taitel et al. 201245
Subtotal (95% CI)
Heterogeneity: τ2 = 0.03; χ2 = 105.79, df = 2 (p < 0.00001); I2 = 98%
Test for overall effect: z = 3.73 (p = 0.0002)
–0.35000839
–0.26354114
–0.55
0.04507045
0.01576793
0.022959
9.3
9.5
9.5
28.3
–0.5 0.0 0.5 1.0–1.0
Adherence with 
30 days’ supply
Adherence with 
90 days’ supply
–0.25 (–0.29 to –0.22)
–0.49 (–0.52 to –0.46)
–0.37 (–0.60 to –0.14)
Antihypertensives
Hermes et al. 201035
Taitel et al. 201245
Subtotal (95% CI)
Heterogeneity: τ2 = 0.03; χ2 = 99.91, df = 1 (p < 0.00001); I2 = 99%
Test for overall effect: z = 3.17 (p = 0.002)
–0.25472015
–0.49
0.01788282
0.015306
9.5
9.5
19.0
–0.24 (–0.31 to –0.17)
–0.43 (–0.48 to –0.38)
–0.34 (–0.52 to –0.15)
Antidiabetics
Hermes et al. 201035
Taitel et al. 201245
Subtotal (95% CI)
Heterogeneity: τ2 = 0.02; χ2 = 18.55, df = 1 (p < 0.00001); I2 = 95%
Test for overall effect: z = 3.49 (p = 0.0005)
–0.23749062
–0.43
0.0367084
0.02551
9.4
9.5
18.9
–0.86 (–0.87 to –0.85)
–0.71 (–0.83 to –0.59)
–0.80 (–0.94 to –0.65)
Antidepressants
Pfeiffer et al. 201237
Taitel et al. 201245
Subtotal (95% CI)
Heterogeneity: τ2 = 0.01; χ2 = 5.50, df = 1 (p < 0.02); I2 = 82%
Test for overall effect: z = 10.79 (p < 0.00001)
–0.8603851
–0.71
0.0654247
0.063776
9.5
9.2
18.7
–0.85 (–1.35 to –0.35)
–0.85 (–1.35 to –0.35)
Digoxin
Steiner et al. 199340
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 3.33 (p = 0.0009)
–0.85 0.255102 5.8
5.8
–0.13 (–0.22 to –0.04)
–0.13 (–0.22 to –0.04)
Mixed classes
Jiang et al. 200736
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 2.68 (p = 0.007)
–0.13 0.048469 9.3
9.3
–0.45 (–0.65 to –0.26)Total (95% CI) 100.0
Heterogeneity: τ2 = 0.10; χ2 = 2611.51, df = 10 (p < 0.00001); I2 = 100%
Test for overall effect: z = 4.57 (p < 0.00001)
Test for subgroup differences: τ2 = 61.39, df = 5 (p < 0.00001); I2 = 91.91%
FIGURE 4 Combined meta-analysis of studies/comparisons that assessed claims-based medication adherence. The
results for different therapeutic classes presented by the same author did not share the same control groups, so
they could be pooled as separate studies in the meta-analysis. Batal et al.39 compared 30 vs. 60 days’ medication
supply, Pfeiffer37 compared 90 vs. < 90 days’ supply and Steiner40 compared 30 vs. ≥ 90 days’ medication supply.
The analysis is based on six retrospective cohort studies. IV, instrumental variable.
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In summary, there is consistent evidence that longer prescriptions increase medication adherence
compared with shorter prescriptions. The overall quality of the evidence for this outcome is moderate.
Wastage
Medication wastage was reported in six of the included studies (five retrospective cohort studies32,36,38,45,48
and one cross-sectional cost analysis42). All measures of wastage were indirectly estimated based on
pharmacy claims refill data. The majority of these studies defined wastage in a similar manner, such as a
‘switch in medication type within the same clinical class or to the same medication but with a different
strength, occurring before the expected refill date’.32 One study also included discontinuation within
its definition.48
It was possible to calculate effect sizes for four cohort studies,32,36,42,45 based either on information reported
in the papers or on data obtained from the study authors. Three different ‘wastage’ outcomes were
reported in the included studies: the percentage of days’ supply wasted, the mean number of days’
supply wasted and the percentage of patients who wasted medication. Two studies reported multiple
outcomes.38,42 The findings related to each of these outcomes are presented in turn below and summarised
in Table 9.
Percentage of days’ supply wasted
Two retrospective cohort studies reported on the percentage of days’ supply wasted.38,48 Both studies were
reported in conference abstracts, and insufficient data were reported to enable an effect size to be
calculated. An attempt was made to contact the authors for further information, but no additional data
were obtained. Both studies found only small differences in the proportion of days’ supply wasted
between patients with different prescription lengths, although neither study reported raw data or statistical
comparisons (see Table 9).
Percentage of patients who wasted medication
Three studies (two retrospective cohort studies38,45 and one cross-sectional cost analysis42) reported on the
percentage of patients who wasted medication. As none of these three studies stated how wastage per
patient was defined, it is not clear whether these patients wasted a small or a large amount of medication.
Effect sizes (ORs) could be calculated for lipid-lowering agents, antihypertensives, antidiabetics and
antidepressants based on data presented in two of the studies.42,45 These data consistently show no
statistical differences in the proportion of patients who wasted medication between longer and shorter
prescriptions for each of the clinical classes evaluated (Figure 5).
The third study38 reported insufficient data to calculate an effect size; however, similarly to the other
studies, the authors found only small differences in wastage between study participants, although no
statistical comparisons were reported.
Mean number of days’ supply wasted
Four studies (three retrospective cohort studies32,36,45 and one cross-sectional cost analysis42) measured the
mean number of days’ supply wasted over 1 year. Two of the studies used wastage data to inform their
cost analysis.42,45 As such, these two studies appear to present unstandardised means (i.e. the actual
mean number of days’ supply wasted over the study period) for each comparison group. The other two
studies32,36 investigated wastage as a primary outcome and reported a standardised mean days’ supply
(i.e. the mean number of days’ supply wasted per 30 days).
Effect sizes (mean difference) for lipid-lowering agents, antihypertensives, antidiabetics, antidepressants
and thyroid hormones could be calculated based on data presented in three of the studies (see Table 9
and Figures 6 and 7).32,36,45 As Murphy et al.32 and Jiang et al.36 report rate data per 30 days, we have
presented mean differences from these studies in a separate forest plot (Figure 7) from Taitel et al.45
(Figure 6).
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TABLE 9 Studies that evaluated medication wastage
Reference, study
type
Condition(s)/
medication(s)
evaluated
Wastage definition and
calculation (as reported
by the study authors)
Duration
of study
90 days’ supply (unless
otherwise stated)
30 days’ supply (unless
otherwise stated) Effect size
Percentage of days’ supply wasted
Faris et al. 2010,48
retrospective cohorta
Medications for
multiple sclerosis,
rheumatoid arthritis,
oncology and growth
hormone
Wastage occurred when
patients switched
medication or stopped
taking therapy (drop-off
waste). The outcome
measured was the
proportion of days’ supply
wasted, calculated as the
sum of switch waste and
drop-off waste divided by
total days supplied
21 months Multiple sclerosis: 2.44%;
rheumatoid arthritis: 2.73%;
oncology: 1.90%; growth
hormone: 4.28% (sample
sizes and SDs were not
reported)
Multiple sclerosis: 2.55%;
rheumatoid arthritis: 3.97%;
oncology: 3.42% growth
hormone: 3.54% (sample
sizes and SDs were not
reported)
An effect size was not
reported and could not be
calculated
Ryvkin and
Garavaglia 2009,38
retrospective cohorta
Antihypertensives,
lipid-lowering agents,
antiulcers (PPIs)
Defined as a switch within
therapeutic class. The
outcome measured was
the proportion of days’
supply wasted
Not
reported
Antihypertensives: 2.0%
(sample sizes and SDs not
reported); lipid-lowering
agents: 1.2% (sample sizes
and SDs not reported); PPIs:
0.7% (sample sizes and SDs
not reported)
Antihypertensives: 2.1%
(sample sizes and SDs not
reported); lipid-lowering
agents: 0.4% (sample sizes
and SDs not reported); PPIs:
0.7% days (sample sizes and
SDs not reported)
An effect size was not
reported and could not be
calculated
Percentage of patients who wasted medication
Ryvkin and
Garavaglia 2009,38
retrospective cohorta
Antihypertensives,
lipid-lowering agents,
antiulcers (PPIs)b
Defined as a switch within
therapeutic class. The
outcome measured was
the proportion of patients
who wasted medication
Not
reported
Antihypertensives: 5.2%
(sample sizes not reported);
lipid-lowering agents: 2.9%
(sample sizes not reported);
PPIs: 1.8% (sample sizes not
reported)
Antihypertensives: 6.3%
(sample sizes not reported);
lipid-lowering agents: 1.2%
(sample sizes not reported);
PPIs: 1.9% (sample sizes not
reported)
An effect size was not
reported and could not be
calculated
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TABLE 9 Studies that evaluated medication wastage (continued )
Reference, study
type
Condition(s)/
medication(s)
evaluated
Wastage definition and
calculation (as reported
by the study authors)
Duration
of study
90 days’ supply (unless
otherwise stated)
30 days’ supply (unless
otherwise stated) Effect size
Taitel et al. 2012,45
retrospective
cohort with a
cost–consequences
analysis
Antidepressants (SSRIs),
antidiabetics (oral
hypoglycaemics),
antihypertensives,
lipid-lowering agents
(statins)
Defined as a switch of drug
type or strength within the
same therapeutic class that
occurred before the
expected refill date. The
outcome measured was
the percentage of patients
who wasted medication
1 year Antihypertensives: 712c out
of 5835 (12.2%); statins:
212 out of 2162 (9.8%);
SSRIs: 39 out of 266
(14.7%); hypoglycaemics:
175 out of 1511 (11.6%)
Antihypertensives: 3928 out
of 33,009 (11.9%); statins:
1104 out of 12,136 (9.1%);
SSRIs: 975 out of 7017
(13.9%) hypoglycaemics:
1255 out of 11,842 (10.6%)
Antihypertensives: OR 0.97
(95% CI 0.89 to 1.06);
statins: OR 0.84 (95% CI
0.72 to 0.98); SSRIs: OR
0.94 (95% CI 0.66 to
1.33); hypoglycaemics: OR
0.90 (95% CI 0.76 to 1.07)
Walton 2001,42
cross-sectional study
Lipid-lowering agents
(HMG CoA reductase
inhibitors)
Defined as a switch within
therapeutic class. The
outcome measured was
the proportion of patients
that switched who
1 year 545 out of 3635 (15.0%) 1909 out of 13,355 (14.3%) OR 0.95 (95% CI 0.85 to
1.05)
Mean number of days’ supply wasted
Jiang et al. 2007,36
retrospective cohorta
Antidepressants (SSRIs),
antihypertensives
(ACEIs), lipid-lowering
agents (statins)
Wastage occurred either
when patients switched to
different medication within
the same class or to similar
medication of a different
strength, so that the
patients’ actual days’
supply was less than the
dispensed days’ supply. The
outcome measured was
the total days’ supply
wasted among a
normalised 30-day period
1 year All classes: mandatory
90 days: 2.5 days per 30-day
period (n= 148); voluntary
90 days: 2.2 days per 30-day
period (n= 582)
All classes: 2.3 days per
30-day period (n= 955)
MD –0.10 (95% CI –0.20
to 0.00)b
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Reference, study
type
Condition(s)/
medication(s)
evaluated
Wastage definition and
calculation (as reported
by the study authors)
Duration
of study
90 days’ supply (unless
otherwise stated)
30 days’ supply (unless
otherwise stated) Effect size
Murphy et al.
2012,32 retrospective
cohort
Antidepressants (SSRIs,
tricyclics), antidiabetics
(biguanides, insulin),
antihypertensives
(alpha-beta blockers,
ACEIs, angiotensin II
receptor antagonists,
calcium channel
blockers, cardioselective
beta-blockers, loop
diuretics, thiazides),
lipid-lowering agents
(HMG CoA reductase
inhibitors, fibric acid
derivatives), thyroid
hormones
Wastage was defined as an
excess days’ supply of
medication resulting from a
switch in medication within
the same therapeutic class
or to the same medication
but of a different strength
occurring before the
expected refill date. The
outcome measured was
the mean number of days
wasted calculated as the
sum of the excess days
divided by the total
number of fills, converted
to 30-day equivalents
1 year Antidepressants: SSRIs:
0.142 days per 30-day
period (SDs not reported)
(n= 3337); tricyclics:
0.147 days per 30-day
period (n= 456).
Antidiabetics: insulins:
0.512 days per 30-day
period (n= 546); biguanides:
0.131 days per 30-day
period (n= 1938).
Antihypertensives:
cardioselective beta-blockers:
0.144 days per 30-day
period (n= 4353); alpha-
beta blockers: 0.202 days
per 30-day period (n = 554);
calcium channel blockers:
0.156 days per 30-day
period (n= 3246); ACEIs:
0.134 days per 30-day
period (n= 4786);
angiotensin II receptor
antagonists: 0.247 days per
30-day period (n = 2224);
loop diuretics: 0.100 days
per 30-day period (n = 556);
thiazides: 0.062 days per
30-day period (n = 1778).
Lipid-lowering agents: HMG
CoA reductase inhibitors:
0.118 days per 30-day
period (n= 10,674); fibric
acid derivatives: 0.079 days
per 30-day period
(n= 1236); thyroid
hormones: 0.383 days per
30-day period (n = 4846)
Antidepressants: SSRIs:
0.157 days per 30-day
period (SDs not reported)
(n = 7969); tricyclics:
0.131 days per 30-day
period (n= 1091).
Antidiabetics: insulins:
0.281 days per 30-day
period (n= 1545);
biguanides: 0.082 days per
30-day period (n= 3429).
Antihypertensives:
cardioselective beta-blockers:
0.087 days per 30-day
period (n= 5458); alpha-
beta blockers: 0.114 days
per 30-day period (n= 934);
calcium channel blockers:
0.127 days per 30-day
period (n= 4249); ACEIs:
0.102 days per 30-day
period (n= 6371);
angiotensin II receptor
antagonists: 0.117 days per
30-day period (n= 2451);
loop diuretics: 0.151 days
per 30-day period
(n = 1179); thiazides:
0.024 days per 30-day
period (n= 2335). Lipid-
lowering agents: HMG
CoA reductase inhibitors:
0.086 days per 30-day
period (n= 10,410); fibric
acid derivatives: 0.079 days
per 30-day period
(n = 1710); thyroid
hormones: 0.252 days per
30-day period (n= 6725)
Antidepressants: SSRIs: MD
0.02 (95% CI –0.03 to
0.06);d tricyclics: MD –0.02
(95% CI –0.06 to 0.03).
Antidiabetics: insulins: MD
–0.23 (95% CI –0.43 to
–0.04); biguanides: MD
–0.02 (95% CI –0.06 to
0.03). Antihypertensives:
cardioselective beta-
blockers: MD –0.06 (95%
CI –0.11 to –0.01); alpha-
beta blockers: MD –0.09
(95% CI –0.20 to 0.03);
calcium channel blockers:
MD –0.03 (95% CI –0.08
to 0.02); ACEIs: MD –0.03
(95% CI –0.07 to 0.00);
angiotensin II receptor
antagonists: MD –0.13
(95% CI –0.24 to –0.02);
loop diuretics: MD 0.05
(95% CI –0.06 to 0.16);
thiazides: MD –0.04 (95%
CI –0.07 to –0.00). Lipid-
lowering agents: HMG
CoA reductase inhibitors:
MD –0.03 (95% CI –0.06
to 0.00); fibric acid
derivatives: MD 0.0
(95% CI 0.00 to 0.00);
thyroid hormones: MD
–0.13 (95% CI –0.24 to
–0.02)
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TABLE 9 Studies that evaluated medication wastage (continued )
Reference, study
type
Condition(s)/
medication(s)
evaluated
Wastage definition and
calculation (as reported
by the study authors)
Duration
of study
90 days’ supply (unless
otherwise stated)
30 days’ supply (unless
otherwise stated) Effect size
Taitel et al. 2012,45
retrospective
cohort with a
cost–consequences
analysis
Antidepressants (SSRIs),
antidiabetics (oral
hypoglycaemics),
antihypertensives,
lipid-lowering agents
(statins)
Defined as a switch of drug
type or strength within the
same therapeutic class that
occurred before the
expected refill date. The
outcome measured was
the average number of
waste days
1 year Antihypertensives:
9.211 days (SD 30.284)e
(n= 5835); statins: 5.757
days (SD 22.205) (n= 2162);
SSRIs: 10.425 days
(SD 32.463) (n= 266);
hypoglycaemics: 7.899 days
per 90-day period
(SD 25.385) (n= 1511)
Antihypertensives:
4.037 days (SD 16.236)
(n = 33,009); statins:
2.251 days (SD 10.673)
(n = 12,136); SSRIs: 3.501
days per 30-day period
(SD 12.941) (n= 7017);
hypoglycaemics: 3.289 days
per 30-day period
(SD 13.441) (n= 11,842)
Antihypertensives: MD
–5.17 (95% CI –5.97 to
–4.38); statins: MD –3.51
(95% CI –4.46 to –2.55);
SSRIs: MD –6.92 (95% CI
–10.84 to –3.01);
hypoglycaemics: MD –4.61
(95% CI –5.91 to –3.31)
Walton 2001,42
cross-sectional study
Lipid-lowering agents
(HMG CoA reductase
inhibitors)
Defined as a switch within
therapeutic class. The
outcome measured was
the mean number of days
wasted, calculated as the
difference between the
average quantity dispensed
and the average quantity
used for each group. If a
switch occurred, the
quantity used was
calculated as the difference
between the date that the
first prescription was
dispensed and the date
that the second, different,
prescription was dispensed
1 year 5.33 days (SD not reported)
(n= 3635)
1.06 days (SD not reported)
‘for each 30-day fill period’
(n = 13.355)
An effect size was not
reported and could not be
calculated. It is not clear
whether or not these
results are standardised for
the same time period;
therefore, it is not clear
whether or not the results
are directly comparable
HMG CoA, 3-hydroxy-3-methylglutaryl coenzyme; MD, mean difference; PPI, proton pump inhibitor; SSRI, selective serotonin reuptake inhibitor.
a Abstract.
b We combined the means from the mandatory and voluntary 90-day groups. SDs were imputed in order to calculate an effect size (based on p> 0.05).
c Numerators have been calculated based on overall sample sizes and percentages.
d SDs were imputed in order to calculate an effect size (p-values were reported for each comparison).
e Means and SDs were obtained from the study authors.
Note
All information in this table is taken directly from the studies indicated in column 1.
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0.84 (0.72 to 0.98)
0.95 (0.85 to 1.05)
Study or subgroup Events Total
30 days
Events Total
90 days Odds ratio
M–H, fixed, 95% CI
Odds ratio
M–H, fixed, 95% CI
Lipid-lowering agents
Taitel et al. 201245
Walton 200142
1014
1909
12,136
13,355
212
545
2162
3635
0.97 (0.89 to 1.06)
Antihypertensives
Taitel et al. 201245 3928 33,009 712 5835
0.90 (0.76 to 1.07)
Antidiabetics
Taitel et al. 201245 1255 11,842 175 1511
0.94 (0.66 to 1.33)
0.5 0.7 1.0 1.5 2.0
Antidepressants
Taitel et al. 201245 975 7017 39 266
Wastage with 
30 days’ supply
Wastage with 
90 days’ supply
FIGURE 5 Studies that assessed the percentage of patients with wasted medication. M–H, Mantel–Haenszel.
–3.51 (–4.46 to –2.55)
Study or subgroup
Mean difference
IV, fixed, 95% CI
Mean difference
IV, fixed, 95% CI
Lipid-lowering agents
Taitel et al. 201245 10.673 12,136 22.205 2162
–5.17 (–5.97 to –4.38)
Antihypertensives
Taitel et al. 201245 16.236 33,009 30.284 5835
–4.61 (–5.91 to –3.31)
Antidiabetics
Taitel et al. 201245 13.441 11,842 25.385 1511
–6.92 (–10.84 to –3.01)
–20 –10 0 10 20
Antidepressants
Taitel et al. 201245 12.941 7017 32.463 266
Wastage with 
30 days’ supply
Wastage with 
90 days’ supply
30 days
SD TotalMean
2.251
4.037
3.289
3.501
90 days
SD TotalMean
5.757
9.211
7.899
10.425
FIGURE 6 Studies that assessed mean days with wasted medication. IV, instrumental variable.
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0.00 (–0.00 to 0.00)
–0.03 (–0.06 to –0.00)
–0.01 (–0.04 to 0.02)
Study or subgroup
Mean difference
IV, random, 95% CI
Mean difference
IV, random, 95% CI
Lipid-lowering agents
Murphy et al. 201232 – fibric acid derivatives
Murphy et al. 201232 – statins
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 5.12, df = 1 (p = 0.02); I2 = 80%
Test for overall effect: z = 0.82 (p = 0.41)
0.0041
1.0203
1710
10,410
12,120
0.0035
1.0332
1236
10,674
11,910
–0.2 –0.1 0.0 0.1 0.2
Wastage with 
30 days’ supply
Wastage with 
90 days’ supply
30 days
SD TotalMean
0.079
0.086
90 days
SD Total
59.8
40.2
100.0
Weight (%)Mean
0.079
0.118
–0.03 (–0.07 to 0.00)
–0.09 (–0.20 to 0.03)
–0.13 (–0.24 to –0.02)
–0.03 (–0.08 to 0.02)
–0.06 (–0.11 to –0.01)
0.05 (–0.06 to 0.16)
–0.04 (–0.07 to –0.00)
–0.04 (–0.06 to –0.02)
Antihypertensives
Murphy et al. 201232 – ACE inhibitors
Murphy et al. 201232 – alpha–beta blockers
Murphy et al. 201232 – angiotensin II receptor antagonists
Murphy et al. 201232 – calcium channel blockers
Murphy et al. 201232 – cardioselective beta-blockers
Murphy et al. 201232 – loop diuretics
Murphy et al. 201232 – thiazides
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 6.64, df = 6 (p = 0.35); I2 = 10%
Test for overall effect: z = 3.70 (p = 0.0002)
0.9578
1.2836
1.9803
1.1081
1.3298
1.3735
0.6282
6371
934
2451
4249
5458
1179
2335
22,977
0.8302
0.9886
1.8864
0.9686
1.1876
0.9432
0.5482
4786
554
2224
3246
4353
556
1778
17,497
0.102
0.114
0.117
0.127
0.087
0.151
0.024
30.6
3.1
3.4
17.1
15.4
3.4
26.9
100.0
0.134
0.202
0.247
0.156
0.144
0.1
0.062
–0.05 (–0.09 to –0.01)
–0.23 (–0.43 to –0.04)
–0.11 (–0.29 to 0.06)
Antidiabetes
Murphy et al. 201232 – biguanides
Murphy et al. 201232 – insulins
Subtotal (95% CI)
Heterogeneity: τ2 = 0.01; χ2 = 3.23, df = 1 (p = 0.07); I2 = 69%
Test for overall effect: z = 1.31 (p = 0.19)
0.8784
2.7515
3429
1545
4974
0.6603
1.6357
1938
546
2484
0.082
0.281
64.1
35.9
100.0
0.131
0.512
0.02 (–0.03 to 0.06)
–0.02 (–0.06 to 0.03)
0.00 (–0.03 to 0.03)
Antidepressants
Murphy et al. 201232 – SSRIs
Murphy et al. 201232 – tricyclics
Subtotal (95% CI)
Heterogeneity: τ2 = 0.00; χ2 = 0.88, df = 1 (p = 0.35); I2 = 0%
Test for overall effect: z = 0.03 (p = 0.98)
1.4283
0.5615
7969
1091
9060
0.9243
0.363
3337
456
3793
0.157
0.131
53.0
47.0
100.0
0.142
0.147
–0.13 (–0.24 to –0.02)
–0.13 (–0.24 to –0.02)
Thyroid hormones
Murphy et al. 201232
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 2.32 (p = 0.02)
3.2802 6725
6725
2.7845 4846
4846
0.252 100.0
100.0
0.383
–0.10 (–0.20 to –0.00)
–0.10 (–0.20 to –0.00)
Mixed classes
Jiang et al. 200736
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 1.99 (p = 0.05)
Test for subgroup differences: χ2 = 11.38, df = 5 (p = 0.04); I2 = 56.1%
1.02 955
955
1.02 730
730
2.3 100.0
100.0
2.4
FIGURE 7 Studies that assessed mean days with wasted medication per 30 days (rate data). For Jiang et al.,36 the means from the mandatory and voluntary 90-day groups were
combined. IV, instrumental variable.
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The data from Taitel et al.45 show that longer prescriptions significantly increase medication wastage
compared with shorter prescriptions for all of the clinical classes evaluated (see Figure 6). Jiang et al.36
reported that the mean number of days with wasted medication was highest for patients who had a
mandatory 90-day supply of (any) medication (2.5 days per 30-day period), followed by a 30-day supply
(2.3 days per 30-day period), and that the mean number of days with wasted medication was lowest for
patients who had a voluntary 90-day supply (2.2 days per 30-day period). However, there was no
significant difference between the groups.36 To estimate the effect size, the two 90-day supply groups
were combined, and a SD was imputed based on a p-value of > 0.05. The data show that wastage was
higher in patients who received a 90-day supply of (any) medication than in those who received a 30-day
supply.36 The results from Murphy et al.32 are less consistent: looking across 14 therapeutic classes, the
results do not significantly favour one prescription length over the other (see Figure 7).32
The data presented by Walton42 on wastage are less clear. It appears that wastage of lipid-lowering
medication was higher in the 90-day supply group than in the 30-day supply group (5.33 days vs. 1.06 days).42
However, based on our reading of the data, it is not completely clear whether or not these two sets of
numbers are standardised to the same time period and, therefore, it is unclear whether or not they are
directly comparable.
Pooled analysis
We conducted an exploratory meta-analysis combining data from three retrospective cohort studies that
measured days of medication supply wasted.32,36,45 The SMDs were pooled for each therapeutic class and
for all classifications (Figure 8). This first required pooling data reported by Murphy et al.32 for each
chemical class, and then pooling these results with those from the other studies that reported data by
therapeutic class. Mean differences with 95% CIs (and SMDs) could not be calculated for three of the
above studies,38,42,48 including two that reported dichotomous data (i.e. percentage of days that medication
was wasted), and so the results of these studies are not included in this analysis.
The overall effect size demonstrates that longer prescriptions are associated with a small but significant
increase in the mean number of days’ supply wasted (SMD –0.15 days, 95% CI –0.23 to –0.08 days;
p < 0.0001), but there was significant statistical heterogeneity between the different studies/comparisons
(τ2 = 0.01; χ2 = 382.90, df = 9; p < 0.00001; I2 = 98%). Given this heterogeneity, the effect size estimate
may not be meaningful, and should, as intended by the original authors, be considered as exploratory.
Quality assessment
Based on a GRADE assessment, the overall quality of the evidence for ‘wastage’ is very low. This
assessment was made because most of the studies that evaluated this outcome did not report enough
information to assess quality, although there was consistency in the direction of effect (where calculable),
and the CIs were generally narrow. There was some evidence of small study effects, which could be
indicative of publication bias. There was also concern regarding the extent to which the evidence
presented is applicable to the UK setting, as all of the studies were conducted in the USA, which has a
very different health-care system from that of the UK. However, we note that two of the studies used
public-funded payers (Medicaid, Veterans Affairs) as their data source.42,45
In summary, current evidence suggests that the proportion of patients with wasted medication does not
differ according to prescription length. However, a longer prescription period (90 days’ supply) shows small
increases in the mean number of days’ supply wasted compared with a shorter prescription period (30 days’
supply), although the results were not always significant. The overall quality of this evidence is very low.
Costs
Costs were reported in five of the included studies.42,44–46,49 Two of the included studies reported cost
comparisons alongside changes in adherence, that is, they conducted a cost–consequences analysis.44,45
The other three studies were cost analyses, as neither adherence nor any other health-related outcomes
were reported.42,46,49
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–0.27 (–0.31 to –0.23)
–0.03 (–0.05 to –0.01)
–0.15 (–0.38 to 0.09)
Study or subgroup Standard mean difference SE Weight (%)
Standard mean difference
IV, random, 95% CI
Standard mean difference
IV, random, 95% CI
Lipid-lowering agents
Taitel et al. 201245
Murphy et al. 201232
Subtotal (95% CI)
Heterogeneity: τ2 = 0.03; χ2 = 83.50, df = 1 (p < 0.00001); I2 = 99%
Test for overall effect: z = 1.24 (p = 0.21)
–0.27
–0.03
0.022959
0.012755
10.2
10.5
20.7
–0.27 (–0.30 to –0.24)
–0.04 (–0.06 to –0.02)
–0.15 (–0.38 to 0.07)
Antihypertensives
Taitel et al. 201245
Murphy et al. 201232
Subtotal (95% CI)
Heterogeneity: τ2 = 0.03; χ2 = 156.33, df = 1 (p < 0.00001); I2 = 99%
Test for overall effect: z = 1.35 (p = 0.18)
–0.27
–0.04
0.015306
0.010204
10.4
10.5
20.9
–0.30 (–0.35 to –0.25)
–0.07 (–0.12 to –0.02)
–0.18 (–0.41 to 0.04)
Antidiabetics
Taitel et al. 201245
Murphy et al. 201232
Subtotal (95% CI)
Heterogeneity: τ2 = 0.03; χ2 = 36.78, df = 1 (p < 0.00001); I2 = 97%
Test for overall effect: z = 1.61 (p = 0.11)
–0.3
–0.07
0.028061
0.02551
10.0
10.1
20.2
–0.49 (–0.61 to –0.37)
0.01 (–0.03 to 0.05)
–0.24 (–0.73 to 0.25)
Antidepressants
Taitel et al. 201245
Murphy et al. 201232
Subtotal (95% CI)
Heterogeneity: τ2 = 0.12; χ2 = 61.33, df = 1 (p < 0.00001); I2 = 98%
Test for overall effect: z = 0.95 (p = 0.34)
–0.49
–0.01
0.061224
0.018112
8.4
10.4
18.8
–0.04 (–0.07 to –0.01)
–0.04 (–0.07 to –0.01)
Thyroid hormones
Murphy et al. 201232
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 2.24 (p = 0.03)
–0.04 0.017857 10.4
10.4
–0.10 (–0.19 to –0.01)
–0.10 (–0.19 to –0.01)
Mixed classes
Jiang et al. 200736
Subtotal (95% CI)
Heterogeneity: not applicable
Test for overall effect: z = 2.06 (p = 0.04)
–0.1 0.048469 9.1
9.1
–0.15 (–0.23 to –0.08)Total (95% CI)
Heterogeneity: τ2 = 0.01; χ2 = 382.90, df = 9 (p < 0.00001); I2 = 98%
Test for overall effect: z = 3.94 (p < 0.0001)
Test for subgroup differences: χ2 = 4.74, df = 5 (p = 0.45); I2 = 0%
100.0
–0.5 0.0 0.5 1.0–1.0
Wastage with 
30 days’ supply
Wastage with 
90 days’ supply
FIGURE 8 Meta-analysis of studies/comparisons that assessed medication waste days. For Jiang et al.36 the means from the mandatory and voluntary 90-day groups were
combined. The analysis is based on three retrospective cohort studies.32,36,45 IV, instrumental variable.
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In all of the studies, costs were reported from the perspective of third-party payers (i.e. public or private sector
insurers), and in one study out-of-pocket costs paid by the patient were also reported.49 These out-of-pocket
costs were payments made by patients for their prescription drugs, depending on their insurance policy, and
did not include any additional costs that might be thought of as out-of-pocket costs in the UK context, such
as travel to the pharmacist. Third-party payer costs in all five studies were based on claims data, and included
the cost of the medication and the dispensing (or filling) fees, although in two studies the inclusion of
dispensing fees had to be assumed as they were not discussed explicitly (e.g. the study by Domino et al.44
included all health-care expenditure for each patient).44,49 Two studies also included the mail-out costs
associated with mail order prescriptions (which are relatively common in the USA).46,49 Three studies included
the cost of drug wastage,42,45,46 and one study included the costs associated with all health-care expenditure
for each patient, as recorded in their Medicaid claims file during the period of observation.44
All of the studies reported costs in US dollars (US$), typically in the year of data collection. However,
Rabbani and Alexander49 adjusted costs to 2005 US$ to account for inflation that occurred during the
relatively long period of data collection (2000–5). None of the studies used discounting to adjust for
differential timing of costs (in economic evaluation, to reflect savings rates and the positive rate of time
preference, it is common practice to place a higher weight on costs that are paid at the present time than
on costs that are to be paid some years in the future). The findings related to each of the cost outcomes
are presented in turn below and summarised in Table 10.
Total costs
Four out of the five studies reported lower costs associated with longer prescription lengths than with
shorter prescription lengths.42,45,46,49 Rabbani and Alexander49 examined the cost savings associated with a
3-month supply by analysing individuals who had received both a 1-month and a 3-month supply within
the same year for the same drug–dose combination. They reported that the total costs per patient were
18% lower when individuals were prescribed longer prescriptions (mean total monthly cost = US$37.95)
than when they were prescribed shorter prescriptions (US$42.72). After controlling for observable
differences between individuals (e.g. demographic, health, insurance and economic status), the mean
monthly cost saving associated with longer prescriptions was US$7.81.49
Conversely, the data presented by Domino et al.44 showed that Medicaid expenditures in all analyses were
higher for 90-day prescriptions than for 30-day prescriptions. Longer prescription lengths were associated
with higher medication costs [ranging from US$25 (antihypertensives) to US$86 (antipsychotics) per
patient per month] as well as with a higher total health-care expenditure [ranging from US$82 (statins)
to US$147 (antidepressants)].
None of the five studies reported a breakdown of the third-party payer costs in terms of the relative
contribution of the cost of the medication and the dispensing (or filling) fees to the total costs.
Only one study42 used a form of sensitivity analysis to address uncertainty in the accuracy of a model
parameter. Three other studies44,45,49 reported some subgroup analyses to examine differences between certain
patient groups44,45,49 or medication types.44,45 Across these four studies42,44,45,49 there were only two specific
scenarios in which the observed effect was in the opposite direction to that reported in the main analyses.42,45
In one scenario, drug costs were based on wholesale drug prices, which were higher than those actually paid
by the insurer,42 and, in the other, analysis was restricted to patients who were new to statin therapy.45 In both
cases, shorter prescriptions were associated with lower costs owing, at least in part, to less drug wastage.
Costs borne by patient
The study by Rabbani and Alexander49 reported lower out-of-pocket costs associated with 90-day
prescriptions than with 30-day prescriptions. In the main analysis, the average monthly out-of-pocket costs
for 90-day prescriptions were US$15.10 (95% CI US$14.68 to US$15.53), compared with US$20.44
(95% CI US$19.99 to US$20.89). These differences were statistically significant and persisted in the
subgroup analyses, which examined the types of drugs that patients had been prescribed (generic or
branded drugs).
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TABLE 10 Studies that evaluated costs
Reference, study
type, setting
Condition(s)/
medication(s)
evaluated
Source of
costs data
Perspective of
study
Costs
measured Units
90-day supply 30-day supply
Difference (90-day compared with
30-day)
Sample size Mean (SD) Sample size Mean (SD) Unadjusted Adjusted
Domino et al.
2011,44 pre–post
controlled study
with a
cost–consequences
analysis, USA
Antidepressants,
antipsychotics,
antihypertensives,
antidiabetics,
seizure disorder
medications,
lipid-lowering
agents (statins)
Medicaid claims
data (obtained
from the
Centres for
Medicare and
Medicaid
Services)
2000–2
Third-party
payer
(Medicaid)
Direct costs
(medication
costs, ‘before
rebates from
manufacturer’)
Costs per
patient in
US$ (year not
reported) after
3 monthsa per
3-month
period
1.0 million
prescription
observations
(165,000 unique
individuals)
NR 1.7 million
prescription
observations
(102,000 unique
individuals)
NR NR bStatins:
+US$94.12**;
diabetes:
+US$114.86**;
antihypertensives:
+US$75.75**;
seizure disorder:
+US$155.25**;
antidepressants
+US$104.61**;
antipsychotics
+US$257.05**
Total
expenditure on
health care as
recorded in their
Medicaid claims
file during the
period of
observation
As above As above NR As above NR NR cStatins:
+US$245.27**;
diabetes:
+US$348.81**;
antihypertensives:
+US$270.32**;
seizure disorder:
+US$288.33**;
antidepressants:
+US$439.98**;
antipsychotics:
+US$279.74**
Parikh et al.
2001,46 cost
analysis, USA
Not reported VASDHS Third-party
payer (VASDHS)
Direct costs
(medication
costs, dispensing
fees and
mail-out costs)
Total costs in
US$ (assumed
1999) over a
90-day period
n= 178,
prescriptions= 346
US$1394 n= 178,
prescriptions= 346
US$3530 –US$2136 (total),
equivalent to
–US$6.17 per
prescription
NA
SYSTEM
A
TIC
REVIEW
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
36
Reference, study
type, setting
Condition(s)/
medication(s)
evaluated
Source of
costs data
Perspective of
study
Costs
measured Units
90-day supply 30-day supply
Difference (90-day compared with
30-day)
Sample size Mean (SD) Sample size Mean (SD) Unadjusted Adjusted
Rabbani and
Alexander 2009,49
cost analysis, USAd
395 medications
for chronic
conditions
2000–5
Medical
Expenditure
Panel Survey
Third-party
payers (including
Medicaid, private
insurance and
Veterans Affairs)
and individuals
(out-of-pocket
costs)
Direct costs
(assumed
included
medication
costs, dispensing
fees and
mail-out costs)
Monthly costs
per patient in
US$ (2005)
n= 2971 individuals,
prescriptions=15,060
US$37.95
(95% CI
US$37.26 to
US$38.64)
n=2971 individuals,
prescriptions=11,792
US$42.72
(95% CI
US$42.01 to
US$43.42)
–US$4.76** –US$7.81**
Individuals only Out-of-pocket
costs
Monthly costs
per patient in
US$ (2005)
US$15.10
(95% CI
US$14.68
to
US$15.53)
US$20.44
(95% CI US
$19.99 to
US$20.89)
–US$5.33** –US$5.91**
Taitel et al. 2012,45
retrospective
cohort with a
cost–consequences
analysis, USA
Antidepressants
(SSRIs),
antidiabetics (oral
hypoglycaemics),
antihypertensives,
lipid-lowering
agents (statins)
California
Medicaid claims
Third-party
payer
(Medicaid)
Direct costs
[medication
costs (including
volume
discounts), and
dispensing fees]
and indirect
costs (drug
wastage)
US$ (assumed
2010) per
person per
year
Antihypertensives:
5835; statins: 2162;
SSRIs: 266;
hypoglycaemics:
1511 (prescriptions)
NR Antihypertensives:
33,009; statins:
12,136; SSRIs: 7017;
hypoglycaemics:
11,841
(prescriptions)
NR Antihypertensives:
–US$10.38;
statins: –US$7.40;
SSRIs: –US$18.48;
hypoglycaemics:
–US$26.13;
overall: –US$13.54
Antihypertensives:
–US$10.80;
statins: –US$7.70;
SSRIs: –US$18.52;
hypoglycaemics:
–US$26.86;
overall: –US$13.95
Walton 2001,42
cross-sectional
study; cost
analysis, USA
Lipid-lowering
agents
VACHCS Third-party
payer
(VACHCS)
Direct costs
(medication
costs and
dispensing fees)
and indirect
costs (drug
wastage)
Average cost
per patient
over 90-day
period in US$
(year not
reported)
13,355 prescriptions US$3.17
(SD NR)
3635 prescriptions US$5.62
(SD NR)
–US$2.45 NR
*p< 0.05; **p < 0.01; ***p< 0.001.
NA, not applicable; NR, not reported; SSRI, selective serotonin reuptake inhibitor; VACHCS, Veterans Administration’s Chicago Health Care System; VASDHS, Veterans Affairs San Diego
Healthcare System.
a Analyses for a longer (18 months) post-intervention follow-up period were also reported; however, this analysis included only 3% (statins) to 18% (hypertension) of patients, as it
excluded users of branded medicines (as these users were affected by a second policy change examined in this study).
b For users of generic medicines, effect sizes for the longer post-intervention follow-up period (18 months) ranged from –US$19 (antihypertensives) to –US$66 (antipsychotics) (per 3-month period).
c For users of generic medicines, effect sizes for the longer post-intervention follow-up period (18 months) ranged from –US$245 (statins) to –US$440 (antidepressants) (per 3-month period).
d Results in this table relate to within-individual analyses. Between-individual analyses were also reported in this study; the results showed that the magnitude of the cost saving associated
with a 3-month medicine supply was larger. (However, there was a risk that these results were biased by unobserved differences between individuals.)
Note
All information in this table is taken directly from the studies indicated in column 1.
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Quality assessment
Based on a GRADE assessment, the overall quality of the evidence for costs is low. This assessment was
made because all of the studies were observational studies and there was inconsistency in the direction of
effect observed. It is probable that this inconsistency was caused, in part, by variation in the quality of
studies. For example, Domino et al.44 used a robust quasi-experimental study design, whereas Parikh et al.46
was based on the hypothetical (rather than observed) cost of shorter prescriptions for a sample of patients
who were prescribed longer prescriptions. We did not conclude that there was any evidence of publication
bias. There was, however, concern regarding the extent to which the evidence presented, which is from the
USA, is applicable to the UK setting, particularly as many patients with long-term conditions in the UK
are likely to be exempted from prescription charges, either because they are aged > 60 years or because of
the nature of their condition.53
In summary, evidence on the relationship between prescription length and costs is inconsistent between
studies. The overall quality of the evidence for the ‘cost’ outcome is low. All studies were US based and
are likely to have limited validity in the UK, where many patients with long-term conditions receive
free prescriptions.
Other outcomes
Three included studies reported on other outcomes.37,41,45 Outcomes included medication persistency,45
number of clinical encounters,37 and number of prescriptions and prescription duration.41
Taitel et al.45 reported on medication persistency, defined as the average number of days on therapy
without a 30-day gap. The authors reported that, across all four clinical classes studied [antihypertensives,
statins, selective serotonin reuptake inhibitors (SSRIs) and hypoglycaemics], persistence was 23% higher in
the 90-day group than in the 30-day group (p < 0.001). Participants in the 90-day group had, on average,
44 more days on therapy than participants in the 30-day group over the 12-month study period.
Controlling for age, gender, number of comorbidities and new-to-therapy status (i.e. patients taking the
drug for the first time) did not affect the results.45 After adjusting for confounders, the greatest difference
in medication persistency was observed for the SSRIs group: medication persistency was 32% higher in the
90-day group than in the 30-day group (p < 0.001).45
In addition to greater adherence among patients with a longer prescription length, Pfeiffer et al.37 reported
that a marginally higher proportion of patients prescribed a longer prescription were more likely to refill
their medication at least once than those prescribed shorter supplies (< 90 days group): 84% and 83%,
respectively (statistical significance was not reported). In addition, a higher proportion of patients in the
shorter prescription group had at least three more clinical encounters than those who received longer
prescriptions in the 90 days after initial diagnosis: 24.9% and 13.7%, respectively (statistical significance
was not reported).
Finally, a retrospective pre–post study (reported in a conference abstract)41 evaluated changes in the
number of prescriptions and the duration of supply following the introduction of 90-day retail dispensing
for patients with diabetes, dyslipidaemia or hypertension.41 The authors reported that 90-day retail
dispensing reduced the number of prescriptions patients filled by an average of 1.2 for antidiabetic drugs,
2.2 for lipid-lowering agents and 4.4 for antihypertensives over an 18-month period. Statistical significance
of the comparisons was not reported for this outcome.41 It is not clear whether this refers to a weighted
average per prescription or to total numbers in the 18-month follow-up.41 The authors did not respond to
our request for further information that would enable interpretation of this finding.
Quality assessment
Based on a GRADE assessment, the overall quality of the evidence for each of the above outcomes was
considered to be very low. There was also concern regarding the extent to which this evidence is
applicable to the UK setting, because all of the studies were conducted in the USA, which has a very
different health-care system from that of the UK.
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Discussion
The systematic review examined the clinical effectiveness and cost-effectiveness of issuing longer versus
shorter duration prescriptions in primary care for patients with stable chronic conditions requiring one or more
repeat prescriptions in terms of patients’ health outcomes and health systems costs. We identified 16 relevant
observational studies, all of which were conducted in the USA. Of the included studies, only one reported
data on a risk factor for health outcomes and five reported on costs. The most commonly reported outcome
was adherence (variously defined), followed by wastage, both of which were based on pharmacy refill data.
There was very limited evidence on health effects associated with different prescription lengths. One
retrospective cohort study, by Batal et al.,39 found that patients receiving a larger quantity of statins at
each fill achieved greater adherence, and that higher adherence was associated with a decrease in final
serum cholesterol level.39 Previous studies have reported an association between increased adherence
and improved health outcomes. For example, a cohort study of patients newly treated with statins in
Quebec, Canada, found that patients with low adherence were more likely to have coronary artery
disease, cerebrovascular disease, and health failure within a 3-year follow-up period.54,55 More generally, a
meta-analysis of 21 studies, involving 46,847 participants with a range of conditions, found a consistent
association between increased adherence and a reduction in all-cause mortality, although good adherence
was found to be associated with healthy behaviours.56 Taken together with the moderate-quality evidence
from nine studies included in this review35–37,39,40,43–45,47 that longer prescriptions increased medication
adherence, this may suggest that increasing prescription lengths could potentially improve clinical
outcomes through increased medication adherence.
There was suggestive evidence from one retrospective cohort study of adults newly diagnosed with
depression that shorter prescriptions may be associated with higher levels of health-care utilisation.37 The
authors do not suggest a reason for this finding. However, given that they found an association between
adherence and prescription length, it could be hypothesised that increased adherence resulted in fewer
adverse events and hence fewer clinical encounters. There is also some evidence from the wider literature
to suggest that improved medication adherence among patients with chronic conditions may reduce
hospitalisation, resulting in a reduction in health-care costs.54,57–59 Conversely, one pre–post controlled
study found that decreasing prescription length was associated with decreased total health-care costs.44
In this study, health-care costs were reduced as a result of lower adherence to medication. The authors
speculated that the changes in adherence may not have been sufficiently large to result in adverse health
outcomes, or that follow-up was not long enough to capture spillover to greater use of other services.
An earlier simulation model, undertaken by the same authors, conducted prior to the introduction of
shorter prescription lengths, predicted that if adherence was unaffected, reducing the days’ supply
would result in increased medication expenditures, because the increased pharmacy dispensing fees would
outweigh the estimated savings from the reduced wastage of drug products.22 This finding is in line with
the other cost studies, which found that lower costs for third-party payers were associated with longer
prescription lengths.42,45,46,49
Longer prescriptions may result in increased wastage; there was very low-quality evidence from five
studies32,36,38,42,45,48 that the proportion of patients with wasted medication did not differ by prescription
length, but that a longer prescription period resulted in small increases in the mean number of days’
supply wasted compared with a shorter prescription period. However, overall, longer prescriptions were
associated with net savings as a result of greater decreases in pharmacy expenditures through reductions
in dispensing fees and drug ingredient costs.42,45 Despite differences in the scale of dispensing fees
between the USA and the UK [US$4.00 (equivalent to £3.83 in 2016)22 vs. £0.9060], similar effects have
been found in the UK; improved prescribing efficiencies may reduce the cost of medications to a level at
which the dispensing fees for monthly fills are greater than the potential wastage of longer fills.7,21 These
findings are in contrast to earlier evidence that restricting prescription lengths in the UK to 28 days would
result in net savings to the NHS owing to decreased medication wastage.12,13
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Only one cost analysis study considered (some of) the costs borne by the patient.49 This study found that
providing a 3-month supply of a prescription drug rather than a 1-month supply reduced patients’ out-of-
pocket expenditure by an average of 29%. Changes in prescription duration may also result in savings by
reducing the frequency of trips to a pharmacy, which may benefit individuals living in rural areas and those
populations for whom access is harder, such as infirm elderly people and people with disabilities.
Limitations of the evidence
All of the studies were conducted in the USA, which has a distinctly different health-care system from that
of the UK, with very different (generally higher) costs. Unlike in the UK, where people receiving repeat
prescriptions do not pay for their medication and where many people are exempt from prescription fees, in
the USA the majority of patients are required by insurance companies to make co-payments. Differences in
prescribing systems could also differentially affect adherence and wastage outcomes. For example, in the
USA, a 3-month supply of medication can be dispensed through mail order, which may reduce dispensing
costs more significantly than in a less automated system,49 although the impact that this has on wastage
is not clear. Murphy et al.32 found less wastage among patients filling retail rather than mail-order
prescriptions, although the difference was not statistically significant. Schmittdiel et al.47 also found greater
adherence among individuals who made greater use of mail order to deliver medications.
Furthermore, the study populations evaluated in these US studies may not be directly generalisable to the
UK population. Two studies were conducted among Medicaid patients,44,45 who, on average, have lower
socioeconomic status than the general population, and four studies were conducted among members of
Veterans health-care systems,37,40,42,46 which serve a population with distinctly different demographics and
health challenges from those of the general population.
Only one of the included studies39 considered the impact of different prescription lengths on clinical
outcomes. Further research is needed on the impact of prescription length on clinical outcomes before any
definite conclusions can be drawn.
There is a lack of evidence on patients’ perspectives of different prescription lengths to inform this review,
and this aspect needs further research. In a study on patients’ perceptions of, and satisfaction with, a
28-day prescribing policy for thyroid hormone, Mitchell et al.23 found widespread dissatisfaction. The most
common reasons cited for being dissatisfied were the inconvenience of having to pick up the prescription/
tablets more frequently, as it interferes with the working day.23 A qualitative study61 that investigated
patients with chronic conditions’ experiences of repeat prescriptions in the NHS found that patients often
described shorter prescriptions as a hassle.61 Respondents reported that managing a repeat prescription
was a time-consuming task. In a response to a call for evidence for the DH’s review of prescription charges
for those with chronic conditions, Katherine White (chair of the Addison’s Disease Self-Help Group)
describes the 28-day prescription policy as disempowering, claiming that it causes anxiety for patients
when they are running low on a prescription, and constrains their ability to travel.62
None of the included studies considered whether or not changing prescription lengths may affect
non-pharmacological interventions, for example a physician’s ability to monitor a condition and
explain non-pharmacological management issues. The impact of prescription length on clinician–patient
relationships warrants further investigation.
All of the studies used indirect measures to assess adherence. The two key measures used were PDC and
MPR. These proxy measures may introduce bias in favour of longer prescriptions. For example, if one
patient receives a 90-day supply of medication and another is prescribed a 30-day supply, but both stop
taking their medication after 14 days, at 90 days pharmacy refill adherence may be calculated as 100% for
the first patient and 33% for the second patient. It is also possible that results may differ by the type of
measure used, as the PDC has been found to provide a more conservative estimate of adherence than the
MPR, and thus may underestimate effectiveness compared with the MPR.63
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Furthermore, refill adherence may not reflect actual medication adherence, as it assumes that medication is
being taken exactly as prescribed.64,65 For example, a patient who takes half of the recommended daily
dose of their medication for all days in a month will have the same PDC as a patient who takes the correct
daily dose for only half the days in the month (PDC = 0.5 in both cases).44 In addition, refill data do not
capture instances of patients self-discontinuing by not refilling their prescriptions. A review of methods for
assessing refill compliance, however, has determined that indirect measures can nevertheless be ‘a useful
source of compliance information’.66
None of the studies explored reasons why adherence may differ between prescription lengths. Reasons for
medication non-adherence are often complex. Non-adherence can be either intentional (e.g. when a
patient actively deviates from the treatment regimen stemming from their health beliefs) or non-intentional
(e.g. passive deviation as a result of carelessness or forgetfulness).67 Some study authors have suggested
that longer prescription lengths may facilitate greater adherence, as longer prescriptions overcome barriers
to non-intentional adherence such as enabling patients to follow a regular medicine regimen39,40 and
reducing logistical barriers such as trips to the pharmacy.43 However, all of the included studies were
observational, and no participants were randomly assigned to the different prescription durations. As such,
the majority of studies are at risk of selection bias owing to systematic differences between patients who
received a longer or shorter prescription. Pfeiffer et al.37 reported that patients who received a 90-day
medication supply were more likely to be treated in primary care settings and to have fewer prior or
subsequent outpatient visits, suggesting that patients who receive longer prescriptions may have more
stable illnesses. Rabbani and Alexander49 also found that men were more likely to receive longer
prescriptions than women, and that white patients were more likely to receive longer prescriptions than
patients from other ethnic backgrounds.
It was not clear from the evidence if differences in drug item prices had an impact on the relationship
between prescription lengths and costs to the health system. Parikh et al.46 restricted their analysis to the
less expensive medications (no more than US$1.50 per day). The authors comment that, for this reason,
cost savings might not be generalisable to more expensive medications the costs of wastage of which
would have been more substantial. This resonates with a UK commentary in which Hickey et al.68
argue that for lower-cost medication such as levothyroxine tablets (which are commonly used to treat
hypothyroidism) with a standard dispensing fee of £0.90 per item, the NHS could save > £7M per year if
28-day prescribing were replaced with 4-monthly prescriptions.
None of the studies considered time spent and cost borne by the prescriber, administrator or pharmacist to
write, process and deliver the prescription, although dispensing fees, which may be seen as paying for
that time/cost, were sometimes taken into account. More research is needed to understand the impact of
prescribing policy on professionals’ workloads and incomes.
Six out of 16 included studies were commissioned or funded by private providers, pharmacies or insurers
(i.e. Walgreens,32,36,45 Accredo Health Group,48 Prime Therapeutics LLC35 and Kaiser Permanente47). It is
possible that such funding may have had an influence on the formulation of the research questions, and,
to some extent, on the findings. For example, it may have introduced a publication bias and had an impact
on the choice of outcomes in favour of wastage or costs over clinical outcomes.
The majority of studies were retrospective cohort studies based on secondary analysis of administrative
data. The use of administrative data limits the quality of the analysis, as there is no control over the types
of patients included in the dataset, and we cannot validate how the data were collected and recorded.69
As such, underlying confounding as a result of selection bias limits the strength of the conclusions that can
be drawn. The negative consequences of reliance on cohort data are highlighted by research into hormone
replacement therapy, with early evidence based on cohort studies later disproved; the study population
was healthier, better educated and from higher socioeconomic backgrounds and had better access to
health care than the control group.70
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Limitations of the review
Although we followed rigorous systematic review methodology, it is possible that some bias may have
been introduced during the review process. For example, some changes to the protocol were made,
including the decision to exclude studies that did not evaluate patients with non-chronic diseases, such as
patients receiving repeat prescriptions for contraception. This decision was made because of the higher
than expected number of studies that evaluated patients with chronic conditions, which were directly
applicable to our systematic review research questions. It is possible, however, that some valuable data
may have been missed through making this decision. In addition, we stated in the protocol that we would
include only patients treated in primary care settings, but then decided to include some studies in which
the setting was unclear, or in which some patients may have received treatment in an outpatient setting.
We made this decision to be inclusive but, as a result, some of these studies may not be directly applicable
to primary care settings. We note, however, that the results from all of the studies appear to be consistent
regardless of setting.
It is also possible that we may have missed evidence by restricting the inclusion/exclusion criteria to studies that
evaluated 28-day versus 3-month prescriptions, or close to these prescription lengths. Studies were identified
in the literature that evaluated other prescription lengths (e.g. Wong et al.24), and data from different
prescription lengths could have helped to inform a model that evaluates an optimal prescription length.
We decided to use the ROBINS-I quality assessment tool, a very recent tool that was published in 2016.
This tool did not capture some biases specific to retrospective studies, such as whether or not there was
bias in the selection of the study cohort, and for this reason we used the accompanying guidance to
critically appraise the risk of bias in each category, but did not always apply the full list of questions.
However, in our study, the results obtained using this tool were similar to those obtained with other
quality assessment measures (e.g. the Newcastle–Ottawa scale52). It appears that the GRADE quality
assessment, in any case, appropriately reflected the overall evidence, and we are confident in these
assessments.
While conducting this review, we also found that some studies included only patients who were new to
treatment, or presented subgroup results for patients who were new to treatment compared with those
who had existing prescriptions. Other studies did not report this information. We did not distinguish
between these population groups in our analyses because this distinction was not considered at the
protocol stage, and because there were not enough studies that reported this information to carry out a
post hoc subgroup analysis. It would be helpful if future studies reported this type of information to
facilitate analysis.
In this review, a number of the included studies presented data by type of chemical class or by therapeutic
class. We did not attempt to compare across therapeutic class, as this was not the remit of the review and
direct comparisons between the effect sizes for different therapeutic classes cannot be made. It does appear
that there may be some differences between therapeutic classes, and this merits further investigation.
Finally, for six35,36,38,41,46,48 out of the 16 included studies, only an abstract or extended abstract was
available and, despite our attempts to contact the authors, no further publications were available. Full peer
review of the quality of the studies was not possible for five of the abstracts,35,36,38,41,48 and the lack of
detailed findings from these six studies limits the overall conclusions that can be drawn. The decision to
include abstracts was based, in discussion with our expert advisors, on the paucity of high-quality data
identified and our decision to be as inclusive as possible.
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Chapter 3 Cost analysis based on available
secondary data
Introduction
We undertook a cost analysis of Clinical Practice Research Datalink (CPRD) data to estimate the cost of
medication wastage associated with shorter and longer prescriptions lengths for five case study conditions.71
In order to estimate the net cost impact of shorter and longer prescriptions lengths, the costs of dispensing
fees and prescribers’ time to issue a prescription were also assessed.
Clinical Practice Research Datalink is a large, longitudinal, primary care data set, comprising routinely
collected, anonymised, electronic health record data from GPs within the NHS in the UK.72 Data are
collected from > 650 general practices and include > 79 million person-years of follow-up, representing
approximately 7% of the UK population. Comparisons between the UK census and CPRD have shown
that patients within the data set are broadly representative of the UK population in terms of age, sex and
ethnicity,72,73 but may not be representative of all practices in the UK based on geography and size.74
Information captured broadly includes demographics, clinical events (symptoms, diagnoses), specialist
referrals, immunisations, laboratory tests and prescription details. Data are also quality checked for
continuity and completeness at both the patient and the practice level. CPRD has been extensively used for
research purposes, including numerous pharmacoeconomic studies.75
This chapter is structured as follows: the first section sets out the objectives of the cost analysis (see
Objectives), the second section describes our methods (see Methods), and our findings are presented in
the third section (see Results); these are then discussed in the final section (see Discussion).
Objectives
The objective of the cost analysis was to estimate differences in the costs of medication wastage and the
additional impact of assessing the costs associated with dispensing fees and prescriber time in patients
receiving medications within the NHS in the UK as either short or long prescription lengths for five
common chronic conditions.
Methods
This retrospective multicohort study evaluated medication wastage and the associated cost of wastage,
dispensing fees, and the cost associated with the time needed to issue a prescription [i.e. how long it takes
a GP to complete the technical process of producing a prescription (note that this does not include clinical
decision-making time or administrative staff time)] in five, condition-specific, random samples of 50,000
patients each, obtained from CPRD. The five samples were derived from all adult patients (aged ≥ 18 years)
receiving one or more prescriptions relevant to a case study condition of interest (Table 11) during the
11-year period between 1 January 2004 and 31 December 2014. The five full samples (i.e. all relevant
prescriptions for each of the five conditions over the 11-year study period available in CPRD) were restricted
to patients with complete data for two variables [numeric daily dose (ndd) and quantity (qty)] required for
the analysis to create five limited samples. The ndd variable is derived using a CPRD algorithm on common
dosage text strings, and has the potential to be equal to zero in cases where the dosage text string is
non-specific or otherwise impossible to accurately quantify (e.g. ‘apply as needed’). The qty variable refers
to the total quantity intended to be dispensed for that specific prescription. The analysis was, therefore,
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limited to patients with complete data (i.e. ndd is not missing or equal to zero and qty is not missing
or equal to zero). This approach has been employed in other similar CPRD studies using these two
variables.77,78 Random samples of 50,000 patients from these limited samples were then taken to form the
five main analysis samples (Table 12). Product codes (CPRD unique code for treatment selected by the GP)
associated with relevant prescriptions used in the treatment of five case study conditions were used to
select the patients to be included in the samples. The five conditions of interest were:
1. glucose control with oral drug therapy in type 2 diabetes mellitus (T2DM)
2. treatment of hypertension in T2DM
3. treatment with statins (lipid management) in T2DM
4. treatment for the secondary prevention of myocardial infarction
5. depression.
These conditions were selected for study based on their chronic nature, the frequency of their occurrence
in the population and the potential for a variety of expected frequencies in prescription changes over the
course of their treatment.
Relevant prescriptions for each of the five conditions were first identified based on a review of NHS clinical
guidelines and the BNF.79–82 Product code lists were then developed by one author (BD) using CPRD
Research Applications Code Browser Version 3.0.0 (CPRD and Medicines and Healthcare products
Regulatory Agency, London, UK) and subsequently assessed for accuracy, completeness and clinical
relevance by one of the study authors (RP), who is a GP. The definitions of the relevant prescriptions and
product code lists of the potentially prescribed medications for each of the five case study conditions are
provided in Table 11 and Appendix 5, respectively.
TABLE 11 Case study conditions and associated prescriptions
Condition Relevant prescriptions
(1) Glucose control with oral drug
therapy in T2DM
Patients receiving one or more prescriptions for any oral antidiabetic drug listed
under BNF section 6.1.2, Antidiabetic drugs,76 in any year from 2004 to 2014
(2) Treatment of hypertension in
T2DM
In addition to receiving an oral antidiabetic drug as defined in (1), patients
receiving one or more prescriptions for any ACEIs, angiotensin II receptor
antagonists, calcium channel blockers, beta-adrenoceptor blockers, alpha-
adrenoceptor blockers, potassium-sparing diuretics and/or thiazide-like diuretics in
any year from 2004 to 2014
(3) Treatment with statins (lipid
management) in T2DM
In addition to receiving an oral antidiabetic drug as defined in (1), patients
receiving one or more prescriptions for any statin in any year from 2004 to 2014
(4) Treatment for the secondary
prevention of myocardial infarction
In addition to receiving concurrenta prescriptions for an ACEI, antiplatelet and
statin for a duration of ≥ 1 year, patients receiving one or more prescriptions for
any beta-adrenoceptor blockers and/or angiotensin II receptor antagonists in any
year from 2004 to 2014
(5) Depression Patients receiving one or more prescriptions for any antidepressant drug listed
under BNF section 4.3, Antidepressant drugs,76 in any year from 2004 to 2014
BNF, British National Formulary; T2DM, type 2 diabetes mellitus.
a All patients receiving at least one prescription for an ACEI, antiplatelet drug and statin were first identified in CPRD. Any
patient from this sample who did not have at least four prescriptions (chosen to represent 1 year of therapy) for each of
these drugs in at least one of the 11 years of data available (i.e. 2004 to 2014) were excluded. From the remaining
patients the additional constraint of receiving one or more prescriptions for any beta-adrenoceptor blockers and/or
angiotensin II receptor antagonists was applied to define the full sample.
Reproduced from Doble et al.71 © Article author(s) (or their employer(s) unless otherwise stated in the text of the article)
2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article
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to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited.
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TABLE 12 Data processing of the five cohorts
Condition
Full
sample
(patients)
Full
sample
(obs)
ndd= 0
or qty= 0
(patients)
ndd= 0
or qty= 0
(obs)
Limited
samplea
(patients)
Limited
samplea
(obs)
Random
sample
(patients)
Random
sample
(obs)
Dropped
prescription
errorb (obs)
Final
sample
(obs)
Same day
switches not
wastagec
(obs)
Glucose control with
oral drug therapy in
T2DM
310,391 21,091,529 170,967 4,518,765 139,424 7,135,397 50,000 2,577,282 6483 2,570,799 548,850
Hypertension in T2DM 230,760 23,886,597 63,802 1,446,199 166,958 16,041,452 50,000 4,803,444 3983 4,799,461 1,588,921
Lipid management in
T2DM
242,741 13,388,759 36,577 776,718 206,164 11,216,086 50,000 2,718,216 913 2,717,303 NA
Secondary prevention
of myocardial
infarction
208,682 44,151,527 87,281 3,270,504 121,401 24,479,014 50,000 10,131,377 767 10,130,610 5,856,361
Depression 1,207,523 32,744,994 424,446 4,438,319 783,077 15,712,941 50,000 1,010,463 3234 1,007,229 12,401
NA, not applicable; obs, observations.
a The limited sample consists of all patients who have received at least one of the relevant prescriptions for a case study condition and do not have any missing or observations equal to
zero for both the ndd and qty variables.
b Prescriptions issued on the same day for medications in the same class and with different product codes (e.g. two different SSRIs or two different statins) were considered prescriber error
and dropped from the analysis.
c Prescriptions for medications with similar clinical indications from different classes issued on the same day were assumed not to incur wastage owing to a treatment switch, but rather
were assumed to be an add-on to therapy or concomitant therapy.
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Treatment patterns evaluated
Treatment patterns were evaluated in each of the five cohorts in a similar manner. Data for each patient
were first ordered in sequence from earliest to latest prescription date. To identify treatment patterns,
three main variables were used: (1) product code (CPRD unique code for treatment selected by the GP;
this is unique to individual brands, formulations, strengths, etc.); (2) drug substance code (derived from
‘drugsubstance’ variable and used to identify different dosages and/or formulations of the same drug
chemical substance); and (3) drug class code [derived from ‘bnfcode’ variable and used to identify drugs
with different chemical compositions, but a similar mechanism of action based on their categorisation in
the BNF (e.g. SSRIs)]. Next, four different types of treatment patterns that may occur in a sequence of
prescriptions were identified for each patient over the course of their available follow-up, namely:
1. refills of the same product
i. product, drug substance and drug class codes are the same for two prescriptions in sequence, for
example two prescriptions for metformin 500-mg tablets
2. substitutions between different dosages or formulations of the same drug substance
i. product codes are different, but drug substance and drug class codes are the same for two
prescriptions in sequence, for example a switch in dosage for the same statin (atorvastatin 10-mg
tablets to atorvastatin 40-mg tablets)
3. substitutions between drugs that are in the same class
i. product and drug substance codes are different, but drug class codes are the same for two
prescriptions in sequence, for example a switch from one statin (atorvastatin 40-mg tablets) to
another statin (simvastatin 40-mg tablets)
4. substitutions between drugs that have similar clinical indications from different classes (e.g. different
drugs used in the secondary prevention of myocardial infarction)
i. product, drug substance and drug class codes are different for two prescriptions in sequence, for example
a switch from an ACEI (captopril 25-mg tablets) to calcium channel blocker (amlodipine 10-mg tablets).
The volume of medication wastage from early refills and treatment switches (defined as a repeat
prescription or new prescription based on the mapped substitutions outlined above, respectively, being
issued prior to the expiry of the previously prescribed quantity) was estimated for prescriptions within the
11-year study period (i.e. any prescriptions not falling within this time period were excluded from the
analyses). This was done by dividing the total qty entered by the GP for the prescribed product by the ndd
prescribed for the event and comparing this with the difference in the two dates associated with the event
and the next prescription in the sequence. Prescriptions issued on the same day for drugs in the same class
and with different product codes (e.g. two different statins) were considered prescriber error and dropped
from the analysis (see column 9 in Table 12). The one exception to this was for antiplatelet drugs in the
secondary prevention of myocardial infarction cohort, as it was assumed that two different antiplatelet
drugs could be prescribed at the same time. In addition, prescriptions for medications with similar clinical
indications from different classes issued on the same day were counted not as a switch, but rather as an
add-on to existing therapy or concomitant therapy (see column 11 in Table 12).
Analysis of medication wastage
As treatment patterns were assessed in sequence, there was the potential to overstate the amount of
wastage that occurred. For example, counting every overlap of prescription days associated with refills of
the same product as wastage (i.e. even prescriptions issued 1 day before the expiry of the previous
prescription would be counted as 1 day’s worth of medication wastage, and two prescriptions issued on
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the same day would count as one prescription as entirely wasted) may overstate actual wastage. A
threshold of 1 year after the initial prescription in a particular series was, therefore, used to estimate
wastage for early refills (i.e. repeat prescriptions), in that any product prescribed over and above the
expected quantity to be consumed within the 1-year time period was considered waste. This is to account
for the fact that patients may fill their prescriptions before their existing supply is exhausted, but still
consume all of the previous prescription before using the new supply.
In addition, although excessive switching of drugs could appear to be wastage, consistent patterns could
suggest a valid, prescribed treatment regimen. To avoid the overestimation of wastage, additional effort
was made to differentiate between add-ons/concomitant therapy and switches for medications with similar
clinical indications from different classes (i.e. product, drug substance and drug class codes are different for
two prescriptions in sequence). Generally, if the difference between the number of changes between
medications with similar clinical indications from different classes and the number of unique drug classes
within an annual period was ≥ 1, then any overlap in prescription dates was not considered wastage as a
result of a switch, but rather as an add-on or concomitant therapy. For example, within an annual period,
a patient may have six changes between clinically related drugs from different classes, but these changes
are only between two different drugs from different classes (i.e. two unique drug classes). As six minus
two is greater than one, these changes were considered not switches, but rather add-on/concomitant
prescriptions. The rationale for this was that, if the number of changes was large, but the number of
unique drugs involved in the changes was low, an add-on or concomitant therapy was being prescribed,
whereas if the number of changes was large and the number of unique drugs involved in the changes was
also large, switches in therapies were occurring and therefore there was the potential for wastage to
occur. A similar approach was applied by Taitel et al.,45 and theirs is the only previous study that has
attempted to differentiate between add-on/concomitant prescriptions and actual switches in therapy.
Additional constraints in counting overlaps in dates for two prescriptions in sequence for medications with
similar clinical indications from different classes were also applied in three of the case study conditions
owing to the potential for a number of the included therapies to be given concomitantly. For the glucose
control in T2DM cohort, overlaps in prescription dates involving metformin with drugs from other classes
were not counted as switches (and therefore wastage), as metformin is usually administered in
combination with other classes of oral antidiabetics.79 For the treatment of hypertension in T2DM cohort,
overlaps in prescription dates involving ACEIs and angiotensin II receptor antagonists with either calcium-
channel blockers or thiazide-like diuretics were not counted as switches, as these therapies are commonly
administered together as second-line therapy.76 Finally, for the secondary prevention of myocardial
infarction cohort, only overlapping prescription dates involving beta-blockers and angiotensin II receptor
antagonists were counted as switches, as patients are likely to receive the other classes of drugs included
in the analysis (ACEIs, antiplatelet drugs and statins) continuously over the course of treatment.81
Costs
To estimate the costs of wastage, defined daily doses (DDDs) associated with each drug substance code
in the five cohorts were first obtained from the World Health Organization’s Anatomical Therapeutic Chemical
(ATC)/DDD Index 2016.83 The NHS Business Services Authority’s prescription cost analysis (PCA) 2015,84
which provides details of the quantity of individual doses and NICs of all the prescriptions in England, was
then used to determine a NIC/quantity value of a specific strength of the medication associated with each
drug substance code. This value was then standardised using the associated DDD to obtain a cost per day for
each drug substance code in all five of the cohorts. Details of these calculations are provided in Appendix 6.
The dispensing fees from the Drug Tariff [£0.90 per standard prescription and 2% of the cost per prescription
(cost per day multiplied by prescription length) for prescriptions over £100]84 and the estimated cost for a
physician to issue a prescription based on the literature were then determined for each prescription. A targeted
literature review was designed (see Appendix 7 for search strategy and study selection details) to determine
the time involved for a physician to issue a prescription (i.e. how long it takes a GP to complete the technical
process of producing a prescription; note that this does not include clinical decision-making time or
administrative staff time). It should be noted that none of the identified studies from the targeted literature
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review reported the time involved for a physician to issue a prescription from a UK-specific primary care
context. It was therefore necessary to prioritise the use of the available evidence for this parameter based on
studies with the largest sample sizes and those studies reporting prescriber time for different types of
prescriptions (e.g. new vs. renewals). Refills were assigned a shorter time than changes in dose/formulation,
within drug classes and between drug classes (48.7 seconds vs. 61.2 seconds).85 Per minute costs related to
GPs’ time (£3.80/minute), derived from the Personal Social Services Research Unit’s (PSSRU’s) Unit Costs of
Health and Social Care, were then applied.86 All costs are reported in 2015 Great British pounds (GBP).
Statistical analysis
Descriptive analyses of trends in treatment switching and early refills were used to assess medication
wastage. The proportion of days’ supply wasted, the mean number of days’ supply wasted and the mean
costs of wastage per prescription were determined for two prescription lengths (< 60 and ≥ 60 days, used
to proxy 28-day and 3-month prescriptions, respectively) over the 11-year period (2004–14). The mean cost
of wastage per prescription was reported for each of the four treatment patterns individually over the
11-year study period and combined for each annual period. Two-sample t-tests using groups (prescription
lengths < 60 days and ≥ 60 days) assuming unequal variance were used to compare the differences
between the < 60 days and ≥ 60 days groups. This statistical test was chosen despite the potential for
skewed data (i.e. costs) because our interest was in testing the arithmetic means and not other
characteristics of the distribution (e.g. log transforming data tests for equality of geometric means).
To determine and compare the total unnecessary costs (TUCs) (costs of medication wastage, dispensing
fees and prescriber time) associated with prescription lengths < 60 days and ≥ 60 days, a model originally
used by Walton42 was adapted and applied to the prescription data from the five cohorts. The model
incorporates the quantity (Q) of medication wastage (where Qdays wasted = Qdays supplied –Qdays used) and the cost
(C) of medication wastage (where Cwastage = Cdrug/day × Qdays wasted) as well as the cost of dispensing a
prescription (Cdispensing) and the cost of prescriber time associated with issuing a prescription (Cprescriber time) to
estimate the TUC. To compare the TUCs between different prescription lengths (< 60 and ≥ 60 days), it
was necessary to standardise the time period over 90 days. The TUCs for the two prescription lengths were
then calculated using the two equations below:
TUC<60 ¼ (Cwastage<60 + Cdispensing<60 + Cprescriber time<60) × (90/Qdays used<60)− (Cdispensing<60 + Cprescriber time<60) (3)
TUC¸60 ¼ (Cwastage¸60 + Cdispensing¸60 + Cprescriber time¸60) × (90/Qdays used¸60)− (Cdispensing¸60 + Cprescriber time¸60). (4)
The terms (90/Qdays used< 60) and (90/Qdays used≥60) standardise the total costs over a period of days (90 days)
and Cdispensing and Cprescriber time are subtracted to reflect that one dispensing fee and prescriber time costs for
one prescription will be incurred for each set period of days (90 days). Each value used in the equations
represents a mean calculated for the entire group of patients for each prescription length in each of the
five cohorts over the 11-year study period. Mean values for the base case analysis are reported in Table 13.
An example scenario is provided in Box 2 to highlight how the model compares the TUCs for prescription
lengths < 60 days and ≥ 60 days over a standardised period of 90 days.
One-way sensitivity analyses were conducted to examine differences in TUC under a variety of different
scenarios, including exclusion of prescriber time costs, ± 50% mean days wasted, ± 50% of the mean cost
of drugs per day, dispensing fees and prescriber time.
All statistical analyses were preformed using Stata®/MP 13.1 (Stata Corp LP, College Station, TX, USA).
The protocol (16_117R) for this study was approved on 21 June 2016 by the Independent Scientific
Advisory Committee (ISAC), the independent body that approves the use of CPRD data.
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Results
Overall cohort selection
Full samples for the five cohorts ranged in size, with four of the cohorts having a similar number of patients
(range 208,682–310,391) and the depression cohort being much larger (1,207,523 patients) (see Table 12,
column 1). The number of observations varied from 13,388,759 in the lipid management cohort to
44,151,527 in the secondary prevention of myocardial infarction cohort (see Table 12, column 2). The
proportion of patients dropped from the full sample to create the limited sample owing to missing or
observations equal to zero in either the ndd or qty variables was quite substantial, ranging from 15% for
the lipid management cohort to 55% for the glucose control in T2DM cohort. The impact on the proportion
of observations was, however, much smaller, ranging from 6% in both the lipid management and
hypertension cohorts to 21% in the glucose control in T2DM cohort. Taking random samples from the
BOX 2 Example comparing TUC for prescription lengths < 60 days and ≥ 60 days for a standardised time period of
90 days
Assume that, on average, the prescription length < 60 days is 35 days and the prescription length ≥ 60 days is
120 days. Also assume that, regardless of prescription length, patients on average switch their prescription
30 days after a prescription is issued. The quantity used is, therefore, 30 days for both prescription lengths
(Qdays used<60 =Qdays used≥60 = 30), but the quantity wasted is much larger for the ≥ 60 days prescription (90 days
wasted compared with only 5 days wasted). Because over a 90-day period both prescription lengths will incur
the same dispensing fees and prescriber time costs (three prescriptions will be issued regardless of prescription
length as a switch occurs every 30 days), the ≥ 60 days prescription will be associated with higher TUCs.
Note that this example has been developed by adapting an example provided by Walton42 to the prescription
lengths considered in our study.
Reproduced from Doble et al.71 © Article author(s) (or their employer(s) unless otherwise stated in the text of the
article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an
Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0)
license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
TABLE 13 Mean values used in the comparison of total costs
Parameters
Glucose
control with
oral drug
therapy T2DM
Hypertension
in T2DM
Lipid
management
in T2DM
Secondary
prevention of
myocardial
infarction Depression
< 60
days
≥ 60
days
< 60
days
≥ 60
days
< 60
days
≥ 60
days
< 60
days
≥ 60
days
< 60
days
≥ 60
days
Mean days used
(Qdays used)
31.61 75.72 32.51 86.91 32.74 122.71 31.41 102.28 27.43 65.03
Mean days wasted
(Qdays wasted)
0.86 4.96 1.23 6.98 0.63 16.21 0.96 6.56 1.87 2.69
Mean drug cost per
day (£) (Cdrug/day)
0.36 0.28 0.084 0.082 0.10 0.10 0.074 0.068 0.14 0.11
Mean dispensing fee
cost (£) (Cdispensing)
0.92 1.05 0.90 0.93 0.90 1.00 0.90 0.97 0.91 0.96
Mean prescriber time
cost (£) (Cprescriber time)
0.36 0.28 3.54 3.55 3.12 3.15 3.76 3.77 3.23 3.18
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limited samples resulted in the number of observations from each cohort ranging from 1,010,463 for the
depression cohort to 10,131,377 for the secondary prevention of myocardial infarction cohort (see Table 12,
column 8). The numbers of observations were slightly reduced after accounting for prescription error
(i.e. prescriptions issued on the same day for medications in the same class with different product codes
were dropped from the sample) (see Table 12, column 9). A number of prescriptions for medications with
similar clinical indications from different classes issued on the same day were also identified, ranging from
12,401 for the depression cohort to 5,856,361 in the secondary prevention of myocardial infarction cohort;
these were assumed to represent add-ons or concomitant therapy, and therefore were not counted as
wastage despite overlapping dates (see Table 12, column 11).
Medication wastage
Over the 11-year study period, there was a statistically significant difference in the proportion of days’
supply wasted, the mean number of days’ supplied wasted and the mean cost of wastage per prescription
between the shorter (< 60 days) and longer (≥ 60 days) prescription groups for all five of the case study
conditions (Table 14). The proportion of days’ supply wasted was consistently larger for the ≥ 60 days
groups across the case study conditions, with the exception of the depression cohort, in which the
< 60 days group wasted 6.3% of days’ supply wasted, compared with 3.7% in the ≥ 60 days group.
The mean number of days’ supply wasted was also consistently larger for the ≥ 60 days groups, but the
difference between the two prescription length groups was much smaller for the depression cohort than
for the other four cohorts. The mean cost of wastage per prescription was the largest for the ≥ 60 days
groups for the glucose control and lipid management cohorts and largest for the < 60 days groups for the
glucose control and depression cohorts. Similar mean costs of wastage per prescription were observed for
the ≥ 60 days groups (range 0.43–0.51) and < 60 days groups (range 0.05–0.09) in the other cohorts.
Medication wastage by treatment pattern
In four out of the five case study conditions, all four treatment patterns resulted in a statistically significant
difference in the mean cost of wastage per prescription between the two prescription lengths (Table 15).
The one exception was for the depression cohort, in which the mean cost of wastage per prescription
for both dosage/formulation and within-class treatment switches did not show statistically significant
differences between the two prescription length groups. The refill treatment pattern consistently had
the largest mean cost of wastage per prescription across the case study conditions, particularly for the
≥ 60 days groups. The one exception was for the depression cohort that also had similarly large mean
costs of wastage per prescription for the dosage/formulation switch treatment pattern compared with the
refill treatment pattern. The lowest mean cost of wastage per prescription was consistently observed for
the between-class switch treatment (switches between medications with similar clinical indications from
different classes) pattern across all case study conditions reporting these values. Note that the lipid
management cohort did not report any between-class treatment switches, as all medications included in
the analysis were from the same class of statins. Low mean costs of wastage per prescription were also
TABLE 14 Comparison of medication wastage over 11-year period 2004–14
Condition
Proportion of days’
supply wasted (%)
Mean number of days’
supply wasted (days)
Mean cost of wastage
per prescription (2015 £)
< 60
days
≥ 60
days p-value
< 60
days
≥ 60
days p-value
< 60
days
≥ 60
days p-value
Glucose control with oral
drug therapy in T2DM
2.7 4.9 < 0.001 0.86 4.96 < 0.001 0.33 1.37 < 0.001
Hypertension in T2DM 3.8 5.0 < 0.001 1.23 6.98 < 0.001 0.09 0.44 < 0.001
Lipid management in T2DM 1.7 4.1 < 0.001 0.63 16.21 < 0.001 0.05 1.43 < 0.001
Secondary prevention of
myocardial infarction
3.3 3.7 < 0.001 0.96 6.56 < 0.001 0.07 0.51 < 0.001
Depression 6.3 3.7 < 0.001 1.87 2.69 < 0.001 0.21 0.43 < 0.001
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TABLE 15 Comparison of the mean cost of medication wastage per prescription over 11-year period 2004–14 by treatment pattern (2015 £)
Condition
Mean cost of refill wastage
per prescription
Mean cost of dosage/
formulation switch wastage
per prescription
Mean cost of within-class
treatment switch wastage
per prescription
Mean cost of treatment
between-class switch wastage
per prescription
< 60 days ≥ 60 days p-value < 60 days ≥ 60 days p-value < 60 days ≥ 60 days p-value < 60 days ≥ 60 days p-value
Glucose control with oral
drug therapy in T2DM
0.23 1.03 < 0.001 0.06 0.17 < 0.001 0.03 0.10 < 0.001 0.009 0.06 < 0.001
Hypertension in T2DM 0.05 0.27 < 0.001 0.04 0.13 < 0.001 0.004 0.013 < 0.001 0.003 0.03 < 0.001
Lipid management in T2DM 0.02 1.10 < 0.001 0.02 0.15 < 0.001 0.008 0.17 < 0.001 NA
Secondary prevention of
myocardial infarction
0.04 0.44 < 0.001 0.01 0.04 < 0.001 0.009 0.029 < 0.001 0.00005 0.0006 < 0.001
Depression 0.04 0.21 < 0.001 0.15 0.14 NS 0.01 0.01 NS 0.01 0.06 < 0.001
NA, not applicable; NS, not significant at p < 0.05 level.
Reproduced from Doble et al. 71 © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless
otherwise expressly granted. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/).
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reported for the within-class switch treatment pattern for the hypertension, lipid management, and
depression cohorts.
Medication wastage over time
On an annual basis, a statistically significant difference in the mean cost of wastage per prescription was
observed between the two prescription lengths for each of the 11 years across the case study conditions
(Table 16). The one exception was for the years 2012 and 2013 for the depression cohort, in which no
statistically significant differences in the mean costs between the two prescription lengths were observed,
despite the magnitude of the mean costs remaining relatively consistent over the 11 years for both groups.
For the most part, the magnitude of the mean costs also remained relatively consistent over the 11-year
study period across the other four case study conditions. There were, however, a few trends in the mean
costs that should be noted.
In the glucose control in T2DM cohort, the mean costs for the ≥ 60 days group in 2004 and 2011 were
slightly higher (range £1.81–3.14) than the other nine annual means (range £0.87–1.40). In the
hypertension cohort, there was a slight trend of decreasing magnitude of the mean cost over the 11 years
for the < 60 days group; a decrease in mean cost was limited to the years 2013 and 2014 in the ≥ 60 days
group. For both the lipid management and the secondary prevention of myocardial infarction cohorts, the
magnitude of the mean costs remained relatively consistent over the 11 years for the prescription length
< 60 days groups, whereas there was a slightly decreasing trend in the magnitude of the mean costs for
the prescription length ≥ 60 days groups.
Differences in total unnecessary costs for short and long prescription lengths
After standardising the TUCs (wastage, dispensing fees and prescriber time) to a 90-day period, shorter
(< 60 days) and longer (≥ 60 days) prescription lengths in each of the five case study conditions were
compared (see Appendix 8). Using the mean values reported in Table 13 resulted in the base case TUCs
and differences reported in Appendix 8. The differences in TUCs reported between the two prescription
length groups resulted in the average TUC for prescriptions ≥ 60 days being lower (range £6.33–9.07 per
prescription) than for prescriptions < 60 days.
The results of the sensitivity analyses for different scenarios are also shown in Appendix 8. The cost savings
reported in the base case for prescriptions ≥ 60 days remained for all tested scenarios. The magnitude of
the savings, however, reduced considerably across all five of the case study conditions when prescriber
time costs were excluded from the models (range £0.72–2.12). The other scenarios tested had relatively
little impact on the magnitude of the savings, with the exception of increases and decreases of 50% in the
cost of prescriber time.
Discussion
Longer prescription lengths (≥ 60 days) are associated with more medication wastage per prescription than
shorter prescription lengths (< 60 days). The largest and smallest differences in the mean cost of wastage
per prescription were observed in the lipid management in T2DM and depression cohorts respectively.
Generally, for both prescription lengths, the largest mean cost of wastage per prescription based on
treatment pattern was observed for refills and the smallest for switches between different classes of
medications with similar clinical indications. Patterns of the annual mean cost of wastage over the 11-year
study period were relatively consistent, with the exception of the decreasing trend in the mean costs for
prescriptions ≥ 60 days for the lipid management in T2DM cohort and the secondary prevention of
myocardial infarction cohort in the last 5 years of the study (i.e. from 2009 to 2014).
When accounting for the additional dispensing fees and prescriber time required when prescriptions are
issued for shorter durations (< 60 days), longer prescription lengths result in lower TUCs (e.g. cost of
medication wastage, dispensing fees and prescriber time). These findings are consistent across all five case
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TABLE 16 Comparison of the mean cost of medication wastage per prescription each year from 2004 to 2014 (2015 £)
Year
Glucose control with oral drug
therapy in T2DM Hypertension in T2DM Lipid management in T2DM
Secondary prevention of
myocardial infarction Depression
< 60 days ≥ 60 days p-value < 60 days ≥ 60 days p-value < 60 days ≥ 60 days p-value < 60 days ≥ 60 days p-value < 60 days ≥ 60 days p-value
2004 0.38 1.81 0.02 0.13 0.46 < 0.001 0.07 1.51 0.002 0.09 0.38 0.005 0.25 0.43 0.003
2005 0.42 1.33 < 0.001 0.12 0.52 < 0.001 0.06 2.36 < 0.001 0.08 0.52 < 0.001 0.22 0.45 0.004
2006 0.42 1.05 < 0.001 0.11 0.43 < 0.001 0.06 2.27 < 0.001 0.08 1.28 0.04 0.22 0.58 0.002
2007 0.39 1.11 < 0.001 0.10 0.47 < 0.001 0.05 1.53 0.002 0.07 0.40 < 0.001 0.22 0.38 0.02
2008 0.34 1.08 < 0.001 0.10 0.53 < 0.001 0.05 1.66 0.003 0.07 0.46 < 0.001 0.21 0.36 0.02
2009 0.30 1.07 < 0.001 0.09 0.47 < 0.001 0.05 1.72 0.002 0.06 0.53 < 0.001 0.21 0.42 0.02
2010 0.33 1.40 0.001 0.08 0.38 < 0.001 0.05 0.99 0.01 0.06 0.48 < 0.001 0.18 0.37 0.02
2011 0.26 3.14 0.02 0.08 0.48 < 0.001 0.04 0.88 0.02 0.06 0.41 < 0.001 0.17 0.38 0.005
2012 0.25 0.93 < 0.001 0.08 0.40 0.001 0.05 0.74 0.02 0.06 0.35 < 0.001 0.18 0.35 NS
2013 0.27 0.87 < 0.001 0.07 0.23 < 0.001 0.04 0.45 0.04 0.05 0.20 < 0.001 0.20 0.44 NS
2014 0.30 1.17 < 0.001 0.08 0.27 < 0.001 0.05 0.80 0.03 0.05 0.19 0.002 0.23 0.59 0.001
NS, not significant at p < 0.05 level.
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study conditions, and the magnitude of the cost savings in issuing longer prescriptions compared with
multiple shorter prescriptions ranged from £6.33 to £9.07 per prescription when TUCs were standardised
to a common 90-day time period. These cost savings could potentially be seen as a lower bound, as they
would probably be much larger if the prescriber time associated with additional consultations, rather than
just the administrative time required to issue a prescription (i.e. how long it takes a GP to complete the
technical process of producing a prescription, not including clinical decision-making time) were considered.
Consideration of the time associated with additional consultations would further increase the cost savings
in favour of the longer prescription lengths. Alternatively, the cost savings could be considered an
overestimate, as it was assumed that a GP would be involved in issuing all prescriptions. Nurses are playing
an increasing role in drug therapy management of some chronic conditions (e.g. diabetes and CVD) and,
as the technical process of producing a prescription is likely to be less costly for nurses, smaller cost
savings would be observed. The cost savings would decrease in magnitude, but would still favour longer
prescription lengths, as, even in the absence of prescriber time costs, savings were still observed for the
longer prescription lengths. Cost savings were largest for the secondary prevention of myocardial infarction
and smallest for glucose control in T2DM cohorts. The cost savings remained for all of the five case study
conditions under a number of one-way sensitivity analyses, but decreased considerably, particularly for the
glucose control and lipid management in T2DM cohorts, when the costs associated with prescriber time
were removed from the models (range £0.72 to £2.12). Increases and decreases of 50% in the number of
days wasted, drug costs per day and dispensing fees had relatively small impacts on the cost savings,
whereas 50% increases and decreases in prescriber time costs had much larger impacts.
Based on the reported cost savings of longer prescription lengths in our study, extrapolating the mean
values to the affected populations in the UK could result in substantial estimated savings to the NHS. For
example, the majority of prescriptions in our CPRD analysis in the depression cohort were for < 60 days
(94.76%). It should be noted that, in the depression cohort as well as the other cohorts, the majority of
prescriptions were for ≤ 30 days, with relatively small proportions of patients having prescription lengths
between 31 and 60 days (18%, 27%, 28%, 27% and 25% for the depression, T2DM, hypertension,
lipid management and myocardial infarction cohorts, respectively). Knowing that roughly 39 million
prescriptions are issued for antidepressants in the UK each year,87 if the 95% issued as supplies of
< 60 days were instead issued as prescriptions for ≥ 60 days, the total savings to the NHS could be as
much as £305M per year. Similarly, using the total number of simvastatin and atorvastatin prescriptions
issued in England in 2015 (roughly 61.6 million),84 and knowing from our CPRD analysis that 97.05% of
prescriptions for statins are for < 60 days, the total savings to the NHS just in England for issuing longer
rather than shorter prescriptions for only two statins could be as much as £424M per year. Note that the
majority of savings for both examples will not be cash releasing, but will be realised as savings of GP time.
Using the cost savings from the models that included only dispensing fees (see Appendix 8) and not
prescriber time costs can give us a rough estimate of the cash-releasing savings within the NHS that may
be realised (£78M and £47M for antidepressants and the two statins, respectively). The magnitude of the
savings for the other case study conditions are also likely to be similarly large given the high prevalence
of the conditions and the large proportions of current prescriptions being issued as < 60-day supplies.
However, these figures represent an upper bound, and should be interpreted with extreme caution, as
they assume that it is clinically appropriate for all prescriptions to be issued for a longer duration, which is
certainly not the case.
Comparison with previous studies
Six previous studies have estimated costs differences associated with long (3-month) and short (1-month)
prescriptions.22,42,44–46,49 All of the existing studies are from various perspectives in the USA (e.g. Veterans
Affairs, Medicaid and non-institutionalised civilian populations). Only one of the studies accounted for
differences in prescriber time (indirectly by assessing differences in all Medicaid expenditures, i.e.
outpatient, inpatient, emergency and pharmacy costs),44 and only four of the studies accounted for the
impact of differences in drug wastage.42,44–46 Prescriptions for a number of chronic diseases were
assessed,44,45,49 but some studies limited their analyses to specific drugs (e.g. simvastatin and lovastatin)42
or did not limit their analyses to any particular therapeutic class of medication.46
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Walton42 applied a similar model to the one used in our study to estimate the TUC (wastage and
dispensing fees only) associated with either 30-day or 90-day supplies of two statin medications. When
compared with the results of our analysis for the lipid management cohort and excluding prescriber time
costs, the difference in the mean TUC between long and short prescription lengths was greater in the US
study (US$2.45 vs. £0.79). It should be noted that the dispensing fee used by Walton42 was also slightly
larger (US$1.79 vs. £0.90), which may partly account for the slightly larger savings reported.
Taitel et al.45 estimated the per-patient savings of switching from 30-day prescriptions to 90-day
prescriptions for four therapeutic classes of medication (statins, antihypertensives, SSRIs and oral
hypoglycaemics). Similarly to our analysis, all four therapeutic classes reported a greater number of
wastage days for 90-day prescriptions than for 30-day prescriptions. However, after adding dispensing fees
and medication costs to the costs of wastage and standardising to per-patient per-year values, savings
were reported of US$7.70 for statins, US$10.80 for antihypertensives, US$18.52 for SSRIs and US$26.86
for oral hypoglycaemics.45 Multiplying our reported savings for longer prescriptions standardised to 90 days
by four, so as to encompass a year, results in estimated savings of £3.16 per prescription per year for
the lipid management cohort, £5.00 for the hypertension cohort, £8.48 for the depression cohort and
£2.88 for the glucose control in T2DM cohort. Thus, in all cases, the estimated savings were somewhat
larger in the Taitel et al.45 US study than our estimates for the UK, although this is to be expected based on
the estimated savings in our study being on a per-prescription per-year basis rather than on a per-patient
per-year basis as reported by Taitel et al.45 Any further differences may be attributed to the inclusion of volume
discounts for medication costs in the study by Taitel et al.,45 and the fact that the drugs included in our study
were not limited to single classes of medications (with the exception of the lipid management cohort), and
were selected to be representative of all of the treatments available for a particular case study condition.
Rabbani et al.49 assessed differences in third-party expenditures for 3-month and 1-month supplies of
395 unique medications for common chronic conditions, including high cholesterol, hypertension,
hypothyroidism and depression.49 Only two of the six payers in their study achieved statistically significant
savings with a 3-month supply (range US$0.34M to US$1.74M), as the majority of savings were accrued
for individuals through reductions in out-of-pocket costs, which were not assessed in our analysis.49
Another major difference between our study and that conducted by Rabbani et al.49 is the latter’s lack of
consideration of the cost of medication wastage, making it difficult to compare the results of this study
with the results of our analysis in a meaningful manner.
Parikh et al.46 estimated a theoretical saving of US$6.17 if 90-day prescriptions were issued instead of
30-day prescriptions.46 In addition to medication and wastage costs, Parikh et al.46 also included mailing
costs for mail-order prescriptions that were not considered in our analysis. The mean cost saving in
our analysis over the five case study conditions when excluding prescriber time costs was £1.30 per
prescription, but it is difficult to compare our results with those presented by Parikh et al.46 because their
analysis was not specific to any particular chronic condition and included only a very small number
of prescriptions (346 unique prescriptions) over a short time period (3 months). The standardisation
approach used by Parikh et al.46 was also different from the models used in our study. Costs of wastage,
dispensing fees (US$1.573–4.275 vs. £0.90) and mailing costs were simply multiplied by three for the
30-day prescriptions to determine the total cost, then subtracted from the actual total costs associated
with 90-day prescriptions. This difference in methodology and dispensing fees might account for the
difference in the magnitude of savings reported in our study.
The first study by Domino et al.22 simulated the effect of a policy change from a maximum of a 100-day
supply for prescriptions to one in which only a 34-day supply was allowed for six specific therapeutic
categories of medications.22 Only three therapeutic categories (sulfonylureas, SSRIs and ACEIs), all of
which were associated with relatively small amounts of wastage in comparison with the other categories
(antiulcers, antipsychotics, non-steroidal anti-inflammatory drugs), were included as treatments for one or
more of the five case study conditions analysed in our study. A comparison of our results is therefore
difficult, but a specific pattern should be noted. When simulating 34-day supplies for all six categories,
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any savings in wastage as a result of the shorter prescription length were offset by increases in dispensing
fees (US$5.60 per prescription).22 Reducing the dispensing fee to US$2.40 resulted in the wastage savings
exceeding dispensing costs for three of the categories (antiulcers, antipsychotics and non-steroidal
anti-inflammatory drugs), none of which was assessed in our analysis. For the remaining three categories, the
reduction in dispensing fees required to achieve savings for 34-day supplies was not noted, although Domino
et al.22 stated that it would have to be much lower, which is consistent with the findings of our analyses.
The second study by Domino et al.44 provides the most comprehensive study to date using a pre–post
controlled partial difference-in-difference-in-differences design to assess the impact of a prescription length
policy change in the North Carolina Medicaid programme (from 100 to 34 days’ supply) on total Medicaid
expenditures (outpatient, inpatient, emergency and pharmacy costs).44 Total Medicaid expenditures
were shown to decrease for patients initially receiving 100-day prescriptions after the implementation
of the shorter prescription length policy (range US$245–440 per person per quarter in all six classes of
medications assessed (antihypertensives, antidiabetic medications, lipid-lowering drugs, seizure disorder
medications, antidepressants and antipsychotics). The results, however, are not stratified by expenditure
category (with the exception of also reporting decreases in expenditures for the targeted prescriptions
across all six medication classes); therefore, it is not clear to what extent changes in outpatient, inpatient
or emergency visits are individually responsible for the decreases in expenditures. In addition to the
difference in study design, a number of methodological contrasts with our study should also be noted.
To be included in the analysis, medical diagnoses were required for four of the six medication classes
(antihypertensives, antidepressants, antipsychotics and seizure disorder medications),44 which is in contrast
to our reliance on product codes to identify our five cohorts of interest. Our analysis could therefore be
capturing a broader range of patients (i.e. those receiving the medications of interest off-label or for other
conditions). The study by Domino et al.44 also accounted for differences in adherence, and indicated that
reduced adherence for shorter prescriptions led to the decreases in expenditures, but this was not assessed
in our study owing to differences in study design and available data. This somewhat counterintuitive
finding may potentially be explained by small adverse health effects as a result of changes in adherence,
patients absorbing any health effects through informal care or tolerating greater disease burden, and the
18-month post-policy period in the study being too short to capture the spillover effects of decreased
medication adherence on other Medicaid services. Furthermore, NHS expenditures in the UK for the
treatment of chronic conditions are likely to differ based on the organisation of primary care and the existence
of a referral system to specialty care compared with those incurred in a US Medicaid patient population;
therefore, the generalisability of the conclusions presented by Domino et al.44 to the UK context are unclear.
It will, however, be important to incorporate a more comprehensive measurement of the potential differences
in NHS expenditures associated with different prescription lengths in any future UK study.
Limitations of the cost analysis
Although our study, to the best of the authors’ knowledge, provides the only available evidence of the
unnecessary costs associated with different prescription lengths from the perspective of the NHS in the UK,
and builds on existing methodological approaches available in the literature (accounts for prescriber time
costs and potential wastage between medications with similar clinical indications from different classes,
rather than single classes of drugs), there are a few limitations that warrant discussion. First, a limitation of
CPRD prescription data is that they do not indicate whether or not a medication has been dispensed, or if
patients took their prescribed medications as recommended (i.e. they indicate only when a prescription has
been issued). Our estimates may, therefore, either over- or understate the amount of wastage that actually
occurred, depending on patient behaviour not captured by CPRD. Assuming that all prescriptions issued
were actually dispensed places an upper bound on the potential savings that would occur if drug wastage
from premature medication switches could be eliminated entirely. In terms of medication adherence,
longer prescription lengths (≈ 3 months) consistently show improved adherence compared with shorter
prescription lengths (≈ 1 month).39,44,45 One of these studies, however, also indicated that reduced
adherence related to shorter prescription lengths led to lower total expenditure from a Medicaid
perspective (outpatient, inpatient, emergency and pharmacy costs).44 In contrast, our study was not
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designed to estimate the impact of different prescription lengths on total NHS expenditures, as this
would require additional linkages to secondary care datasets (e.g. Hospital Episode Statistics) and more
comprehensive analysis of CPRD through consideration of additional data files (e.g. clinical, consultations
and laboratory test files). Chapter 5 provides a model-based analysis that attempts to capture these
‘downstream’ costs as well as health outcomes. The main objective of our study was, however, to estimate
differences in TUCs (medication wastage, dispensing fees and prescriber time costs) associated with
different prescription lengths, therefore it may be pertinent to conduct more comprehensive analyses using
linked data in future research.
Second, the five case study conditions were purposively rather than randomly selected to represent the
impact of medication refill and switching behaviour on wastage; they may not be representative of
prescribing behaviour in other chronic conditions. However, those selected do represent some of the
most common chronic conditions treated with prescribed medications. Nine of the top 20 prescribed
medications within NHS England were included in at least one of the case study conditions in our analyses,
and, combined, they accounted for around £378M drug expenditure in NHS England in 2015 (4% of the
total), and are, therefore, highly policy relevant. In common with other studies,22,45 our analyses have
shown that the amount of wastage, and therefore its associated cost, can differ depending on the
therapeutic category of the medications being analysed. Our analysis also excluded patients in whom
one or more observations were missing or had zero values for either the ndd and/or qty variables. This
approach resulted in substantial proportions (15–55%) of patients from the full samples being dropped
and therefore limits the generalisability of the results from our original random samples. Appropriate
methods to impute these variables are, however, limited, and our approach was similar to other studies
using CPRD data.77,78
Third, the identification of patients within CPRD with the five case study conditions (see Table 11) was
based solely on product codes, rather than on a specific medical diagnosis (identified using Read codes in
CPRD). This was straightforward for four of the five conditions, but required additional assumptions for the
secondary prevention of myocardial infarction cohort. To avoid the additional complexity of using Read
codes, patients were identified according to whether or not they had prescriptions for drugs as per clinical
guidelines, for example patients receiving concurrent prescriptions for an ACEI, antiplatelet and statin for a
duration of ≥ 1 year.81 As the main aim of our study was to estimate drug wastage, the possible inclusion
of patients without a previous myocardial infarction event, but still receiving at least four of the
prescriptions of interest for ≥ 1 year, provided our analysis with relevant information concerning drug
wastage, dispensing fees and prescriber time.
Fourth, an overlap of dates between prescriptions does not necessarily mean wastage has occurred, as
consumption of early refills may be delayed until the initial supply is exhausted, and treatment changes
might actually be add-ons to existing prescriptions or concomitant therapy rather than switches in therapy.
To ensure that wastage was not overestimated, a threshold of 1 year after the initial prescription in a
particular series was used to estimate wastage for early refills and a threshold of < 1 in the difference
between the number of drug changes between medications with similar clinical indications from different
classes and the number of unique drug classes within an annual period was used to identify wastage from
between-class treatment switches. There is, however, a possibility that our analysis approach could have
overestimated the amount of medication wastage.
Fifth, for pragmatic purposes, we dichotomised prescription lengths into ‘short’ versus ‘long’, with a cut-off
point of 60 days. This will have classified 56-day prescriptions as ‘short’. Although this will have resulted in
a loss of sensitivity (there may be differences in TUC between 1- and 2-month prescriptions), the overall
conclusions are not affected: 3-month prescriptions are associated with higher drug wastage than 1- or
2-month prescriptions, but the reduction in administration costs (e.g. dispensing fees and prescriber time)
more than compensates for this, leading to overall lower TUC with the longer prescription lengths.
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Finally, a number of assumptions were required to assign unit costs to the estimated proportions of
wastage. Mean cost per day values derived using DDDs, NICs and quantities at the drug substance level
were calculated and then applied to any prescription categorised under that particular drug substance.
This approach is not ideal; given the inability to link CPRD data to individual unit costs specific to each
prescription, it was necessary, but it means that the direction and magnitude of any resulting bias is
difficult to predict.
Furthermore, NICs do not include any discounts that may be applied or include any adjustment for revenue
received by the NHS if a prescription charge is paid at the time the prescription is dispensed, or if the
patient has purchased a pre-payment certificate, and therefore may be different from the net cost incurred
specifically by the NHS. Patients with T2DM are exempt from the prescription charge,88 and, overall, almost
90% of prescriptions dispensed in the NHS in England are exempt.5 Given a current prescription charge of
£8.40 (as in August 2016), and with only 10% of prescriptions attracting a patient charge, revenue to the
NHS is, on average, £0.84 per prescription. If this average revenue per prescription is incorporated into our
TUC models, the predicted net savings to the NHS from issuing longer prescriptions decreases on average
by £1.56 (range £1.45–1.69) from the base case values across all five of the case study conditions. Applying
the adjusted cost savings accounting for losses in revenue from prescription charges to the NHS from
switching to longer prescriptions for antidepressants and the two statins (simvastatin and atorvastatin)
would reduce projected savings from £305M to £246M and from £424M to £323M, respectively.
All of these limitations risk biasing the results. The projected savings should, therefore, be interpreted with
caution, especially if they are to be extended to other types of medications that are not prescribed at
relatively low unit costs to a large population of patients. Proportional savings for high-costs drugs used to
treat relatively small patient groups may not be similarly observed.
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Chapter 4 Disease-specific decision-analytic
modelling
Introduction
We combined evidence from the systematic review (see Chapter 2) with the CPRD cost analysis estimates
(see Chapter 3) and adapted existing decision models to predict the medium- and longer-term costs and
health consequences of different adherence levels associated with shorter and longer prescriptions. The
analysis involved three discrete case studies of three classes of commonly prescribed medications. They are
presented from the perspectives of costs to the NHS, and health outcomes for patients.
Decision modelling is used extensively in the UK as a tool for assessing and accounting for uncertainty in
the medium- to longer-term costs, health consequences and cost-effectiveness of new health technologies
and, to a lesser extent, policy changes.89 For example, in the field of pharmacy, a recent study examined
the longer-term costs and health consequences of the New Medicine Service (NMS), a pharmacist-led
intervention in the UK designed to tackle low adherence with newly prescribed medications.90 However,
our study is the first to use a decision modelling approach to examine the impact of changes in
prescription length on longer-term health service costs and health consequences.
This chapter is structured as follows: the first section sets out the objectives of the decision-analytic
modelling (see Objectives); in the second section, our methods are described (see Methods); and our
findings are presented in the third section (see Results) and discussed in the final section (see Discussion).
Objectives
The overall objective of the decision modelling was to predict the medium- and longer-term costs and
health consequences that may be associated with shorter and longer prescription lengths.
In comparison with the studies of the relationship between prescription length and adherence identified in
the systematic review, the specific objectives of this chapter were to:
l examine the longer-term costs and health consequences of different prescription lengths [in contrast
with the evidence examined in the systematic review, which generally had a shorter follow-up (median
follow-up of 14 months and a mean follow-up of 20.3 months)]
l assess costs from the perspective of the NHS in the UK [in contrast with the evidence in the review,
which was solely US based and rarely accounted for transaction costs (dispensing fees and prescriber
time) or drug wastage costs]
l examine the potential relationship between prescription length and health consequences [in contrast
with the systematic review, which identified just one study that examined health consequences
(achievement of target cholesterol levels)39].
Methods
Our approach involved developing three case study scenarios that examined the potential impact of
prescription length on the costs and health consequences of three classes of commonly prescribed medications:
l case study 1 – primary prevention of cardiovascular events in patients with recent-onset T2DM
l case study 2 – treatment of depression in adults with SSRIs
l case study 3 – secondary prevention of cardiovascular events in patients with hypertension.
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For each case study, we adapted existing decision models developed to inform NICE guidance to determine the
cost-effectiveness of commonly prescribed medications. These three case studies were chosen primarily because
they represent a range of clinical situations in the UK in which variation in prescription lengths may have a
significant impact on costs and/or health outcomes. They are also the disease areas examined in our systematic
review and CPRD analysis, and for which many decision models already exist for our case study drugs.
The model adaptations were based on relevant parameters identified in the systematic review and CPRD
analysis or, when necessary, from additional evidence identified in other published studies, for example,
clinical evidence reviews produced for NICE guidance. When data were unavailable, appropriate
assumptions were made. In particular, our approach relied on two key assumptions:
1. Treatment effects observed in model active and placebo/no treatment arms of clinical trials were
assumed to represent the maximum effect comparing zero and perfect adherence.
2. A linear dose–response curve was assumed (e.g. it was assumed that 50% adherence would generate
50% of the treatment effect).
These simplifying assumptions were necessary in the absence of evidence to the contrary. Although
the systematic review identified studies on the relationship between prescription length and adherence,
these studies did not examine the relationship between those identified levels of adherence and health
outcomes. The implications of these assumptions on our main findings are explored in the Discussion
section of this chapter. As is common in all decision models that include a ‘no treatment’ arm, it was
necessary to assume that health outcome data from the ‘placebo’ arm of clinical trials were equivalent
to ‘no treatment.’ However, because the placebo effect means that being treated with a placebo is not
the same as knowingly not being treated at all, this may have led to an overestimation of the QALYs
associated with no treatment. As a result, we may have underestimated the health gain from increased
adherence as a result of longer prescription lengths.
Our general approach is depicted in Figure 9, in which the expected costs and outcomes of the 3-month or
28-day repeat strategies are presented as weighted averages of the costs and QALYs associated with perfect
and zero adherence (assumed to be the long-term costs and QALYs associated with treatment vs. placebo/no
treatment, respectively). Given that our systematic review showed that 3-month repeat prescriptions are
associated with higher adherence than 28-day repeat prescriptions, in the absence of evidence to the
contrary, we assumed that the 3-month repeats would yield the expected costs and QALYs associated with
perfect adherence, that is, p = 1 in Figure 9. The RR of being adherent varies between 0 and 1. The RR gives
Longer-term costs and QALYs as per active treatment arm of existing model
Longer-term costs and QALYs as per placebo arm of existing model
Longer-term costs and QALYs as per active treatment arm of existing model
Longer-term costs and QALYs as per placebo arm of existing model
Zero adherence
Perfect adherence
Zero adherence
Perfect adherence
28-day 
prescription
3-month 
prescription 1-p
p
RR.p
1-RR.p
FIGURE 9 General approach to modelling. p, probability of perfect adherence in active treatment arm of existing
model (in our modelling, we have assumed p= 1); RR, relative risk of being adherent to a 28-day prescription
compared with a 3-month prescription.
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the full range of possible values for the incremental cost and QALYs gained from 3-month versus 28-day
repeat prescriptions. The most plausible value for the RR is extracted from the systematic review.
It should be noted that, prior to the inclusion of transaction costs (dispensing fees and prescriber time) and
the costs of wastage, the method described in Figure 9 always yielded an identical ICER between the two
strategies. As the RR changes, incremental costs and QALYs change exactly in proportion so that the ratio
between the two remains constant. However, the values are associated with different incremental net benefits
(INBs), an absolute measure of the net gain to society from one strategy compared with another. The INB is
calculated from a simple rearrangement of the ICER (Equation 5, which is explained graphically in Figure 10):
ICER ¼ ΔC
ΔE
· λ (5)
INB ¼ λΔE−ΔC ¸ 0, (6)
where λ =willingness to pay for a unit of outcome and E = QALYs (NICE assigns a value of
£20,000–30,000 to λ).
Changing RR represents a movement along the ICER line from point a to point b in Figure 10, but
increases the INB from x to y.
This general approach described in this section represents the ‘default’ approach to analysis in the absence
of superior evidence. Where the data allowed, we made appropriate modifications and enhancements to
Cost (£)
QALYs
∆C
∆E
a
b
INBλ = 0 INBλ = x INBλ = y
FIGURE 10 Incremental net benefit vs. ICER. ΔC, incremental costs; ΔE, health effects. The diagram shows a
cost-effectiveness plane. The gradient of the line 0ab is equal to the ICER. The gradient of the lines INBλ is equal to the
threshold, λ. The INB line that passes through the origin (INBλ= 0) shows the locus of points where INB= 0. The parallel
lines INBλ= x and INBλ= y show the locus of points where INB= x and INB= y, respectively, where y> x> 0. Points a and
b represent the incremental costs and QALYs gained with strategies a and b vs. comparator, respectively. They have the
same ICERs with respect to the origin and to each other, but point b is associated with a higher INB than point a.
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the default as described in the specifics for each case study below. A summary of our approach is provided
in Table 17, and the strengths, limitations and plausibility of the assumptions are considered in the
Discussion section later in this chapter.
Results
The results for each case study are reported separately and structured as per the overview of our methods
presented in Table 17. All cost data are reported in 2015 GBP. Costs were inflated when necessary to
2015 levels using the PSSRU Hospital and Community Health Service indices.86
Summaries of the original source models for each of the three case studies are provided in Table 18. The
three decision models chosen for this study represent the full range of modelling techniques currently used in
health economic evaluation: a decision tree, a Markov model and a patient-level simulation. Further
information about each model can be found in the full NICE report for each model (see Table 18 for the
relevant references), where more detail can be found than was possible to include in this document. All three
models were commissioned by NICE for the most recent clinical guidance in the relevant disease areas, and
have thus been used to inform policy in the recent past. The choice of modelling technique is justified in the
NICE guidance for the particular disease area considered. For example, the decision tree was considered
appropriate for the modelling of SSRIs because the clinical data reviewed by the guideline development group
related to a relatively short 9-month treatment period. In contrast, the modelling of the primary prevention of
cardiovascular events in patients with recent-onset T2DM was supported by high-quality clinical studies on a
range of longer-term health outcomes, and hence a patient-level simulation was most appropriate in this
case. Further details on all aspects of the design of the source models can be found in the full NICE report.
In this chapter, each case study is presented in order of the complexity of the adjustments made to the
source model. In the first case study, only the outputs (lifetime costs and QALYs) of the source model were
adapted to reflect different prescription lengths. In the second case study, the source model did not include
TABLE 17 Method overview
Stage 1: identify relevant data and decision models
1(a) Identify relevant studies from the systematic review estimating the relationship between prescription length,
adherence and/or health outcomes
1(b) Review NICE guidelines and other literature to identify an appropriate existing decision model that has been used
to assess the cost-effectiveness of relevant medications
1(c) Identify additional data, including
l transaction costs (dispensing fees and prescriber time) and any other costs deemed to be relevant (if not
already included in the existing decision model)
l data on the cost of wastage
l data on the relationship between treatment and placebo
Stage 2: adapt the decision model
2(a) Drawing on the data identified in stage 1 or, when necessary, appropriate assumptions, adjust the input
parameters and/or model outputs of the identified decision model to account for different costs, QALYs and levels
of adherence associated with no treatment and treatment with different prescription lengths
2(b) Report the health consequences, costs, ICERs and INBa for
l treatment vs. placebo
l treatment with 3-month vs. 28-day prescription lengths
2(c) Address uncertainty in the results through sensitivity analyses based on the methods used by NICE in the original
source models
a A cost per QALY threshold of £20,000 was used for all INB calculations. This is the lower end of the cost-effectiveness
threshold over which treatments are less likely to be recommended for use in the NHS. Thus, our INB calculations may
be interpreted as cautious underestimates.
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TABLE 18 Characteristics of the source models
Characteristic
Case study 1: primary
prevention of cardiovascular
events in patients with
recent-onset T2DM
Case study 2: treatment of
depression in adults with
SSRIs
Case study 3: secondary
prevention of cardiovascular
events in patients with
hypertension
Type of model Patient-level simulation model,
12-month cycles, 1000 ‘outer
loop’ iterations
Decision tree Markov model, 6-month cycles,
2000 iterations
Source of
model
The original model is the UKPDS
model. It was adapted by NICE
for CG2879
NICE CG9082 NICE CG12791
Time horizon 40 years (equivalent to lifetime,
given that the average starting
was between 60 and 65 years)
14–15 months (2- to 3-month
acute treatment phase, 6-month
maintenance treatment phase,
6-month follow-up phase)
Lifetime, with an assumed
upper age of 100 years (most
have died by then)
Comparators The model was run separately
for three discrete stages of
disease progression (initial
therapy, first intensification and
second intensification). In each
stage, at least seven comparators
were modelled (e.g. for initial
therapy this included placebo
and metformin)
One analysis focused on
pharmacological intervention
(10 different antidepressants
were assessed). Another analysis
focused on combination therapy
(CBT combined with SSRI
treatment compared with SSRI
treatment alone)
Four groups of alternative
antihypertensive drugs
(ACEIs/ARBs, beta-blockers,
calcium-channel blockers,
thiazide-type diuretics) and no
treatment
Patients 50,000 patients (each simulated
100 times – ‘inner loop’
iterations)
100 patients in each treatment
group with either moderate or
severe depression
1000 patients
Selected base
case patient
characteristics
For initial therapy scenario:
gender = 57.1% male; mean
age= 59.8 years
NA 65-year-old male with a 2%
CVD risk, 1% heart failure risk
and 1.1% T2DM risk
Perspective NHS for costs and patients for
health outcomes
NHS for costs and patients for
health outcomes
NHS for costs and patients for
health outcomes
Health
outcome
QALYs reflecting the impact of
treatment on the first occurrence
of seven diabetes-related
complications (fatal or non-fatal
MI, other IHD, stroke, heart
failure, amputation, renal failure
and eye disease measured in
terms of blindness in one eye)
and death. Based on data from
the UKPDS RCT92
QALYs (utility scores were based
on a study by Sapin et al. 2004,
a study that was identified
through a systematic review)93
QALYs reflecting prevention
of cardiovascular events
(non-fatal unstable angina,
myocardial infarction, heart
failure and stroke, and
cardiovascular-related deaths)
and side effects (onset of heart
failure and diabetes) (various
sources; see tables 92 and 93
in appendix I of NICE CG12791)
Clinical input
parameters
Treatment effects on HbA1c,
weight, hypoglycaemic episodes
and treatment dropouts owing
to intolerance taken from a
clinical review network
meta-analysis
Odds and probabilities of
dropout (after 2–3 months),
remission (after 8–9 months) and
relapse (after 14–15 months)
(identified in a literature review
or through expert opinion)
Baseline risks (from a range of
sources reported in NICE
CG12791 (see appendix I) and
treatment effects
Cost
parameters
Complications and event costs
(mainly from UKPDS RCT),92 and
drug unit costs from the NHS
Drug Tariff 2014; both are
reported in table 84, appendix F
of NICE guideline 2879
Resource utilisation (identified in
a literature review or through
expert opinion). Unit costs: drug
costs (e.g. BNF and Electronic
Drug Tariff data), primary and
secondary care costs (e.g. PSSRU
estimates of standard GP care
and specialist mental health
outpatient care for patients with
severe depression)
See I.3.7 in CG12791
Discounting 3.5% per annum (for costs and
benefits)
None (owing to a short time
horizon)
3.5% per annum (for costs and
benefits)
continued
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a placebo or no treatment arm. We therefore modified the model inputs to represent this and the additional
transaction and drug wastage costs associated with different prescription lengths. The model outputs were
then adjusted to account for different levels of adherence associated with different prescription lengths.
In the third case study, model inputs were adjusted to account for different prescription lengths. This
included both the additional costs as well as the impact of different levels of adherence on relative treatment
effects. Access to each economic model was provided through contact with the relevant authority.
Table 19 provides a summary of the identified data and key assumptions for each case study, and a
summary of the results for each case study are provided in Tables 20–22.
TABLE 18 Characteristics of the source models (continued )
Characteristic
Case study 1: primary
prevention of cardiovascular
events in patients with
recent-onset T2DM
Case study 2: treatment of
depression in adults with
SSRIs
Case study 3: secondary
prevention of cardiovascular
events in patients with
hypertension
Sensitivity
analyses
Probabilistic sensitivity analyses
were reported to evaluate and
combine all sources of
uncertainty in the model.
One-way sensitivity analyses
using stochastic model runs
Deterministic one-way sensitivity
analysis on the upper and lower
95% credibility intervals around
the clinical input parameters
Variety of univariate and
multivariate deterministic
sensitivity analyses to test the
impact of uncertainty in model
parameters and assumptions
Reference(s) for
full description
of economic
model
NICE: appendix F;79 UKPDS
Outcomes Model 194
NICE: chapters 8 and 1095 NICE: appendix I91
Key limitations
of model
No placebo treatment group was
included in the first and second
intensification of treatment.
Patients on initial treatments
therefore moved to metformin–
sulfonylurea (first intensification)
then metformin–NPH insulin
(second intensification) after a
period of time
Treatment continued for only
9 months with follow-up for a
further 6 months. Although this
model was developed to inform
current NICE guidance and is
consistent with other SSRI studies
(e.g. Cipriani et al.96), this may not
reflect current clinical practice, and
would not capture longer-term
costs and health consequences
Although a range of multi-way
sensitivity analyses were
reported, the modelling did not
include a probabilistic sensitivity
analysis
CBT, cognitive–behavioural therapy; CG, clinical guideline; IHD, ischaemic heart disease; MI, myocardial infarction; NA, not
applicable; NPH, neutral protamine Hagedorn; UKPDS, UK Prospective Diabetes Study.
TABLE 19 Identified data and key assumptions used in the adapted models
Data
Case study 1: primary
prevention of cardiovascular
events in patients with
recent onset T2DM
Case study 2: SSRIs for
depression
Case study 3: secondary
prevention of
cardiovascular events
(1) Costs (UK) and health
consequences of relevant
treatment vs. no treatment
or placebo
A placebo comparator included
in the source model (NICE
NG28)79
Clinical evidence review
in NICE CG90 included
evidence on treatment
vs. placebo82
‘No treatment’ included in
the source model (NICE
CG127)91
(2) Relationship between
adherence and health
consequences
Assumed linear Assumed linear Assumed linear
(3) Relationship between
prescription length and
adherence
Hermes and Taitel papers
identified in systematic
review35,45
Taitel and Pfeiffer papers
identified in systematic
review37,45
Hermes and Taitel papers
identified in systematic
review35,45
(4) Dispensing fees NHS Drug Tariff60 NHS Drug Tariff60 NHS Drug Tariff60
(5) Prescriber time and
wastage costs
CPRD analysis
(see Chapter 3)
CPRD analysis
(see Chapter 3)
CPRD analysis
(see Chapter 3)
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TABLE 20 Case study 1: mean years on initial treatment, lifetime costs, QALYs and incremental analysis (2015 £)
Years on
initial
treatmenta
Total
lifetime
cost (£)
The total cost includes
Total
lifetime
QALYs
Incremental analysis
Incremental
net benefit (£)UKPDS (£)b
Treatment
costs (£)
Additional
costs (£)c Costs (£) QALYs ICER
Placebo and treatment arms in source model
Placebo 2.30 20,450 14,036 5590 NA 8.912 NA NA NA NA
Treatment (metformin) 3.80 19,639 13,969 4950 NA 9.033 –811 0.121 Dominant 3231
28-day and 3-month prescribing based on Hermes et al.35 (RR= 0.891)
28-day 3.64 19,797 13,977 5020 69.37 9.020 NA NA NA NA
3-month 3.80 19,677 13,969 4950 38.76 9.033 –158 0.013 Dominant 423
28-day and 3-month prescribing based on Taitel et al.45 (RR = 0.863)
28-day 3.59 19,818 13,979 5038 68.58 9.016 NA NA NA NA
3-month 3.80 19,677 13,969 4950 38.76 9.033 –179 0.017 Dominant 511
Sensitivity analysis
28-day and 3-month prescribing based on upper bound of Hermes et al.35 (RR = 0.926)
28-day 3.64 19,769 13,974 4997 70.40 9.020 NA NA NA NA
3-month 3.80 19,677 13,969 4950 38.76 9.033 –130 0.009 Dominant 308
28-day and 3-month prescribing based on lower bound of Taitel et al.45 (RR= 0.851)
28-day 3.59 19,827 13,979 5045 68.25 9.016 NA NA NA NA
3-month 3.80 19,677 13,969 4950 38.76 9.033 –189 0.018 Dominant 548
NA, not applicable; UKPDS, UK Prospective Diabetes Study.
a All initial treatments intensified to metformin-sulfonylurea (first intensification) then metformin-NPH insulin (second intensification) after a period of time.
b UKPDS: costs incurred within UKPDS Outcomes Model 1 as a result of survival time and long-term complications.
c Additional costs are the sum of transactional (dispensing fees and prescriber time) and drug wastage costs for the period of time the average patient received initial treatment.
Note
2012/13 costs included in the original model were adjusted to 2014/15 costs using the PSSRU Hospital and Community Health Service indices.86
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TABLE 21 Case study 2: results (2015 £)
Moderate depression Severe depression
Total
costs (£)
Total
QALYs
Net
benefit (£)
Incremental analysis
Total
costs (£)
Total
QALYs
Net
benefit (£)
Incremental analysis
Costs (£) QALYs ICER INB (£) Costs (£) QALYs ICER INB (£)
Placebo and ‘typical treatment’ armsa
Placebo 201,315 61.13 1,021,249 NA 225,470 49.38 762,142 NA
Treatment 188,274 62.78 1,067,300 –13,041 1.65 Dominant 46,051 212,965 51.37 814,349 –12,505 1.99 Dominant 52,207
28-day and 3-month prescribing scenarios based on Taitel et al.45 (RR = 0.748)
28-day 219,983 62.36 1,027,268 NA 247,988 50.87 769,315 NA
3-month 189,445 62.78 1,066,129 –30,538 0.42 Dominant 38,862 214,135 51.37 813,178 –33,853 0.50 Dominant 43,863
28-day and 3-month prescribing scenarios based on Pfeiffer et al.37 (RR = 0.542)
28-day 223,187 62.02 1,017,273 NA 251,067 50.46 758,070 NA
3-month 189,445 62.78 1,066,129 –33,743 0.76 Dominant 48,856 214,135 51.37 813,178 –36,931 0.91 Dominant 55,108
Sensitivity analyses
28-day and 3-month prescribing scenarios based on upper bound of Taitel et al.45 RR estimate (RR= 0.780)
28-day 219,487 62.42 1,028,814 NA 247,512 50.93 771,055 NA
3-month 189,445 62.78 1,066,129 –30,043 0.36 Dominant 37,315 214,135 51.37 813,178 –33,376 0.44 Dominant 42,123
28-day and 3-month prescribing scenarios based on lower bound of Pfeiffer et al.37 RR estimate (RR = 0.540)
28-day 223,221 62.02 1,017,168 NA 251,099 50.45 757,952 NA
3-month 189,445 62.78 1,066,129 –33,776 0.76 Dominant 48,961 214,135 51.37 813,178 –36,963 0.91 Dominant 55,226
NA, not applicable.
a The ‘typical treatment’ comparator included a weighted average of the costs associated with 10 groups of antidepressant medications based on PCA figures published by NHS England,
which show the total number of items dispensed in the community (the data were for 2014, the most recent available data). The proportions calculated were: citalopram (0.341),
duloxetine (0.034), escitlopram (0.022), fluoxetine (0.150), fluvoxamine (0.001), mirtazapine (0.146), paroxetine (0.036), reboxetine (0.001), sertraline (0.187), venlafaxine (0.081).
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Case study 1: primary prevention of cardiovascular events in patients with
recent onset type 2 diabetes mellitus
The results for each case study are structured as per the methods overview presented in Table 17.
Stage 1: identify relevant data and decision models
1a
The systematic review (see Chapter 2) identified two studies, both of which indicated a positive relationship
between prescription length and adherence in antidiabetic medications.35,45 This positive relationship was
consistent with that identified in all studies in the systematic review, regardless of disease area. No studies
examined the relationship between prescription length (or adherence) and health outcomes, and no
decision models were identified.
TABLE 22 Case study 3: results (2015 £)
Total
lifetime
cost (£)
Total
lifetime
QALYs
Net
benefit (£)
Incremental analysis
INB (£)Costs (£) QALYs ICER
Source model: no intervention and weighted treatment comparators
No intervention 5117 9.57 186,283 NA NA NA NA
Weighted treatment 4503 10.16 198,602 –614 0.59 Dominant 12,319
First approach based on Hermes et al.35 (RR = 0.916)
28-day 5413 10.12 196,756 NA NA NA NA
90-day 4795 10.16 198,310 –618 0.05 Dominant 1554
First approach based on Taitel et al.45 (RR= 0.851)
28-day 5470 10.07 195,879 NA NA NA NA
90-day 4795 10.16 198,310 –675 0.09 Dominant 2431
Second approach based on Hermes et al.35 (RR = 0.916)
28-day 5416 10.10 196,680 NA NA NA NA
90-day 4795 10.16 198,310 –621 0.05 Dominant 1630
Second approach based on Taitel et al.45 (RR = 0.851)
28-day 5476 10.06 195,773 NA NA NA NA
90-day 4795 10.16 198,310 –681 0.09 Dominant 2537
Sensitivity analysis
First approach based on upper bound of Hermes et al.35 RR estimate (RR = 0.928)
28-day 5406 10.11 196,859 NA NA NA NA
90-day 4795 10.16 198,310 –611 0.04 Dominant 1451
First approach based on lower bound of Taitel et al.45 RR estimate (RR = 0.846)
28-day 5474 10.07 195,831 NA NA NA NA
90-day 4795 10.16 198,310 –678 0.09 Dominant 2479
NA, not applicable.
Note
Two approaches were used. The first approach involved adapting the QALY outputs of the model to account for different
adherence levels. The second approach involved adjusting model inputs to account for different adherence levels (i.e. the
relative treatment effects, vs. no treatment, for each health state). Both approaches involved adapting the cost inputs to the
model to reflect different prescription lengths.
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1b
Relevant NICE guidance on the management of T2DM in adults was reviewed. The most recent NICE
guidance (NG28, updated July 2016) included a decision model that assessed the cost-effectiveness of a
large number of pharmacological blood glucose-lowering therapies for adults with T2DM at three discrete
stages of disease progression (initial therapy, first stage and second stage treatment intensification).79
Table 18 provides an overview of the model that was developed by NICE but is itself a modified version
of the UK Prospective Diabetes Study (UKPDS) Outcomes Model Version 1, which is described in detail
elsewhere.79,97 Briefly, the model is a patient-level simulation that estimates the first occurrence of each of
seven diabetes-related complications (fatal or non-fatal myocardial infarction, other ischaemic heart disease,
stroke, heart failure, amputation, renal failure and eye disease) and death in order to estimate lifetime
QALYs for UK populations with T2DM. It is based on patient-level data from the UKPDS, a landmark,
randomised, multicentre trial of glycaemic therapies in patients with newly diagnosed T2DM, which
extends to 20 years of follow-up.97 The model is run in Microsoft Excel, with a time horizon of a lifetime.
The modifications made to the model by NICE included the addition of data on the costs and treatment
effects of the various interventions under examination. The model is the first to analyse the cost-effectiveness
of initial therapy (i.e. monotherapy with one oral antidiabetic drug) for T2DM in a setting relevant to the UK.
In this case of initial therapy, for example, lifetime costs and QALYs for seven therapies (six pharmacological
interventions, e.g. metformin, and placebo) were compared on the assumption that patients would later
move on to metformin–sulfonylurea and metformin–neutral protamine Hagedorn insulin as first- and
second-stage intensification treatments.
1c
The original model already included a placebo comparator. Hence, it was not necessary to identify
additional data on the incremental health benefits of commonly prescribed medications when compared
with ‘no treatment’.
As the decision model did not include dispensing fees, we identified these from the NHS Drug Tariff.60 The
costs of prescriber time (see Table 13) and wastage (see Table 14) were identified in the CPRD analysis of
initial glucose control in type 2 diabetes (see Chapter 3).
Stage 2: adapt the decision model
2a
In this case study, we focused on the impact of different prescription lengths at the initial therapy stage.
The existing structure of the model and all model inputs remained unchanged, as the identified model
already examined the costs and consequences of a wide range of pharmacological interventions for T2DM
that are currently prescribed in general practice in the UK.
2b
Metformin versus placebo Table 20 shows the lifetime costs and QALYs for metformin and placebo
(two of the seven comparators in the original model), which were estimated using the original source
model, with the cost outputs of the model inflated to 2015 prices. Metformin was chosen for use in this
case study because it is current first-line practice, and was the most cost-effective option, dominating
all other comparators, yielding expected lifetime costs and QALYs of £19,639 and 9.033, respectively.
For comparison, vildagliptin was associated with lifetime costs and QALYs of £21,043 and 8.954.
Unsurprisingly, the lifetime QALYs associated with the placebo were lower than those of the other six
treatments. However, costs were higher for the placebo than for metformin, owing to a higher risk of
diabetes-related complications and higher treatment costs as a result of more rapid progression to
first- and second-stage intensification therapies (metformin–sulfonylurea and metformin–NPH). For these
reasons, metformin dominated placebo (INB £3231). In a pairwise probabilistic comparison of treatment
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options for initial therapy reported in the NICE guidelines, there were no instances in which placebo was
cost-effective at the £20,000 per QALY threshold.
Three-month versus 28-day prescribing of metformin We estimated the lifetime costs and QALYs
associated with 3-month and 28-day prescribing of metformin. As stated previously, we assumed that the
3-month prescribing yielded equivalent costs and outcomes to the metformin treatment arm in the source
model (i.e. p = 1 as per Figure 9). To this was added additional annual transactional (dispensing fees and
prescriber time) and drug wastage costs {£10.34 per annum [dispensing fees (£0.90) + prescriber time
(£0.28) +wastage costs (£1.37)] × [365/90]} for the period of time the average patient received initial
treatment (2.3 years).
For the 28-day prescriptions, we took a weighted average of the costs and QALYs of the metformin and
placebo arms according to the RR of being adherent reported by Hermes et al.35 and Taitel et al.,45 which
were 0.891 and 0.863, respectively. These are reported as two separate scenario analyses.35,45 The total
costs and QALYs for the 28-day prescriptions in the first scenario are calculated as (0.891 × metformin arm
costs or QALYs) + (0.109 × placebo arm costs or QALYs). To these calculated total costs were added the
additional transactional and drug wastage costs for the period of time the average patient received initial
treatment (3.64 years in the first scenario). In both scenarios, 3-month prescriptions were less costly and
yielded higher QALYs than 28-day prescriptions, with expected INBs of £423 and £511, respectively.
2c
We assessed uncertainty in our estimates using the lower bound of the 95% CI in the RR estimate
reported by Taitel et al.45 (RR = 0.851) and the upper bound of the RR estimate reported by Hermes et al.35
(RR = 0.926). In both cases, the INB was positive (see sensitivity analyses reported in Table 20).
Case study 2: selective serotonin reuptake inhibitors
Stage 1: identify relevant data and decision models
1a
The systematic review (see Chapter 2) identified two studies that had examined the relationship between
prescription length and adherence in antidepressant medications.37,45 No studies examined the relationship
between prescription length (or adherence) and health outcomes, and no decision models were identified.
1b
We reviewed relevant NICE guidance on depression in adults. The most recent NICE guidance (CG90,
published October 2009 and updated April 2016) included a decision model that examined the
cost-effectiveness of alternative pharmacological interventions (10 different groups of antidepressants were
assessed overall) with or without cognitive–behavioural therapy (CBT).95 Table 18 provides an overview of
the model, which is a decision tree with a 15-month time horizon. The model is operated in Microsoft
Excel.
As Figure 11 shows, in an example with two treatment arms, there are 12 possible pathways through the
model. Each pathway has probability nodes attached to three discrete treatment phases. These treatment
phases are a three-month acute treatment phase, a 6-month maintenance period (which together form a
9-month ‘treatment phase’) and a 6-month follow-up phase. Probability nodes in the model reflect the
likelihood of dropout (during the acute phase), no remission (during the maintenance period) and relapse
(during the follow-up phase). Costs (from the NHS perspective; see Table 29, Appendix 9) and QALYs
(derived from another study93) are assigned to each of the pathways through the model. The results for
each analysis were reported for two separate cohorts of 100 patients with moderate and severe
depression. Patients with severe depression faced higher patient monitoring costs than those with
moderate depression because they had hospital outpatient mental health consultations. Deterministic
sensitivity analysis was carried out on the upper and lower 95% credible intervals around some of the
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input parameters (e.g. response and dropout probabilities). The guideline states that probabilistic sensitivity
analysis was not possible because of limited access to data from a network meta-analysis from which many
of the input parameters were derived.95
1c
Although the original decision model did not include a placebo arm, the full NICE guidance did include
a separate clinical evidence review, which included data on the health consequences of specific
pharmacological interventions when compared with placebo. These data were used to inform our model
adaptations.
As the decision model did not include dispensing fees, we identified these from the NHS Drug Tariff.60
The costs of prescriber time (see Table 13) and wastage (see Table 14) were identified in the CPRD analysis
of depression (see Chapter 3).
Stage 2: adapt the decision model
2a
In this case study, we maintained the overall model structure since the identified model had recently been
updated by NICE in 2016 and already examined the costs and consequences of antidepressants currently
prescribed in general practice. However, when the original treatment arms emanating from the decision
node in the model were two comparable pharamacological interventions (or a pharamacological
Follow-up
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(9–15 months)
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treatment
phase
(3–9 months)
Acute 
treatment
phase
(0–3 months)
No relapse
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Remission
No remission
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FIGURE 11 Case study 2: adapted decision tree.
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intervention with and without CBT), in our adapted model (see Figure 11), we substituted instead 3-month
and 28-day prescribing of a ‘typical’ SSRI.
The unit cost data for our ‘typical’ SSRI were based on a weighted average of the costs associated with
10 groups of antidepressant medications. The weighted average was calculated using unit cost data for
each group of medications in the source model and data from the PCA (published by NHS England), which
showed the total number of items dispensed in the community in 2014 for each group of medications.84
For the 3-month and 28-day arms of the decision tree, we added the appropriate transaction and wastage
costs to these SSRI unit costs.
The health consequence data for our ‘typical’ SSRI were based on data reported in the NICE clinical
evidence review on the absolute risk of dropout, no remission and relapse for a placebo arm, and the RR
for an escitalopram treatment arm. These data were used to calculate the probability nodes in the decision
tree where the placebo arm represented our zero adherence scenario and the escitalopram treatment arm
represented our perfect adherence scenario (see Table 28, Appendix 9, for an overview of the health
consequence data). As the NICE guideline development group concluded that there was sufficient doubt
about the clinical importance of differences between antidepressant treatments to not justify the
development of recommendations for specific drugs,95 we did not examine data on the relative efficacy of
other antidepressants compared with escitalopram.
2b
Replicating the approach taken by NICE using the source model, we reported the model outputs in terms
of the total costs and QALYs of the two arms of the decision tree for two separate cohorts of 100 patients
with moderate and severe depression (see Table 21).
Selective serotonin reuptake inhibitors versus placebo We compared the costs and QALYs of SSRI of
a treatment arm versus a placebo arm, prior to inclusion of the additional transaction and wastage costs
associated with 28-day and 3-month prescribing. For patients with moderate and severe depression, SSRI
treatment was less costly (£188,274 vs. £201,315 in the case of moderate depression) than placebo with
higher QALY gains (62.78 vs. 61.13 in the case of moderate depression) (see Table 21). Comparing SSRI
treatment with placebo for moderate and severe depression resulted in INBs of £46,051 and £52,207.
Three-month versus 28-day prescribing of SSRIs Our 3-month treatment arm was based on data for
perfect adherence. As described in case study 1, the costs and QALYs for our 28-day treatment arm were
calculated using a weighted average of the costs and QALYs associated with perfect and zero adherence
based on the evidence from studies on the relationship between prescription length and adherence
identified in the systematic review. These studies, by Pfeiffer et al.37 and Taitel et al.,45 reported a RR of
0.542 and 0.748 respectively. Where RR = 0.542, 3-month prescriptions were less costly than 28-day
prescriptions (£189,445 vs. £223,221 in the case of moderate depression) and with higher QALY gains of
0.76 QALYs (62.78 vs. 62.02). In both moderate and severe depression, the INB was positive (see Table 21).
When the RR = 0.748, 3-month prescriptions were less costly than 28-day prescriptions (£189,445 vs.
£219,983 in the case of moderate depression) and had higher QALY gains of 0.42 QALYs (62.78 vs. 62.36
in the case of moderate depression). Again, in both moderate and severe depression, the INB was positive
(see Table 21).
2c
First, we assessed uncertainty in our estimates using the lower bound of the 95% CI in the RR estimate
reported by Pfeiffer et al.37 (RR = 0.540) and the upper bound of the RR estimate reported by Taitel et al.45
(RR = 0.780). In both cases, for moderate and severe depression, the ICERs remained negative and the INB
was positive (see the sensitivity analyses reported in Table 21).
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Second, following the original source model, we also completed sensitivity analyses around maximum and
minimum plausible values of the health state utilities and the RR of dropout, no remission and relapse
(for SSRI when compared with placebo). These values are shown in Table 28, Appendix 9. In all cases, the
ICER remained negative and the INB was positive. For example, using the lower bound estimates of the RR
of dropout, no remission and relapse, the INB for moderate depression ranged from £53,346 (when based
on Taitel et al.45 data) to £76,593 (when based on Pfeiffer et al.37 data).
Case study 3: secondary prevention of cardiovascular events
Stage 1: identify relevant data and decision models
1a
The systematic review (see Chapter 2) identified two studies, both of which indicated a positive relationship
between prescription length and adherence in antihypertensive medications.35,45 As in the other case studies,
we found no studies that had examined the relationship between prescription length (or adherence) and
health outcomes, and no decision models were identified.
1b
We reviewed relevant NICE guidance on pharmacological interventions for adults with hypertension. The most
recent NICE guidance (CG127, updated 2011) included an economic model that assessed the cost-effectiveness
of four groups of alternative antihypertensive medications (ACEIs/ARBs, beta-blockers, calcium-channel blockers,
thiazide-type diuretics) and a ‘no treatment’ comparator.91 Table 18 provides an overview of the model, which
is a Markov model with seven health states (event-free/well, myocardial infarction, unstable angina, stroke,
diabetes, heart failure and death). Figure 12, Appendix 9, provides a schematic representation of the model. All
patients start in the event-free/well health state and, during each 6-month cycle of the model, a proportion of
all patients enter each of the other health states. The likelihood of moving between states during each model
cycle is determined by transition probabilities, which vary according to patient characteristics (e.g. age, sex,
ethnicity and baseline health event risks) and the prescribed medication. The baseline risk for each health state
in an untreated population is based on published studies, and these risks are adjusted for each prescribed
medication using published data on the RRs versus no treatment (see Table 30, Appendix 10). Health state
utilities are also derived from published studies, and these are used to calculate QALYs. The annual costs
associated with each health state (from the NHS perspective), and the costs of medications, are used as inputs
in the model drawn from a variety of published studies and the BNF (see Table 18). The model is run in
Microsoft Excel for 1000 patients at a time, with a time horizon of a lifetime.
1c
It was not necessary to identify additional input data on the costs and health consequences of zero
adherence, as the source model included a ‘no treatment’ comparator. As the decision model did not
include dispensing fees, we identified these from the NHS Drug Tariff.60 The costs of prescriber time
(see Table 13) and wastage (see Table 14) were identified in the CPRD analysis of ‘secondary prevention of
myocardial infarction.’
Stage 2: adapt existing model
2a
In this case study, we maintained the overall model structure, since the source model already examined the
costs and consequences of the antihypertensive interventions currently prescribed in general practice. For all
our analyses, our cohort was based on a 65-year-old male with an annual CVD risk of 2%, heart failure risk of
1% and diabetes risk of 1.1%, as was the case in the base case model reported in the NICE guidance.
2b
Antihypertensives versus ‘no treatment’ The source model provided estimates of the total lifetime
costs and QALYs for each of the four groups of antihypertensive medications and the ‘no treatment’
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comparator (these are reported in Table 31 (see Appendix 10) alongside the ICER for each treatment
compared with ‘no treatment’). For example, for the ‘no treatment’ comparator, the total costs were
£5117 and the total QALYs were 9.57. Using the estimates for the four groups of antihypertensive
medications, we created our own ‘typical treatment’ comparator, which was a weighted average of the
costs and QALYs associated with each of the four groups of antihypertensive medications. The weighted
average was based on PCA figures published by NHS England, which showed the total number of items
dispensed in the community in 2014 for each of the four groups of antihypertensive medications.84 For this
‘typical treatment’ comparator, the total costs were £4503 and QALYs were 10.16. When comparing the
‘typical treatment’ with the ‘no treatment’ comparator, the INB was positive at £12,319. These results are
shown in Table 22.
Three-month versus 28-day prescribing of antihypertensives We estimated the lifetime costs and
QALYs associated with 3-month and 28-day prescribing of antihypertensive medications using two
different approaches. Both approaches involved adapting the cost inputs to the model to reflect different
prescription lengths. However, the second approach differs from the first in that the relative treatment
effects (vs. no treatment) for each health state (e.g. diabetes; see Table 30, Appendix 10) were also
adjusted to reflect different adherence levels.
First approach First, we created 3-month and 28-day treatment groups by adjusting the cost inputs and
the QALY outputs of the source model. The cost inputs in the model for each of the four antihypertensive
treatment groups were adjusted by adding the additional transactional and drug wastage costs to the
annual drug costs already included in the model. These additional costs were calculated on an annual basis
as the sum of the additional costs per prescription multiplied by the annual number of prescriptions.
In the 3-month treatment group, after the additional costs of £21.01 per annum {[dispensing fees
(£0.90) + prescriber time (£3.77) +wastage costs (£0.51)] × [365/90]} were added to the four treatment
groups in the model, the total cost and total QALY outputs were calculated as per the ‘typical treatment’
comparator described above.
In the 28-day treatment group, the total QALYs were a weighted average of the QALYs in the ‘typical
treatment’ and the ‘no treatment’ comparators. The weighted average was calculated using the method
described in the other case studies and based on evidence from the studies by Hermes et al.35 and Taitel
et al.45 on the relationship between prescription length and adherence, which reported RRs of 0.92 and
0.85, respectively.35,45 Thus, using the Hermes data as an example, the total QALYs were calculated as the
sum of 0.92 multiplied by ‘typical treatment’ QALYs and 0.08 multiplied by ‘no treatment’ QALYs.
The total costs in the 28-day treatment group were a weighted average of a perfect and a zero adherence
scenario using the same RRs identified in the Hermes et al.35 and Taitel et al.45 studies. The perfect adherence
scenario was calculated as per the 3-month treatment group above, but with £61.68 of additional costs per
annum {[dispensing fees (£0.90) + prescriber time (£3.76)+wastage costs (£0.07)] × [365/28]}. The zero
adherence scenario was calculated as per the perfect adherence scenario, however the RRs associated with
treatment (vs. no treatment) for each health state were adjusted in the model from RR < 1 (as reported in
Table 30, Appendix 10) to RR = 1.
The results for this first approach are reported in Table 22. In all analyses, the 3-month prescriptions were
less costly and yielded more QALYs than the 28-day prescriptions. The expected INB ranged from £1554
(using Hermes et al.’s35 RR) to £2431 (using Taitel et al.’s45 RR).
Second approach In our second approach, the 3-month treatment group remained unchanged. For the
28-day treatment group, the cost inputs were adjusted following the same method used in the first
approach. The relative treatment effects associated with each of the four treatments (vs. no treatment)
were also adjusted for each of the six health states in the model (myocardial infarction, unstable angina,
stroke, diabetes, heart failure and death). These relative treatment effects (24 in total) were adjusted using
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a weighted average of those used in the source model and a zero adherence scenario (i.e. relative
treatment effect = 1) using the data from the Hermes et al.35 and Taitel et al.45 studies. Thus, in an example
using the Hermes data, where RR = 0.92, the relative treatment effect for unstable angina when prescribed
thiazide-type diuretics was 0.901 [(0.893 × 0.92) + (1 × 0.08) where 0.893 = relative treatment effect in the
source model].
The results are reported in Table 22. In all analyses, the 3-month prescriptions are less costly and yield
more QALYs than 28-day prescriptions. The expected INB ranges from £1630 (using Hermes et al.’s35 RR)
to £2537 (using Taitel et al.’s45 RR).
2c
First, we assessed uncertainty in our estimates using the lower bound of the 95% CI in the RR estimate
reported by Taitel et al.45 and the upper bound of the RR estimate reported by Hermes et al.35 (see
Table 22). Second, we replicated the four-way sensitivity analysis used in the NICE source model. This
included a range of plausible estimates for age, annual risk of CVD, diabetes and heart failure. In all cases,
the ICERs remained negative and the INB was positive.
Discussion
The systematic review and CPRD analyses reported in Chapters 2 and 3 provided consistent evidence that
longer prescription lengths are associated with increased adherence but increased wastage. However, the
CPRD analyses showed that reductions in transaction costs associated with longer prescriptions more than
compensated for the increased wastage costs, at least in the case studies considered. The modelling
component presented in the current chapter builds on these findings by attempting to quantify the overall
costs incurred by the NHS, and the resulting outcomes from 3-month versus 28-day prescription lengths
over a longer time horizon.
In all three case studies, longer prescriptions were associated with lower costs and higher QALYs than
shorter prescription lengths. The underlying reason for this finding was improved adherence in the
3-month scenarios, which resulted from the evidence identified in the systematic review. However, in
contrast to the studies in the systematic review, our models were able to account for the medium- and
longer-term QALY gains and cost savings accrued by the NHS through reductions in health-care utilisation
that arose from improved adherence. As a result, the INB for 3-month prescription lengths was always
positive. Notably, this was the case despite the models having different time horizons owing to the nature
of the case study treatments. Case studies 1 and 3 focus on the prevention of future cardiovascular events,
so increased adherence reduces the expected costs. In contrast, case study 2 focused on SSRI treatment
for moderate and severe depression, a chronic or episodic condition, and hence there are no potential
‘downstream’ savings from avoided future events. In this second case study, the lower costs in the 28-day
arm are also a result of reduced drug costs for patients who discontinued their treatment during the acute
treatment phase (i.e. reduced persistence; see Table 29, Appendix 9) and thus were prescribed treatment
for only 28 days rather than for 3 months.
The finding of QALY gains and cost savings associated with 3-month prescription lengths was also
consistently found in our sensitivity analyses, which assessed a plausible range of various inputs to the
models including the RRs of being adherent. The finding would also be unaffected by any change to the
two key assumptions introduced in the Methods section of this chapter on the relationship between
adherence and health outcomes (namely the assumptions of a linear dose–response curve and the
maximum effect being equivalent to a comparison of model active and placebo/no treatment arms of
clinical trials), although the magnitude of QALY gains, cost savings and INB would be affected. Longer
prescriptions would only be associated with a negative INB if they resulted in a decline in treatment effect.
This appears unlikely, as our systematic review of the evidence (see Chapter 2) suggests a statistically
significantly positive association with adherence, and it is reasonable to suppose improved adherence will
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not be associated with reduced treatment effect. The major caveat to bear in mind alongside this,
however, is that the studies included in the review are rated as having a high risk of bias.
Compared with the literature review, which identified just one study that had examined the relationship
between health outcomes and prescription length,39 our study has provided an indication of the
magnitude of change in health outcomes (QALYs) that might be associated with 3-month prescription
lengths in comparison with 28-day prescription lengths as a consequence of the impact on adherence to
treatment. Unsurprisingly, owing to the finding in the systematic review of a positive relationship between
prescription length and adherence, all of the results reported in this section suggested that longer
prescriptions were associated with more QALYs. This was also the finding of the Batal et al.39 study,
although that study was restricted to a single health-related outcome (cholesterol level) and short-term
follow-up. By examining longer-term follow-up, we have been able to include the health consequences of
a reduction in longer-term complications and associated treatments.
The finding of a negative relationship between costs and prescription length in the case studies in this
section was consistent with four42,45,46,49 of the five42,44–46,49 studies identified in the systematic review,
but the relationship arose for different reasons. As these four studies in the systematic review had examined
the costs to third-party payers over a short time horizon, cost savings arose in longer prescriptions in those
studies because of reductions in some of the administrative costs of prescribing medication, for example
dispensing fees. However, these studies did not account for the changes in wider health-care expenditure
that would result, particularly in the longer term, from the changes in health status associated with different
adherence levels. Conversely, although the fifth study identified in the systematic review44 did examine
those wider health-care expenditures, it was the only study to identify a positive relationship between
prescription length and costs. This is likely to be because the health-care expenditures were examined over
only a short time horizon, whereas two of the case studies in this section examined the costs of health care
associated with the longer-term health consequences over a lifetime. Furthermore, the five studies42,44–46,49
identified in the systematic review that examined the relationship between prescription length and costs
were US based and generally from a particular perspective (e.g. Veterans Affairs or Medicaid), and thus may
not be directly comparable to the UK setting.
Limitations of the decision modelling
The three case studies are based on existing, good-quality decision models, all of which have been used to
inform policy in the past. However, there are a number of limitations to our analyses.
First, our assumption of a positive relationship between prescription length and adherence was based on a
small number of studies (n = 2 in each case study) identified in the systematic review. The limitations of
these studies are fully assessed in the systematic review section, but, crucially, they were observational,
not randomised experimental studies, and so are potentially subject to bias. Other potential sources of bias
include those common to all decision modelling, namely validity of all input data on cost and effectiveness,
whether or not the structure of the model is plausible and whether or not the model is ‘consistent’
(Philips et al.98). In contrast to other studies that have used decision modelling, including the evaluation of
the NMS by Boyd et al.,90 which assessed the longer-term cost and health impacts of a policy change in
pharmacy to support increased adherence, our study was limited because it was not based on evidence
from a robust RCT.
Second, we assumed that the accrued costs and QALYs in the treatment arms of the models equated to
‘perfect adherence’, or at least to ‘best adherence’, and that the placebo or no treatment arms represented
zero adherence. Given prior belief (informed by the systematic review) that longer prescriptions are associated
with better adherence, we set the 3-month prescription costs and QALYs equal to the treatment arm costs
and QALYs. The 28-day prescription costs and QALYs were assumed to be a weighted average of the
treatment and placebo arm according to the RR of being adherent (as described in theMethods section of
this chapter, the RR of being adherent in those studies was based on two standard measures of adherence: a
dichotomised measure, based on the percentage of patients with ≥ 80%medication adherence, and the
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MPR, i.e. days covered per measurement period). These were necessary assumptions owing to the lack of
better-quality data.
There are several points to note. First, except for the additional transaction and wastage costs, the ICER is
insensitive to the ‘starting point’ for the analysis. For example, the opposite extreme would have been
to assume that the 28-day prescription arm costs and QALYs were equal to those in the placebo/no
treatment arm, and to define the 3-month prescription arm as a weighted average of 1 – 1/RR of the
treatment arm costs and QALYs and 1/RR of the no treatment arm. This would yield the same ICER as
illustrated in Figure 10 and Equation 5:
ICER ¼ ΔC
ΔE
· λ (7)
INB ¼ λΔE−ΔC ¸ 0, (8)
where λ =willingness to pay for a unit of outcome and E = QALYs (NICE assigns a value of
£20,000–30,000 to λ).
Second, as stated in the Methods section of this chapter, we have used ‘no treatment’ and ‘placebo’
interchangeably in the analysis and, as a result, we may have underestimated the health gain from
increased adherence as a result of longer prescription lengths.
Other limitations were that we assumed adherence did not change over the period of the analysis, and,
although we took a NHS perspective, we excluded any revenue gained by the NHS from prescription
charges. Patients with diabetes are exempt from the prescription charge, and almost 90% of prescriptions
dispensed in the community in England do not attract any charge; therefore, any revenue would be
minimal and thus unlikely to change the results of our analysis.88 Costs of drugs were based on the lowest
price brand and pack size listed in the BNF, and we did not consider any combination preparations. If more
expensive versions were used, then the cost savings through reduced wastage would be higher than those
suggested here.
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Chapter 5 Conclusions and recommendations for
further work
The systematic review and CPRD cost analyses provided consistent evidence that longer prescriptionlengths were associated with modest improvements in adherence but also with increased wastage.
However, despite increased waste, there was evidence that longer prescriptions result in net cost savings
as a result of reductions in costs associated with dispensing fees and prescriber time, which outweigh
wastage costs. Based on the findings of the CPRD analyses, the biggest impact on costs was prescribers’
time. Overall, the CPRD analyses predicted that TUC savings ranged from £6.33 to £9.07 for the five
conditions studied (glucose control with oral drug therapy in T2DM, treatment of hypertension in T2DM,
lipid management in T2DM, treatment for the secondary prevention of myocardial infarction, and
depression) when total costs were standardised to a common 90-day time period. Switching to longer
prescriptions could potentially result in substantial savings to the NHS. For example, if the 95% of
prescriptions for antidepressants that are for < 60 days’ supply were issued as longer prescriptions, the
total savings for the NHS could be as much as £305M per year. If the model is restricted to just dispensing
fees, savings would be in the region of £78M per year. This portion could be considered cash releasing,
and the remaining portion would be accounted for by freed-up GP time.
The decision modelling exercise quantified overall costs and outcomes associated with longer versus
shorter duration prescriptions over a longer time horizon. In all three cases, after accounting for differences
in prescribing time, dispensing fees and wastage costs, longer prescription lengths were associated with
lower costs incurred by the NHS as a result of reductions in the cost of treating disease-specific health
complications. In all cases, longer prescriptions were assumed to lead to better health outcomes as a result
of increased medication adherence.
The quality of evidence included in this study is considered to be weak; the findings from all three research
strands are based on retrospective analysis of administrative data. Despite the limitations of the study, the
consistency between the results of the systematic review and CPRD analyses, and across case studies within
the CPRD analyses, increases the confidence in our conclusions that longer prescriptions are associated with
short-term cost savings as a result of reductions in transaction costs. Broadening our analysis to consider
differences in adherence and out-of-pocket expenses incurred by the patient, such as patient time and
travel costs, is likely to further increase the cost savings associated with issuing longer prescription lengths.
There is less certainty with regard to long-term costs. The validity of the finding from the decision
modelling that long-term cost savings were achieved is underpinned by the assumption that improved
adherence is associated with improved health outcomes. This study provides no direct evidence of the
impact of differing prescription lengths on health outcomes.
Overall, the current evidence base does not support current policies promoting shorter prescription lengths
over longer prescription lengths. If medication adherence is positively correlated with health outcomes,
as seems to be suggested by the wider literature,54,55 there may be clinical benefits of increasing the length
of repeat prescriptions for patients with chronic conditions. Based on the reported cost savings associated
with longer prescription lengths in our study, extrapolating the mean values to populations with stable
chronic conditions in the UK could also result in substantial savings to the NHS.
Recommendations for future research
There is a need to more reliably evaluate the impact of differing prescription lengths on adherence, patient
health outcomes and impact on total costs to the NHS. This need can be addressed through a variety of
means. First, a prospective cluster RCT could provide some insights into the health impacts of different
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prescription lengths for well-defined patient groups. For example, within a chosen disease group, one
could consider comparing patients who are new to treatment with patients who have been receiving
treatment for years, exploring the different parameters of long-term management and adherence. Second,
observational studies focusing on patient experience, the patient–provider relationship and on the
provider’s time management would complement the evidence base by looking at outcomes that have so
far been rarely studied in relation to prescription length, adding a much-needed individual-centred
dimension to the more widely researched cost aspect of prescribing issues. Third, more modelling studies
could build on the growing accessibility, linkage possibilities and quality of large primary care databases to
look at the effectiveness and cost-effectiveness of prescription length on a wider range of conditions in a
fashion similar to the one used in this study. Overall, the priority for future research should be to identify
conditions or groups of patients that should receive shorter or longer prescriptions. To determine the need
for any further research, an expected value of perfect information (EVPI) analysis should be performed. It
has not been possible to conduct an EVPI analysis based on data generated in this study, as the analysis of
uncertainty in the modelling in Chapter 3 was limited to a multiway sensitivity analysis, rather than to a
probabilistic sensitivity analysis.
A further strand of future research could be to explore means of quantifying the high risk of bias in the
existing literature. The obvious approach would be through a well-conducted prospective randomised
study as suggested above. In the absence of this, the only alternative would be to seek expert opinion. This
could be elicited using a recognised tool such as the Sheffield Elicitation Framework (SHELF).99 The results
of this systematic review of the effect of longer duration of prescriptions on adherence and the associated
manuscripts would form the background material, and the meta-analysis would form the prior distribution
of effect. At the workshop, participants would dissect the manuscripts in detail, with a view to quantifying
the bias, and revise the prior distribution to generate a posterior distribution of effect. Inputting this
posterior distribution into the decision models and converting them to probabilistic analyses would allow a
value of information analysis to determine whether or not a randomised trial would be of value to society.
Future studies should seek to standardise measurements of adherence and wastage to ease interpretation
of findings and to increase comparability across settings. In addition, future research should shift from
comparing dichotomous prescription lengths to comparing a range of different prescription lengths in
order to identify the optimal prescription length for patients receiving repeat prescriptions for stable
chronic conditions.
CONCLUSIONS AND RECOMMENDATIONS FOR FURTHER WORK
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
Acknowledgements
We would like to thank a number of people who contributed to the successful completion of thisstudy. Jody Larkin (Research Librarian, Knowledge Services, RAND Corporation) contributed to the
development of the systematic review protocol and conducted the literature searches for the systematic
review.
Jon Sussex (RAND Europe) acted in a quality assurance role and provided valuable insight throughout the
project. Rachel Elliott (Professor of Medicines and Health, School of Pharmacy, University of Nottingham)
provided advice and guidance for the economic modelling. Finally, we would like to thank the patient and
public involvement representatives of the INsPIRE group for their support and comments.
Contributions of authors
Céline Miani [Senior Analyst, Cambridge Centre for Health Services Research (CCHSR), RAND Europe]
co-led the systematic review and co-co-ordinated the preparation of this report for publication.
Adam Martin (Analyst, CCHSR, RAND Europe) contributed to the systematic review and co-led the
economic modelling.
Josephine Exley (Senior Analyst, CCHSR, RAND Europe) co-led the systematic review and co-co-ordinated
the preparation of this report for publication.
Brett Doble (Research Associate, CCHSR, Institute of Public Health, University of Cambridge) co-led the
CPRD analysis.
Ed Wilson (Senior Research Associate, CCHSR, Institute of Public Health, University of Cambridge) co-led
the CPRD analysis and the economic modelling.
Rupert Payne (Consultant Senior Lecturer, Centre for Academic Primary Care, University of Bristol)
provided expert advice and guidance for the whole study.
Anthony Avery (Professor of Primary Health Care, Dean of the School of Medicine, School of Medicine,
University of Nottingham) provided advice and guidance for the whole study.
Catherine Meads (Research Leader, CCHSR, RAND Europe) provided intellectual oversight for the
whole study.
Anne Kirtley (Insight Research Analyst, Strategy Division, Wellcome Trust) contributed to the
systematic review.
Molly Morgan Jones (Associate Director, RAND Europe) was the principal investigator on the project
from September 2015. She was involved in the reviewing of findings and provided oversight for the study.
Sarah King (Visiting Fellow, Institute of Public Health, University of Cambridge) conceived the study and
co-led the systematic review.
All authors reviewed and contributed to the overall synthesis.
DOI: 10.3310/hta21780 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 78
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Miani et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
79
Publications
Doble B, Payne R, Harshfield A, Wilson ECF. Retrospective, multicohort analysis of the Clinical Practice
Research Datalink (CPRD) to determine differences in the cost of medication wastage, dispensing fees and
prescriber time of issuing either short (< 60 days) or long (≥ 60 days) prescription lengths in primary care
for common, chronic conditions in the UK. BMJ Open 2017;7:e019382.
Data sharing statement
All available data are included as appendices to the report.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
80
References
1. NHS Digital. Prescription Cost Analysis, England – 2015. URL: www.hscic.gov.uk/catalogue/
PUB20200/pres-cost-anal-eng-2015-fact.pdf (accessed May 2016).
2. Petty DR, Zermansky AG, Alldred DP. The scale of repeat prescribing – time for an update. BMC
Health Serv Res 2014;14:76. http://dx.doi.org/10.1186/1472-6963-14-76
3. NHS Employers, Pharmaceutical Services Negotiating Committee, General Practitioners
Committee. Guidance for the Implementation of Repeat Dispensing. London: NHS Confederation
Publications Team; 2013.
4. NHS Digital. Prescription Cost Analysis, England – 2015. Data Top 20. URL: http://content.digital.
nhs.uk/article/2021/Website-Search?productid=20437&q=Prescription+cost+analysis++England
+2015&sort=Relevance&size=10&page=1&area=both#top (accessed May 2016).
5. Prescribing and Medicines Team, NHS Digital. Prescriptions Dispensed in the Community: England
2005–2015. Leeds: NHS Digital; 2016.
6. National Audit Office. Prescribing Costs in Primary Care. London: National Audit Office; 2007.
7. Trueman P, Lowson K, Blighe A, Meszaros A, Wright D, Glanville J, et al. Evaluation of the Scale,
Causes and Costs of Waste Medicines: Final Report. York and London: York Health Economics
Consortium and The School of Pharmacy, University of London; 2010.
8. Pharmaceutical Services Negotiating Committee. Medicines Wastage and 28 Day Prescribing
Guidance. London: Pharmaceutical Services Negotiating Committee; 2007.
9. NHS Cambridgeshire. Repeat Medication for 28 Days. Cambridge: Cambridgeshire Primary Care
Trust; 2009.
10. NHS North East Essex. Prescribing Interval Policy. Essex: North East Essex PCT; 2010.
11. NHS Dorset Clinical Commissioning Group. Medicines Code Chapter 15: Policy for Repeat
Prescribing and Medication Review. Dorset Clinical Commissioning Group; 2013.
12. Hawksworth G, Wright D, Chrystyn H. A detailed analysis of the day to day unwanted medicinal
products returned to community pharmacies for disposal. J Soc Adm Pharm 1996;13:215–22.
13. Pharmaceutical Services Negotiating Committee. PSNC Briefing 08613: Medicines Wastage and
Prescription Duration. London: Pharmaceutical Services Negotiating Committee; 2013.
14. All Wales Medicines Strategy Group. All Wales Review and Guidance for Prescribing
Intervals. 2013.
15. Sun AP, Kirby B, Black C, Helms PJ, Bennie M, McLay JS. Unplanned medication discontinuation
as a potential pharmacovigilance signal: a nested young person cohort study. BMC Pharmacol
Toxicol 2014;15:11. http://dx.doi.org/10.1186/2050-6511-15-11
16. British National Formulary. Controlled Drugs and Drug Dependence. URL: www.evidence.nhs.uk/
formulary/bnf/current/guidance-on-prescribing/controlled-drugs-and-drug-dependence
(accessed May 2016).
17. Davies JE, Taylor DG. Individualisation or standardisation: trends in National Health Service
prescription durations in England 1998–2009. Prim Health Care Res Dev 2013;14:164–74.
https://doi.org/10.1017/S146342361200045X
18. Duerden M, Millson D, Avery A, Smart S. The Quality of GP Prescribing. London: The King’s
Fund; 2011.
DOI: 10.3310/hta21780 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 78
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Miani et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
81
19. General Practitioners Committee. Prescribing in General Practice. London: BMA; 2013.
20. General Medical Council. Good Practice in Prescribing and Managing Medicines and Devices.
London: General Medical Council; 2013.
21. White KG. UK interventions to control medicines wastage: a critical review. Int J Pharm
Pract 2010;18:131–40.
22. Domino ME, Olinick J, Sleath B, Leinwand S, Byrns PJ, Carey T. Restricting patients’ medication
supply to one month: saving or wasting money? Am J Health Syst Pharm 2004;61:1375–9.
23. Mitchell AL, Hickey B, Hickey JL, Pearce SH. Trends in thyroid hormone prescribing and consumption
in the UK. BMC Public Health 2009;9:132. http://dx.doi.org/10.1186/1471-2458-9-132
24. Wong MC, Tam WW, Wang HH, Cheung CS, Tong EL, Cheung NT, et al. Duration of initial
antihypertensive prescription and medication adherence: a cohort study among 203,259 newly
diagnosed hypertensive patients. Int J Cardiol 2015;182:503–8. http://dx.doi.org/10.1016/
j.ijcard.2014.12.058
25. Department of Health (DH). Making Best Use of Medicines: Report of a Department of Health
Roundtable Event Hosted by The King’s Fund. London: DH; 2011.
26. Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions:
Version 5.1.0 [updated March 2011]; 2011. URL: http://handbook.cochrane.org (accessed
May 2016).
27. Liberati A, Altman D, Tetzlaff J, Mulrow C, Gøtzsche P, Ioannidis J, et al. The PRISMA statement
for reporting systematic reviews and meta-analyses of studies that evaluate health care
interventions: explanation and elaboration. Ann Intern Med 2009;15:W65–94.
28. King S, Miani C, Larkin J, Exley J, Martin A, Kirtley A. Clinical and cost-effectiveness of issuing
longer versus shorter duration (3 month vs. 28 day) prescriptions for prescribed medication in
patients with stable, chronic conditions. PROSPERO 2015:CRD42015027042. URL: www.crd.york.
ac.uk/PROSPERO/display_record.asp?ID=CRD42015027042 (accessed June 2016).
29. The World Bank. World Bank Country and Lending Groups. URL: http://data.worldbank.org/
about/country-and-lending-groups#Low_income (accessed June 2016).
30. Sterne J, Hernán M, Reeves B, Savovic´ J, Berkman N, Viswanathan M, et al. The Risk Of Bias
In Non-randomized Studies – of Interventions (ROBINS-I) Assessment Tool; 2016. URL:
https://sites.google.com/site/riskofbiastool//welcome/home (accessed July 2016).
31. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12:
Interpreting Results and Drawing Conclusions. In Higgins JPT, Green S, editors. Cochrane
Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration; 2011.
32. Murphy P, Khandelwal N, Duncan I. Comparing medication wastage by fill quantity and
fulfillment channel. Am J Pharm Benefits 2012;4:e166–71.
33. Higgins J, Green S, editors. 9.4.6 Combining Dichotomous and Continuous Outcomes; 2011.
URL: http://handbook.cochrane.org/chapter_9/9_4_6_combining_dichotomous_and_continuous_
outcomes.htm (accessed September 2016).
34. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing Data and Undertaking Meta-Analyses.
In Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions:
The Cochrane Collaboration; 2008. https://doi.org/10.1002/9780470712184.ch9
35. Hermes M, Gleason PP, Starner CI. Adherence to chronic medication therapy associated with
90-day supplies compared with 30-day supplies. J Manag Care Pharm 2010;16:141–2.
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
82
36. Jiang JZ, Khandelwal N, Lee KY. Comparing medication adherence and wastage among three different
retail programs. Value Health 2007;10:A29. https://doi.org/10.1016/S1098-3015(10)68621-4
37. Pfeiffer PN, Szymanski BR, Valenstein M, McCarthy JF, Zivin K. Trends in antidepressant
prescribing for new episodes of depression and implications for health system quality measures.
Med Care 2012;50:86–90. http://dx.doi.org/10.1097/MLR.0b013e3182294a3b
38. Ryvkin M, Garavaglia S. Wasted medication: How big is the problem? Value Health 2009;12:A82.
https://doi.org/10.1016/S1098-3015(10)73471-9
39. Batal HA, Krantz MJ, Dale RA, Mehler PS, Steiner JF. Impact of prescription size on statin adherence
and cholesterol levels. BMC Health Serv Res 2007;7:175. https://doi.org/10.1186/1472-6963-7-175
40. Steiner JF, Robbins LJ, Roth SC, Hammond WS. The effect of prescription size on acquisition of
maintenance medications. J Gen Intern Med 1993;8:306–10. https://doi.org/10.1007/BF02600143
41. Thiebaud P, Patel BV. Does 90-day prescription supply at retail improve compliance in a managed
care setting? Value Health 2006;9:A136. http://dx.doi.org/10.1016/s1098-3015(10)64725-0
42. Walton S. A model for comparing unnecessary costs associated with various prescription fill-quantity
policies: illustration using VA data. J Managed Care Pharm 2001:7;384–90. https://doi.org/
10.18553/jmcp.2001.7.5.386
43. Schectman JM, Bovbjerg VE, Voss JD. Predictors of medication-refill adherence in an indigent
rural population. Med Care 2002;40:1294–300. http://dx.doi.org/10.1097/01.MLR.0000036412.
26803.92
44. Domino ME, Martin BC, Wiley-Exley E, Richards S, Henson A, Carey TS, Sleath B. Increasing time costs
and copayments for prescription drugs: an analysis of policy changes in a complex environment.
Health Serv Res 2011;46:900–19. http://dx.doi.org/10.1111/j.1475-6773.2010.01237.x
45. Taitel M, Fensterheim L, Kirkham H, Sekula R, Duncan I. Medication days’ supply, adherence,
wastage, and cost among chronic patients in Medicaid. Medicare Medicaid Res Rev 2012;2:E1–13.
http://dx.doi.org/10.5600/mmrr.002.03.a04
46. Parikh SP, Dishman BR, Smith TL. Ninety-day versus thirty-day drug-dispensing systems. Am J
Health Syst Pharm 2001;58:1190–1.
47. Schmittdiel JA, Nichols GA, Dyer W, Steiner JF, Karter AJ, Raebel MA. Health care system-level
factors associated with performance on Medicare STAR adherence metrics in a large, integrated
delivery system. Med Care 2015;53:332–7. http://dx.doi.org/10.1097/MLR.0000000000000328
48. Faris RJ, Filipek TM, Tang J, Wanta TM, Takagi MA, Steinberg SC. A retrospective comparative
analysis of medication waste from day supply plan design in specialty pharmacy. J Manag Care
Pharm 2010;16:516.
49. Rabbani A, Alexander GC. Cost savings associated with filling a 3-month supply of prescription
medicines. Appl Health Econ Health Policy 2009;7:255–64. http://dx.doi.org/10.2165/
11313610-000000000-00000
50. National Institute for Health and Care Excellence. Methods for the Development of NICE Public
Health Guidance (third edition). Appendix E Algorithm for Classifying Quantitative (Experimental
and Observational) Study Designs: National Institute for Health and Care Excellence; 2012.
51. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic
Evaluation of Health Care Programmes. 4th edn. Oxford: Oxford University Press; 2015.
52. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa
Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses; 2014.
URL: www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed May 2016).
DOI: 10.3310/hta21780 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 78
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Miani et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
83
53. NHS Business Services Authority. Medical Exemption Certificates. 2012. URL: www.nhsbsa.nhs.uk/
1126.aspx (accessed August 2016).
54. Dragomir A, Côté R, White M, Lalonde L, Blais L, Bérard A, Perreault S. Relationship between
adherence level to statins, clinical issues and health-care costs in real-life clinical setting. Value
Health 2010;13:87–94. http://dx.doi.org/10.1111/j.1524-4733.2009.00583.x
55. Perreault S, Ellia L, Dragomir A, Côté R, Blais L, Bérard A, Lalonde L. Effect of statin adherence on
cerebrovascular disease in primary prevention. Am J Med 2009;122:647–55. http://dx.doi.org/
10.1016/j.amjmed.2009.01.032
56. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnston JA. A meta-
analysis of the assocation between adherence to drug therapy and mortality. BMJ 2006;333:15.
https://doi.org/10.1136/bmj.38875.675486.55
57. McGrady ME, Hommel KA. Medication adherence and health care utilization in pediatric chronic
illness: a systematic review. Pediatrics 2013;132:730–40. http://dx.doi.org/10.1542/peds.2013-1451
58. Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to
lower health care use and costs despite increased drug spending. Health Aff 2011;30:91–9.
http://dx.doi.org/10.1377/hlthaff.2009.1087
59. Wong ES, Bryson CL, Hebert PL, Liu CF. Estimating the impact of oral diabetes medication
adherence on medical costs in VA. Ann Pharmacother 2014;48:978–85. https://doi.org/
10.1177/1060028014536981
60. NHS Business Services Authority on behalf of the Department of Health. Part IIIA: Professional
Fees (Pharmacy Contractors), in NHS Electronic Drug Tariff. 2016. URL: www.drugtariff.nhsbsa.
nhs.uk/#/00336026-DD_1/DD00335916/Part%20IIIA%20-%20Professional%20Fees%20
(Pharmacy%20Contractors) (accessed August 2016).
61. Wilson PM, Kataria N, McNeilly E. Patient and carer experience of obtaining regular prescribed
medication for chronic disease in the English National Health Service: a qualitative study. BMC
Health Serv Res 2013;13:192. http://dx.doi.org/10.1186/1472-6963-13-192
62. Addison’s Disease Self Help group. Letter to Professor Gilmore on Review of Prescription Charges
for Those With Long-term Conditions. 2009. URL: www.addisons.org.uk/forum/index.php?/files/
file/124-2009-review-of-prescription-charges/ (accessed July 2016).
63. Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting measures
of adherence with simple drug use, medication switching, and therapeutic duplication. Ann
Pharmacother 2009;43:36–44. http://dx.doi.org/10.1345/aph.1K671
64. Christensen DB, Williams B, Goldberg HI, Martin DP, Engelberg R, LoGerfo JP. Assessing
compliance to antihypertensive medications using computer-based pharmacy records. Med Care
1997;35:1164–70. https://doi.org/10.1097/00005650-199711000-00008
65. Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int
2015;2015:217047. http://dx.doi.org/10.1155/2015/217047
66. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods,
validity, and applications. J Clin Epidemiol 1997;50:105–16. https://doi.org/10.1016/
S0895-4356(96)00268-5
67. Payne R. Understanding can lead to a solution for non-adherence. Prescriber 2014;25:27–8.
https://doi.org/10.1002/psb.1284
68. Hickey JL, Beckett W, Pearce S. Restriction of levothyroxine prescriptions – inconvenient for
patients and economically ineffective. BMJ 2007;334:1076.
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
84
69. Schlomer BJ, Copp HL. Secondary data analysis of large data sets in urology: successes and errors
to avoid. J Urol 2014;191:587–96. http://dx.doi.org/10.1016/j.juro.2013.09.091
70. Gauch RR. Hormone Replacement Therapy – The silver bullet that misfired. In It’s Great! Oops, No
It Isn’t: Why Clinical Research Can’t Guarantee the Right Medical Answers. Dordrecht: Springer
Netherlands; 2009. pp. 155–71.
71. Doble B, Payne R, Harshfield A, Wilson ECF. Retrospective, multicohort analysis of the Clinical
Practice Research Datalink (CPRD) to determine differences in the cost of medication wastage,
dispensing fees and prescriber time of issuing either short (< 60 days) or long (≥ 60 days)
prescription lengths in primary care for common, chronic conditions in the UK. BMJ Open
2017;7:e019382. https://doi.org/10.1136/bmjopen-2017-019382
72. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, Smeeth L. Data
Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827–36.
http://dx.doi.org/10.1093/ije/dyv098
73. Mathur R, Bhaskaran K, Chaturvedi N, Leon DA, vanStaa T, Grundy E, Smeeth L. Completeness
and usability of ethnicity data in UK-based primary care and hospital databases. J Public Health
2014;36:684–92. http://dx.doi.org/10.1093/pubmed/fdt116
74. Campbell J, Dedman D, Eaton S, Gallagher A, Williams T. Is the GPRD GOLD population
comparable to the UK population? Pharmacoepidemiol Drug Saf 2013;22:280.
75. Medicines and Healthcare products Regulatory Agency (MHRA). The Clinical Practice Research
Datalink (CPRD). 2016. URL: www.cprd.com/home/ (accessed August 2016).
76. Joint Formulary Committee. British National Formulary (online). London: BMJ group and
Pharmaceutical Press. URL: www.evidence.nhs.uk/formulary/bnf/current/ (accessed August 2016).
77. Brodie MJ, Chung S, Wade A, Quelen C, Guiraud-Diawara A, François C, et al. Clobazam and
clonazepam use in epilepsy: results from a UK database incident user cohort study. Epilepsy Res
2016;123:68–74. http://dx.doi.org/10.1016/j.eplepsyres.2016.04.003
78. Francis NA, Hood K, Lyons R, Butler CC. Understanding flucloxacillin prescribing trends and
treatment non-response in UK primary care: a Clinical Practice Research Datalink (CPRD) study.
J Antimicrob Chemother 2016;71:2037–46. http://dx.doi.org/10.1093/jac/dkw084
79. National Institute for Health and Care Excellence. Type 2 Diabetes in Adults: Management
(NG28). London: National Institute for Health and Care Excellence; 2015.
80. National Institute for Health and Care Excellence. Cardiovascular Disease: Risk Assessment and
Reduction, Including Lipid Modification (CG181). London: National Institute for Health and Care
Excellence; 2015.
81. National Institute for Health and Care Excellence. Myocardial Infarction: Cardiac Rehabilitation
and Prevention of Further MI (CG172). London: National Institute for Health and Care
Excellence; 2013.
82. National Institute for Health and Care Excellence. Depression in Adults: Recognition and
Management (CG90). London: National Institute for Health and Care Excellence; 2016.
83. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2016; 2015.
URL: www.whocc.no/atc_ddd_index/ (last accessed August 2016).
84. NHS Business Services Authority. Prescription Cost Analysis (PCA) Data; 2015. URL: www.nhsbsa.
nhs.uk/PrescriptionServices/3494.aspx (accessed August 2016).
85. Hollingworth W, Devine EB, Hansen RN, Lawless NM, Comstock BA, Wilson-Norton JL, et al.
The impact of e-prescribing on prescriber and staff time in ambulatory care clinics: a time motion
study. J Am Med Inform Assoc 2007;14:722–30. https://doi.org/10.1197/jamia.M2377
DOI: 10.3310/hta21780 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 78
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Miani et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
85
86. Curtis L, Burns A. Unit Costs of Health and Social Care 2015. Canterbury: PSSRU, University of
Kent; 2015.
87. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and
risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551.
http://dx.doi.org/10.1136/bmj.d4551
88. NHS Choices. NHS in England – Help with Health Costs; 2016. URL: www.nhs.uk/NHSEngland/
Healthcosts/Pages/Prescriptioncosts.aspx (accessed August 2016).
89. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisals
2013. London: National Institute for Health and Care Excellence; 2013.
90. Boyd M, Waring J, Barber N, Mehta R, Chuter A, Avery AJ, et al. Protocol for the New Medicine
Service Study: a randomized controlled trial and economic evaluation with qualitative appraisal
comparing the effectiveness and cost effectiveness of the New Medicine Service in community
pharmacies in England. Trials 2013;14:411. http://dx.doi.org/10.1186/1745-6215-14-411
91. National Guideline Centre. Hypertension in Adults: Diagnosis and Management. Clinical Guideline 127.
London: National Guideline Centre; 2011.
92. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients
using the EQ-5D (UKPDS 62). Med Decis Making 2002;22:340–9. https://doi.org/10.1177/
027298902400448902
93. Sapin C, Fantino B, Nowicki ML, Kind P. Usefulness of EQ-5D in assessing health status in
primary care patients with major depressive disorder. Health Qual Life Outcomes 2004;2:20.
http://dx.doi.org/10.1186/1477-7525-2-20
94. Clarke PM, Gray AM, Briggs A, Farmer AJ, Fenn P, Stevens RJ, et al. A model to estimate the
lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective
Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004;47:1747–59.
http://dx.doi.org/10.1007/s00125-004-1527-z
95. National Collaborating Centre for Mental Health. National Institute for Health and Clinical
Excellence: Guidance. Leicester: British Psychological Society and Royal College of Psychiatrists;
2010 (updated 2016).
96. Cipriani A, Furukawa T, Salanti G, Geddes J, Higgins J, Churchill R, et al. Comparative efficacy
and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.
Lancet 2009;373:746–58. http://dx.doi.org/10.1016/s0140-6736(09)60046-5
97. Clarke P, Gray A, Legood R, Briggs A, Holman R. The impact of diabetes-related complications on
healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65).
Diabet Med 2003;20:442–50. http://dx.doi.org/10.1046/j.1464-5491.2003.00972.x
98. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic
modelling in health technology assessment: a review and consolidation of quality assessment.
Pharmacoeconomics 2006;24:355–71. https://doi.org/10.2165/00019053-200624040-00006
99. O’Hagan A, Buck CE, Daneshkhah A, Eiser JR, Garthwaite PH, Jenkinson DJ, et al. Uncertain
Judgements: Eliciting Experts’ Probabilities. Chichester: John Wiley & Sons Ltd; 2006. https://doi.org/
10.1002/0470033312
100. Westbrook JI, Li L, Georgiou A, Paoloni R, Cullen J. Impact of an electronic medication management
system on hospital doctors’ and nurses’ work: a controlled pre-post, time and motion study. J Am
Med Inform Assoc 2013;20:1150–8. http://dx.doi.org/10.1136/amiajnl-2012-001414
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
86
101. Franklin BD, O’Grady K, Donyai P, Jacklin A, Barber N. The impact of a closed-loop electronic
prescribing and administration system on prescribing errors, administration errors and staff time:
a before-and-after study. Qual Saf Health Care 2007;16:279–84. https://doi.org/10.1136/
qshc.2006.019497
102. Laurant M, Reeves D, Hermens R, Braspenning J, Grol R, Sibbald B. Substitution of doctors by
nurses in primary care. Cochrane Database Syst Rev 2005;2:CD001271. http://dx.doi.org/10.1002/
14651858.CD001271.pub2
103. Shum C, Humphreys A, Wheeler D, Cochrane MA, Skoda S, Clement S. Nurse management of
patients with minor illnesses in general practice: multicentre, randomised controlled trial.
BMJ 2000;320:1038–43. https://doi.org/10.1136/bmj.320.7241.1038
104. Venning P, Durie A, Roland M, Roberts C, Leese B. Randomised controlled trial comparing
cost effectiveness of general practitioners and nurse practitioners in primary care. BMJ
2000;320:1048–53. https://doi.org/10.1136/bmj.320.7241.1048
105. Murphy GE, Simons AD, Wetzel RD, Lustman PJ. Cognitive therapy and pharmacotherapy. Singly
and together in the treatment of depression. Arch Gen Psychiatry 1984;41:33–41. https://doi.org/
10.1001/archpsyc.1984.01790120037006
106. Joint Formulary Committee. British National Formulary. 56 ed. London: BMJ Group and
Pharmaceutical Press; 2008.
107. Curtis L. Unit Costs of Health and Social Care 2008. Canterbury: PSSRU, University of Kent; 2009.
108. The Secretary of State for Health, the NHS Commissioning Board and the Welsh Ministers.
Amendments to the Drug Tariff. 2016. URL: www.nhsbsa.nhs.uk/PrescriptionServices/Documents/
PPD%20Drug%20Tariff/July_2016.pdf (accessed August 2016).
DOI: 10.3310/hta21780 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 78
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Miani et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
87

Appendix 1 Search strategy
This appendix provides the full list of search terms used in each database searched. Search terms arepresented first for the peer-reviewed literature and then for the grey literature searches.
Peer-reviewed literature searches
MEDLINE (PubMed)
Prescription length*[title/abstract] OR prescription duration*[title/abstract] OR medication duration*[title/
abstract] OR “medication length”[title/abstract] OR “length of prescription”[title/abstract] OR “length
of prescriptions”[title/abstract] OR “duration of prescription”[title/abstract] OR “duration of
prescriptions”[title/abstract] OR “durations of prescriptions”[title/abstract] OR “drug prescribing”[title/
abstract] OR “multiple drug prescriptions”[title/abstract] OR prescribing pattern*[title/abstract] OR
prescription pattern*[title/abstract] OR prescribing behavior*[title/abstract] OR prescribing behaviour*[title/
abstract] OR prescribing practice*[title/abstract] OR prescribing standard*[title/abstract] OR (installment
[title/abstract] AND dispensing[title/abstract]) OR repeat prescri*[title/abstract] OR “repeat dispensing”[title/
abstract] OR prescribing interval*[title/abstract] OR prescription interval*[title/abstract] OR “28 day
supply”[title/abstract] OR “34 day supply”[title/abstract] OR (“28 day"[title/abstract] AND (“drug
supply”[title/abstract] OR prescribing[title/abstract] OR prescription[title/abstract])) OR “56 day supply”[title/
abstract] OR (“56 day"[title/abstract] AND (“drug supply"[title/abstract] OR prescribing[title/abstract] OR
prescription[title/abstract])) OR “28 day drug limit”[title/abstract] OR “56 day drug limit”[title/abstract] OR
“one month prescription”[title/abstract] OR “one month prescriptions”[title/abstract] OR “1 month
prescription”[title/abstract] OR “1 month supply”[title/abstract] OR “one month supply”[title/abstract] OR
“3 month prescriptions”[title/abstract] OR “three month prescription”[title/abstract] OR “three month
prescriptions”[title/abstract] OR “3 month prescription”[title/abstract] OR “3 month supply”[title/abstract]
OR “three month supply”[title/abstract] OR “90 day supply”[title/abstract] OR “30 day supply”[title/
abstract] OR “60 day supply”[title/abstract] OR dosage unit*[title/abstract] OR “prescription
standardization”[title/abstract] OR “prescription standardisation”[title/abstract] OR prescription restriction*
[title/abstract] OR prescribing restriction*[title/abstract] OR “restricting prescriptions”[title/abstract] OR
“restricting medication”[title/abstract] OR medication restriction*[title/abstract] OR dispensing restriction*
[title/abstract] OR prescribing trend*[title/abstract] OR prescription trend*[title/abstract] OR dispensing
trend*[title/abstract] OR “trends in dispensing”[title/abstract] OR “trends in prescribing"[title/abstract] OR
prescription suppl*[title/abstract] OR medication suppl*[title/abstract] OR term prescription*[title/abstract]
OR ((short course*[title/abstract] OR long course*[title/abstract]) AND (prescription*[title/abstract] OR
medication*[title/abstract])) OR “short prescription”[title/abstract] OR “long prescription”[title/abstract] OR
“short prescriptions”[title/abstract] OR “long prescriptions”[title/abstract] OR standardized prescri*[title/
abstract] OR “standardised prescription”[title/abstract] OR “standardised prescribing”[title/abstract] OR
(Standardization[title/abstract] AND (prescribing[title/abstract] OR prescription*[title/abstract])) OR
(Standardisation[title/abstract] AND (prescribing[title/abstract] OR prescription*[title/abstract])) OR
individualized prescri*[title/abstract] OR individualised prescri*[title/abstract] OR (individualization[title/
abstract] AND prescrib*[title/abstract]) OR (individualisation[title/abstract] AND prescrib*[title/abstract]) OR
Drug Prescriptions/trends OR Drug Prescriptions/supply and distribution
Results: 8242 – animal = 8207.
EMBASE
(prescription* NEAR/2 length*):ti,ab OR (prescription* NEAR/2 duration*):ti,ab OR (medication* NEAR/2
duration*):ti,ab OR (medication* NEAR/2 length*):ti,ab OR “drug prescribing”:ti,ab OR “multiple drug
prescriptions”:ti,ab OR (prescri* NEXT/1 pattern*):ti,ab OR (prescribing NEXT/1 behaviour*):ab,ti
(prescribing NEXT/1 behavior*):ab,ti OR (prescribing NEXT/1 practice*):ab,ti OR (prescribing NEXT/1
standard*):ab,ti OR “installment dispensing”:ti,ab OR (repeat NEXT/1 prescri*):ti,ab OR (repeat NEXT/1
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dispens*):ti,ab OR (prescri* NEXT/1 interval*):ti,ab OR (prescri* NEXT/1 interval*):ti,ab OR ((28 OR 30 OR
34 OR 56 OR 60 OR 90) NEXT/1 day NEXT/1 supply):ti,ab OR ((28 OR 30 OR 34 OR 56 OR 60 OR 90)
NEXT/1 day NEXT/1 drug NEXT/1 supply):ti,ab OR ((28 OR 30 OR 34 OR 56 OR 60 OR 90) NEXT/1 day
NEXT/1 prescri*):ti,ab OR ((28 OR 30 OR 56 OR 60 OR 90) NEXT/1 day NEXT/1 drug NEXT/1 limit):ti,ab OR
“one month prescription”:ti,ab OR “1 month prescription”:ti,ab OR “one month supply”:ti,ab OR “1
month supply”:ti,ab OR (3 NEXT/1 month NEXT/1 prescription*):ti,ab OR (three NEXT/1 month NEXT/1
prescription*):ti,ab OR “3 month supply”:ti,ab OR “three month supply”:ti,ab OR (dosage NEXT/1 unit*)
OR “prescription standardization”:ti,ab OR “prescription standarisation”:ti,ab OR (prescri* NEAR/1
restrict*):ti,ab OR (medication* NEAR/1 restrict*):ti,ab OR (dispensing NEXT/1 restrict*):ti,ab OR (prescri*
NEAR/2 trends):ti,ab OR (dispensing NEAR/2 trends):ti,ab OR ((prescription OR medication) NEXT/1 suppl*):
ti,ab OR ((short OR long) NEXT/1 (course OR term) NEXT/1 (prescription* OR medication*)):ti,ab OR ((short
OR long) NEXT/1 prescription*):ti,ab OR ((standardised OR standardized OR standardization OR
standardisation) NEXT/2 prescri*):ti,ab OR ((individualized OR individualized OR individualization OR
individualisation) NEXT/1 prescri*):ti,ab
Results: 6266 – duplicates/animal = 3600.
Cumulative Index to Nursing and Allied Health Literature
TI “prescription length*” OR AB “prescription length*” OR TI “prescription duration*” OR AB
“prescription duration*” OR TI “length* of prescription*” OR AB “length* of prescription*” OR TI
“duration* of prescription*” OR AB “duration* of prescription*” OR TI “drug prescribing” OR AB “drug
prescribing” OR TI “multiple drug prescriptions” OR AB “multiple drug prescriptions” OR TI “prescri*
pattern*” OR AB “prescri* pattern*” OR TI “prescribing behavior*” OR AB “prescribing behavior*”
OR TI “prescribing behaviour*” OR AB “prescribing behaviour*” OR TI “prescribing practice*” OR AB
“prescribing practice*” OR TI “prescribing standard*” OR AB “prescribing standard*” OR TI “installment
dispensing” OR AB “installment dispensing” OR TI “repeat prescri*” OR AB “repeat prescri*” OR TI
“28 day supply” OR AB “28 day supply” OR TI “30 day supply” OR AB “30 day supply” OR TI “30 day
drug supply” OR AB “30 day drug supply” OR TI “28 day drug supply” OR AB “28 day drug supply” OR
TI “34 day drug supply” OR AB “34 day drug supply” OR TI “34 day supply” OR AB “34 day supply OR TI
“28 day prescri*” OR AB “28 day prescri*” OR TI “30 day prescri*” OR AB “30 day prescri*” OR TI
“34 day prescri*” OR AB “34 day prescri*” OR TI “28 day drug limit*” OR AB “28 day drug limit*” OR TI
“30 day drug limit*” OR AB “30 day drug limit*” OR TI “34 day drug limit*” OR AB “34 day drug limit*”
OR TI “56 day supply” OR AB “56 day supply” OR TI “56 day drug supply” OR AB “56 day drug supply” OR
TI “56 day prescri*” OR AB “56 day prescri*” OR TI “56 day drug limit*” OR AB “56 day drug limit*” OR TI
“60 day supply” OR AB “60 day supply” OR TI “60 day drug supply” OR AB “60 day drug supply” OR TI
“60 day prescri*” OR AB “60 day prescri*” OR TI “60 day drug limit*” OR AB “60 day drug limit*”
OR TI “90 day supply” OR AB “90 day supply” OR TI “90 day drug supply” OR AB “90 day drug supply” OR
TI “90 day prescri*” OR AB “90 day prescri*” OR TI “90 day drug limit*” OR AB “90 day drug limit*” TI
“one month prescription*” OR AB “one month prescription*” OR TI “1 month prescription*” OR AB “1
month prescription*” OR TI “1 month supply” OR AB “1 month supply” OR TI “one month supply” OR AB
“one month supply” OR TI “three month prescription*” OR AB “three month prescription*” OR TI “3 month
prescription*” OR AB “3 month prescription*” OR TI “3 month supply” OR AB “3 month supply” OR TI
“three month supply” OR AB “three month supply” OR TI “dosage unit*” AND AB “dosage unit*” OR TI
“prescription standardization*” OR AB “prescription standardization*” OR TI “prescription standardisation*”
OR AB “prescription standardisation*” OR TI “prescri* restriction*” OR AB “prescri* restriction*” OR TI
“restricting prescription*” OR AB “restricting prescription*” OR TI “restricting medication*” OR AB
“restricting medication*” OR TI “medication restriction*” OR AB “medication restriction*” OR TI “dispensing
restriction*” OR AB “dispensing restriction*” OR TI “prescri* trend*” OR AB “prescri* trend*” OR TI
“dispensing trend*” OR AB “dispensing trend*” OR TI “trends in dispensing” OR AB “trends in dispensing”
OR TI “trends in prescribing” OR AB “trends in prescribing” OR TI “prescription suppl*” OR AB “prescription
suppl*” OR TI “medication suppl*” OR AB “medication suppl*” OR TI “term prescription*” OR AB “term
prescription*” OR TI “short course prescription*” OR AB “short course prescription*” OR TI “long course
prescription*” OR AB “long course prescription*” OR TI “short course medication*” OR AB “short course
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medication*” OR TI “long course medication*” OR AB “long course medication*” OR TI “short
prescription*” OR AB “short prescription*” OR TI “long prescription*” OR AB “long prescription*” OR TI
“standardized perscri*” OR AB “standardized perscri*” OR TI “standardised perscri*” OR AB “standardised
perscri*” OR TI “standarization of prescri*” OR AB “standarization of prescri*” OR TI “standarisation of
prescri*” OR AB “standarisation of prescri*” OR TI “individualized prescri*” OR AB “individualized prescri*”
OR TI “individualised prescri*” OR AB “individualised prescri*” OR TI “individualization prescri*” OR AB
“individualization prescri*” OR TI “individualisation prescri*” OR AB “individualisation prescri*”
Results: 1737 – duplicates = 367.
Web of Science
Refined by: [excluding] DOCUMENT TYPES: ( LETTER OR NEWS ITEM OR EDITORIAL MATERIAL OR BOOK
CHAPTER OR NOTE OR BOOK REVIEW OR DISCUSSION ) AND [excluding] WEB OF SCIENCE CATEGORIES:
( OPERATIONS RESEARCH MANAGEMENT SCIENCE OR VETERINARY SCIENCES OR COMPUTER SCIENCE
ARTIFICIAL INTELLIGENCE OR MATHEMATICAL COMPUTATIONAL BIOLOGY OR COMPUTER SCIENCE
THEORY METHODS OR METEOROLOGY ATMOSPHERIC SCIENCES OR MECHANICS OR FORESTRY OR
TELECOMMUNICATIONS OR MATHEMATICS OR MATERIALS SCIENCE MULTIDISCIPLINARY OR ECOLOGY
OR FOOD SCIENCE TECHNOLOGY OR AUTOMATION CONTROL SYSTEMS OR ASTRONOMY
ASTROPHYSICS ) AND [excluding] WEB OF SCIENCE CATEGORIES: ( STATISTICS PROBABILITY OR
POLYMER SCIENCE OR MATHEMATICS INTERDISCIPLINARY APPLICATIONS OR AGRICULTURE DAIRY
ANIMAL SCIENCE OR PLANT SCIENCES OR PHYSICS PARTICLES FIELDS OR BIOCHEMISTRY MOLECULAR
BIOLOGY OR OCEANOGRAPHY OR ENGINEERING MULTIDISCIPLINARY ) AND [excluding] RESEARCH
AREAS: ( WATER RESOURCES OR MATERIALS SCIENCE OR MINING MINERAL PROCESSING OR
METALLURGY METALLURGICAL ENGINEERING OR MATHEMATICS ) AND [excluding] WEB OF SCIENCE
CATEGORIES: ( PHYSICS FLUIDS PLASMAS OR ENERGY FUELS OR AGRICULTURE MULTIDISCIPLINARY )
Indexes=SCI-EXPANDED, CPCI-S Timespan=All years
TS=(prescription* NEAR/2 length*) OR TS=(prescription* NEAR/2 duration*) OR TS=(“duration of
medication*”) OR TS=(“length* of medication*”) OR TS=(“drug prescribing”) OR TS=(“multiple drug
prescriptions”) OR TS=(“prescription pattern*”) OR TS=(“prescribing pattern*”) OR TS=(“prescri*
pattern*”) OR TS=(“prescribing behavior*”) OR TS=(“prescribing behaviour*”) OR TS=(“prescription
behavior*”) OR TS=(“prescription behaviour*”) OR TS=(“prescri* practice*”) OR TS=(“prescription
standard*”) OR TS=(“prescribing standard*”) OR TS=(“installment dispensing”) OR TS=(“repeat
dispens*”) OR TS=(“repeat* prescription*”) OR TS=(“repeat* prescribing*”) OR TS=(“prescribing
interval*”) OR TS=(“prescription interval*”) OR TS=(“28 day supply”) OR TS=(“30 day supply”) OR TS=
(“34 day supply”) OR TS=(“56 day supply”) OR TS=(“60 day supply”) OR TS=(“90 day supply”) OR TS=
(“28 day drug supply”) OR TS=(“30 day drug supply”) OR TS=(“34 day drug supply”) OR TS=(“56 day
drug supply”) OR TS=(“60 day drug supply”) OR TS=(“90 day drug supply”) OR TS=(“28 day prescri*”)
OR TS=(“30 day prescri*”) OR TS=(“34 day prescri*”) OR TS=(“56 day prescri*”) OR TS=(“60 day
prescri*”) OR TS=(“90 day prescri*”) OR TS=(“28 day drug limit*”) OR TS=(“30 day drug limit*”) OR TS=
(“34 day drug limit*”) OR TS=(“56 day drug limit*”) OR TS=(“60 day drug limit*”) OR TS=(“90 day drug
limit*”) OR TS=(“one month prescription”) OR TS=(“1 month prescription”) OR TS=(“one month supply”)
OR TS=(“1 month supply”) OR TS=(“three month prescription*”) OR TS=(“3 month prescription*”) OR
TS=(“three month supply”) OR TS=(“3 month supply”) OR TS=(“dosage unit*”) OR TS=(“prescription
standardization”) OR TS=(“prescription standardisation”) OR TS=(prescri* NEAR/1 restrict*) OR TS=
(medication* NEAR/1 restrict*) OR TS=(“dispensing restrict*”) OR TS=(dispensing NEAR/2 trends) OR TS=
(prescri* NEAR/2 trends) OR TS=(“prescription suppl*”) OR TS=(“medication suppl*”) OR TS=(“short term
prescription*”) OR TS=(“short term medication*”) OR TS=(“short course prescription*”) OR TS=(“short
course medication*”) OR TS=(“long term prescription*”) OR TS=(“long term medication*”) OR TS=(“long
course prescription*”) OR TS=(“long course medication*”) OR TS=(“short prescription*”) OR TS=(“long
prescription*”) OR TS=((standardized OR standardised OR standardization OR standardisation) NEAR/2
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prescri*) OR TS=((individualized OR indvidualised OR individualization OR individualization) NEAR/1
(prescription* OR prescribing))
8592 – duplicates/animal = 3002.
Cochrane
“length of prescription”:ti,ab OR “prescription length”:ti,ab OR “prescription duration”:ti,ab OR “drug
prescribing”:ti,ab OR “multiple drug prescription*”:ti,ab OR “prescri* pattern”:ti,ab OR “prescribing
behavior”:ti,ab OR “prescri practice”:ti,ab OR “prescri* standard*”:ti,ab OR “repeat dispens*”:ti,ab OR
“repeat prescri*”:ti,ab OR “prescri* interval*”:ti,ab OR “28 day supply":ti,ab OR “30 day supply":ti,ab
or “34 day supply":ti,ab OR “60 day supply":ti,ab or “90 day supply":ti,ab OR “28 day prescri*”:ti,ab OR
“30 day prescri*”:ti,ab or “34 day prescri*":ti,ab OR “60 day prescri*”:ti,ab or “90 day prescri*”:ti,ab
or “56 day prescri*”:ti,ab OR “one month prescription”:ti,ab OR “1 month prescription”:ti,ab OR “one
month supply”:ti,ab OR “1 month supply”:ti,ab OR “three month prescription”:ti,ab OR “3 month
prescription”:ti,ab OR “3 month supply”:ti,ab OR “three month supply”:ti,ab OR “dosage unit*”:ti,ab OR
“prescription standardization”:ti,ab OR “prescri* restriction*”:ti,ab OR “medication restrict*”:ti,ab OR
“dispensing restriction*”:ti,ab OR “dispensing NEAR/2 trend*”:ti,ab OR “prescription NEAR/2 trend*”
OR “medication supply”:ti,ab OR “medication supplies”:ti,ab OR “short term prescription*”:ti,ab OR “long
term prescription*”:ti,ab OR “prescription suppl*”:ti,ab OR ((standardized OR standardised OR
standardization OR standardisation) NEAR/2 prescri*) OR ((individualized OR indvidualised OR
individualization OR individualization) NEAR/1 (prescription* OR prescribing))
After duplicates: 69.
National Institute for Health and Care Excellence
“length of prescription” OR “prescription length” OR “medication length” OR “prescription trends” OR
“medication trends” OR “multiple prescriptions” OR “30 day supply” OR “60 day supply” OR “90 day
supply” OR “one month supply” OR “three month supply” OR “prescription supply” OR “medication
supply” OR “short term prescription” OR “long term prescription” OR “standardised prescription” OR
“individualised prescription” OR “prescribing behaviour”
**added 5 records.
Total
15,250 (No year limits).
(Limiting to 1995 ≈ 13,470/Limiting to 2000 ≈ 12,150/Limiting to 2005 ≈ 9950).
Grey literature searches
The New York Academy of Medicine
prescribing patterns; prescription length; one month supply; 28 day supply; length of prescription; multiple
drug prescription; dispensing restriction; prescribing trends; prescribing behavior; individualized prescribing;
individualized prescription; month supply;
Open Archives Initiative harvester
Ti: Prescribing patterns; ti: length of prescription; ti: prescription standardization; ti: dispensing regulation;
ti: 30 day supply; ti: repeat dispensing; ti: medication prescription; ti: individualized prescri*; ti: multiple
drug prescri*; ti: short term prescri*; ti: long term prescri*; ti: prescription trends; ti: prescribing trends;
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OpenGrey
“prescribing patterns”; “prescription length”; “prescription standardization”; “dispensing regulations”;
“prescription trends”; “prescription patterns”; “individualized prescri*”; “prescribing trends”; “28 day
supply”; “multiple prescriptions”;
Total
14.
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Appendix 2 Detail of stage 1 of the screening
T itles and abstracts of studies identified in the searches were entered into an EndNote database. Thesenior systematic reviewer (SK) sifted through the database to identify clusters of articles that were
obviously not relevant. She suggested a list of terms that would allow for identification of such articles.
JE and CMiani reviewed and validated this list. References that were obviously not relevant were tagged by
the information specialist (JL). JL searched for and tagged citations with at least one of the following terms
in the title:
Conditions, populations and settings
Helicobacter pylori, allergic, haemorrhage, contact lens, chemotherapy, dentist, dental, malaria, hormone
therapy, acne, obesity, antifungal, antibiotic, vitamin D, HIV, human immunodeficiency virus, tuberculosis,
leprosy, eye, contraceptive, hypnotics, fracture, menopause, palliative, catheter, DNA, suicide, counselling,
education, biomarker, nutrition, animals, pregnancy, preterm, foetal, fetal, neonatal, surgery, postoperative,
acute (TITLE with ‘acute’ AND ‘chronic’ were not excluded), outpatient, hospital, inpatient, vaccine,
vaccination, meningitis, MRSA, anesthesia, anaesthesia, stroke, infection, birth, transplant, MRI, emergency
department, prison, influenza, critical care.
Low-income economies as listed by the World Bank29
Afghanistan (when not referring to US/British soldiers), Benin, Burkina Faso, Burundi, Cambodia, Central
African Republic, Chad, Comoros, Congo, Ethiopia, Gambia, Guinea, Guinea-Bissau, Haiti, North Korea OR
Democratic People’s Republic of North Korea, Liberia, Malawi, Mali, Mozambique, Nepal, Niger, Rwanda,
Sierra Leone, Somalia, South Sudan, Tanzania, Togo, Uganda, Zimbabwe.
Two reviewers (JE and CMiani) then screened the articles tagged in the outpatient, hospital and inpatient
categories to make sure that no studies considering primary care AND secondary/tertiary care were
excluded. Upon the recommendation of the wider team, they also screened the articles tagged in the
vitamin D and hormone therapy categories to make sure that no relevant studies were excluded.
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Appendix 3 Studies excluded at full-text
review stage
TABLE 23 Table of excluded studies
Reference Reason for exclusion
Adherence improves with 90-day medication supply. Drug Benefit Trends,
7 April 2010, p. 66
Article type: news piece
Beattie, J. People with CVD identified 5 areas of medication-related problems
that influenced adherence and informed decision making. Evid Based Nurs
2007;10:127
Article type: commentary
Bobat N, Cubbin I, Lowe DA, Vickers S. A review of the prescribed medicines
wastage audit for the NHS community pharmacies of Western Cheshire. Int J
Pharm Pract 2011;19:57–8
Quality: not enough information in
the abstract
Bond C, Matheson C, Williams S, Williams P, Donnan P. Repeat prescribing:
a role for community pharmacists in controlling and monitoring repeat
prescriptions. Br J Gen Pract 2000;50:271–5
Relevance: the article does not
compare different prescription lengths
Bradley F, Elvey R, Ashcroft DM, Noyce P. Influence of prescription charges on
repeat prescribing in primary care. J Clin Pharm Ther 2007;32:269–75
Relevance: the article does not
compare different prescription lengths
Cubitt T, De Quincey M. Repeat prescribing management – a cause for concern?
Br J Gen Pract 1999;49:580
Article type: letter
Cuiper N. Faster and safer delivery of repeat prescriptions. Pharmaceutisch
Weekblad 2006;141:68–9
Not available
Darlath W. Asthma: long term medication. Med Monatsschr fur Pharm
1989;12:74–9
Not available
De Leeuw M. Doctor little focused on discontinuation of long-term medication:
it is worthwhile to stop more often. Pharmaceutisch Weekblad 2009;144:16–21
Not available
De Smet PA, Dautzenberg M. Repeat prescribing: scale, problems and quality
management in ambulatory care patients. Drugs 2004;64:1779–800
Relevance: the article does not
compare different prescription lengths
Del Mar C. Improving prescribing practices in primary care. A randomised trial
and economic analysis of a multicomponent intervention showed small, but
important, gains. PLOS Med 2006;3:e229
Article type: commentary
Domino ME, Olinick J, Sleath B, Leinwand S, Byrns PJ, Carey T. Restricting
patients’ medication supply to one month: saving or wasting money? Am J
Health Syst Pharm 2004;61:1375–9
Study type: simulation. Moreover, this
article has been updated by Domino
et al.,44 included in this review
Drury VW. Repeat prescribing – a review. J R Coll Gen Pract 1982;32:42–5 Relevance: the article does not
compare different prescription lengths
Gaziano T, Cho S, Sy S, Pandya A, Levitt NS, Steyn K. Increasing prescription
length could cut cardiovascular disease burden and produce savings in South
Africa. Health Aff (Millwood) 2015;34:1578–85
Relevance: setting too different from
the UK context (underserved areas in
poor neighbourhoods in South Africa)
Hawksworth G, Wright D, Chrystyn H. A detailed analysis of the day to day
unwanted medicinal products returned to community pharmacies for disposal.
J Soc Adm Pharm 1996;13:215–22
Relevance: the article does not
compare two prescriptions length for
the same drug and it is not possible to
identify which conditions the article
covers
Helling DK, Yesalis CE, Norwood GI, Burmeister LF, Lipson DP, Fisher WP, et al.
Effects of capitation payment for pharmacy services on pharmacist-dispensing
and physician-prescribing behavior: I. Prescription quantity and dose analysis.
Drug Intell Clin Pharm 1981;15:581–9
Not available
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TABLE 23 Table of excluded studies (continued )
Reference Reason for exclusion
Ivers N, Schwalm JR, Kingsbury K, Guo H, Tu J, Grimshaw J, et al. Long-term
statin adherence in secondary prevention: a provincial retrospective cohort study.
Can J Cardiol 2012;28:S225
Relevance: population is not a stable,
chronically ill population
Kawazoe H, Iihara N, Doi C, Morita S. Impact of prescription-term deregulation
with revised medical service fees on drug therapy management. Yakugaku Zasshi
2005;125:959–69
Relevance: the article does not
compare different prescription lengths
Kazerooni R, Nguyen JB, Bounthavong M, Tran MH, Madkour N. New start versus
continuing users on aripiprazole: implications for policy. Am J Manag Care
2015;21:e43–50
Relevance: the article does not
compare different prescription lengths
Keenan W. Reforming drug prescribing policies could save NHS millions. Nurs
Stand 2014;28:32
Relevance: the article does not
compare different prescription lengths
Lawrie E, Arkley J, Keane D, McNaughton S, Philip C, Kinnear M. Repeat
prescribing systems and waste. Pharm World Sci 2009;31:89–90
Not available
Leslie RS, Laskowski TR, Adams RS, Patel BV. Implementation and evaluation of a
90-day retail benefit addition and Rx coupon program. J Manage Care Pharm
2009;15:588
Relevance: the article does not
compare different prescription lengths
Mitchell AL, Hickey B, Hickey JL, Pearce SHS. Trends in thyroid hormone
prescribing and consumption in the UK. BMC Public Health 2009;9:132
Relevance: the article does not
compare different prescription lengths
Mitchell AL, Hickey B, Hickey JL, Pearce SHS. UK trends in prescribing thyroid
hormone and patient satisfaction survey. Endocrine Abstracts 2009;19:P345
Duplicate
Rabbani A, Alexander GC. Cost savings associated with filling a three-month
supply of prescription medicines. Value Health 2009;12:A83
Duplicate
Ray WA, Schaffner W, Oates JA. Therapeutic choice in the treatment of
hypertension – initial treatment of newly diagnosed hypertension and secular
trends in the prescribing of antihypertensive medications for Medicaid patients.
Am J Med 1986;81:9–16
Relevance: the article does not
compare different prescription lengths
Reenan J. Rx for physician prescribing practices. Virtual Mentor 2006;8:359–61 Article type: editorial
Reinhardt UE. Proper benchmark for drug prescribing needs to be found. BMJ
2002;324:1039
Article type: letter
Rey ME, Villalbi JR. Potential impact of primary health-care reform on prescription
patterns in Spain – the Ciutat-Badia experience. Medicina Clinica 1987;89:141–3
Not available
Richards RN. Prescription restrictions. Can Med Assoc J 1972;106:854 Article type: letter
Rigler S, Webb M, Redford L, Brown E. Antidepressant prescribing trends in
long-term care. J Am Geriatr Soc 1999;47:S38
Not available
Sun SX, Lee KY, McMurray J. Impact of a 90-day retail refill program on
prescription drug utilisation and expenditures. Drug Benefit Trends
2007;19:314–19
Not available
Taitel M, Lou Y, Huang Z, Suwalski M. A comparison of patients with and
without 90-day fills at a retail pharmacy: observing medication changes from
single source brand to generic. Value Health 2013;16:A250
Not relevant
Tulloch AJ. Repeat prescribing for elderly patients. Br Med J (Clin Res Ed)
1981;282:1672–5
Relevance: the article does not
compare different prescription lengths
Van Der Schoor P. Repeat prescription can be more efficient – the time has come:
a round table discussion. Pharmaceutisch Weekblad 2005;140:832–6
Not available
White KG. UK interventions to control medicines wastage: a critical review. Int J
Pharm Pract 2010;18:131–40
Article type: review (does not follow
systematic review methodology)
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TABLE 23 Table of excluded studies (continued )
Reference Reason for exclusion
Wilson PM, Kataria N, McNeilly A. Patient and carer experience of obtaining
regular prescribed medication for chronic disease in the English National Health
Service: a qualitative study. BMC Health Serv Res 2013;13:192
Relevance: the article does not
compare different prescription lengths
Wong MC, Tam WW, Wang HH, Chan WM, Kwan MW, Cheung CS, et al. The
association between initial antihypertensive prescription interval and medication
adherence: a cohort study among 203,259 patients. Hypertension 2014;64:A435
Relevance: the article compares
30-day prescriptions with shorter
prescriptions
DOI: 10.3310/hta21780 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 78
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Miani et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
99

Appendix 4 Risk-of-bias assessments: Risk Of
Bias in Non-Randomized Studies – of Interventions
TABLE 24 Risk-of-bias assessment (cohort-study types)
Bias domain Signalling questions Elaboration
Response
options
Bias as a result of
confounding
(1.1) Is there potential for
confounding of the effect of
intervention in this study?
In rare situations, such as when studying
harms that are very unlikely to be related to
factors that influence treatment decisions, no
confounding is expected and the study can be
considered to be at low risk of bias owing to
confounding, equivalent to a fully randomised
trial. There is no NI option for this signalling
question
Y/PY/PN/N
If Y/PY to 1.1
(1.2) Was the analysis based
on splitting participants’
follow-up time according to
intervention received?
If participants could switch between
intervention groups then associations
between intervention and outcome may be
biased by time-varying confounding. This
occurs when prognostic factors influence
switches between intended interventions
NA/Y/PY/PN/N/NI
If Y/PY to 1.2
(1.3) Were intervention
discontinuations or switches
likely to be related to factors
that are prognostic for the
outcome?
If intervention switches are unrelated to the
outcome, for example when the outcome is
an unexpected harm, then time-varying
confounding will not be present and only
control for baseline confounding is required
NA/Y/PY/PN/N/NI
Baseline confounding
(1.4) Did the authors use an
appropriate analysis method
that controlled for all the
important confounding areas?
Appropriate methods to control for measured
confounders include stratification, regression,
matching, standardisation, and inverse
probability weighting. They may control for
individual variables or for the estimated
propensity score. Inverse probability weighting
is based on a function of the propensity score.
Each method depends on the assumption that
there is no unmeasured or residual confounding
NA/Y/PY/PN/N/NI
If Y/PY to 1.4
(1.5) Were confounding areas
that were controlled for
measured validly and reliably
by the variables available in
this study?
Appropriate control of confounding requires
that the variables adjusted for are valid and
reliable measures of the confounding
domains. For some topics, a list of valid and
reliable measures of confounding domains
will be specified in the review protocol, but
for others such a list may not be available.
Study authors may cite references to support
the use of a particular measure. If authors
control for confounding variables with no
indication of their validity or reliability pay
attention to the subjectivity of the measure.30
Subjective measures (e.g. based on self-report)
may have lower validity and reliability than
objective measures such as laboratory findings
NA/Y/PY/PN/N/NI
continued
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TABLE 24 Risk-of-bias assessment (cohort-study types) (continued )
Bias domain Signalling questions Elaboration
Response
options
(1.6) Did the authors control
for any post-intervention
variables?
Controlling for post-intervention variables that
are affected by the intervention is not
appropriate. Controlling for mediating
variables estimates the direct effect of
intervention and may introduce bias.
Controlling for common effects of
intervention and outcome introduces bias
NA/Y/PY/PN/N/NI
Baseline and time-varying confounding
(1.7) Did the authors use an
appropriate analysis method
that adjusted for all the
important confounding areas
and for time varying
confounding?
Adjustment for time-varying confounding is
necessary to estimate the effect of starting
and adhering to intervention, in both
randomised trials and NRSI. Appropriate
methods include those based on inverse
probability weighting. Standard regression
models that include time-updated
confounders may be problematic if
time-varying confounding is present
NA/Y/PY/PN/N/NI
If Y/PY to 1.7
(1.8) Were confounding areas
that were adjusted for
measured validly and reliably
by the variables available in
this study?
See 1.5 above NA/Y/PY/PN/N/NI
Risk-of-bias judgement Low/moderate/
serious/critical/NI
Bias in selection of
participants into
the study
(2.1) Was selection of
participants into the study
(or into the analysis) based on
participant characteristics
observed after the start of
intervention?
This domain is concerned only with selection
into the study based on participant
characteristics observed after the start
of intervention. Selection based on
characteristics observed before the start of
intervention can be addressed by controlling
for imbalances between experimental
intervention and comparator groups in
baseline characteristics that are prognostic for
the outcome (baseline confounding). Selection
bias occurs when selection is related to an
effect of either intervention or a cause of
intervention and an effect of either the
outcome or a cause of the outcome.
Therefore, the result is at risk of selection bias
if selection into the study is related to both
the intervention and the outcome
Y/PY/PN/N/NI
If N/PN to 2.1 go to 2.4
(2.2) Were the post-
intervention variables that
influenced selection likely
to be associated with
intervention?
NA/Y/PY/PN/N/NI
(2.3) Were the post-
intervention variables that
influenced selection likely to
be influenced by the outcome
or a cause of the outcome?
NA/Y/PY/PN/N/NI
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TABLE 24 Risk-of-bias assessment (cohort-study types) (continued )
Bias domain Signalling questions Elaboration
Response
options
(2.4) Do start of follow-up
and start of intervention
coincide for most
participants?
If participants are not followed from the start
of the intervention, then a period of follow-up
has been excluded, and individuals who
experienced the outcome soon after
intervention will be missing from analyses.
This problem may occur when prevalent,
rather than new (incident), users of the
intervention are included in analyses
Y/PY/PN/N/NI
If Y/PY to 2.2 and 2.3, or N/PN to 2.4
(2.5) Were adjustment
techniques used that are likely
to correct for the presence of
selection biases?
It is, in principle, possible to correct for
selection biases, for example by using inverse
probability weights to create a pseudo-
population in which the selection bias has
been removed, or by modelling the
distributions of the missing participants or
follow-up times and outcome events, and
including them using missing data
methodology. However, such methods are
rarely used, and the answer to this question
will usually be ‘no’
NA/Y/PY/PN/N/NI
Risk-of-bias judgement Low/moderate/
serious/critical/NI
Bias in
classification of
interventions
(3.1) Were intervention
groups clearly defined?
A prerequisite for an appropriate comparison
of interventions is that the interventions are
well defined. Ambiguity in the definition
may lead to bias in the classification of
participants. For individual-level interventions,
criteria for considering individuals to have
received each intervention should be clear and
explicit, covering issues such as type, setting,
dose, frequency, intensity and/or timing of
intervention. For population-level interventions
(e.g. measures to control air pollution), the
question relates to whether or not the
population is clearly defined, and the answer
is likely to be ‘yes’
Y/PY/PN/N/NI
(3.2) Was the information
used to define intervention
groups recorded at the start
of the intervention?
In general, if information about interventions
received is available from sources that could
not have been affected by subsequent
outcomes, then differential misclassification
of intervention status is unlikely. Collection
of the information at the time of the
intervention makes it easier to avoid such
misclassification. For population-level
interventions (e.g. measures to control air
pollution), the answer to this question is likely
to be ‘yes’
Y/PY/PN/N/NI
(3.3) Could classification of
intervention status have been
affected by knowledge of the
outcome or risk of the
outcome?
Collection of the information at the time of
the intervention may not be sufficient to avoid
bias. The way in which the data are collected
for the purposes of the NRSI should also avoid
misclassification
Y/PY/PN/N/NI
Risk-of-bias judgement Low/moderate/
serious/critical/NI
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TABLE 24 Risk-of-bias assessment (cohort-study types) (continued )
Bias domain Signalling questions Elaboration
Response
options
Bias as a result of
departures from
intended
interventions
(4.1) Were there deviations
from the intended
intervention beyond what
would be expected in usual
practice?
Deviations that happen in usual practice
following the intervention (e.g. cessation of a
drug intervention because of acute toxicity)
are part of the intended intervention and
therefore do not lead to bias in the effect of
assignment to intervention. Deviations may
arise due to expectations of a difference
between intervention and comparator
(e.g. because participants feel unlucky to have
been assigned to the comparator group and
therefore seek the active intervention, or
components of it, or other interventions).
Such deviations are not part of usual practice,
so may lead to biased effect estimates.
However, these are not expected in
observational studies of individuals in routine
care
Y/PY/PN/N/NI
If Y/PY to 4.1
(4.2) Were these deviations
from intended intervention
unbalanced between groups
and likely to have affected the
outcome?
Deviations from intended interventions that
do not reflect usual practice will be important
if they affect the outcome, but not otherwise.
Furthermore, bias will arise only if there is
imbalance in the deviations across the two
groups
NA/Y/PY/PN/N/NI
If your aim for this study is to assess the effect of initiating and adhering to intervention (as in a
per-protocol analysis), answer questions 4.3 to 4.6
(4.3) Were important
cointerventions balanced
across intervention groups?
Risk of bias will be higher if unplanned
cointerventions were implemented in a way
that would bias the estimated effect of
intervention. Cointerventions will be
important if they affect the outcome, but not
otherwise. Bias will arise only if there is
imbalance in such cointerventions between
the intervention groups. Consider the
cointerventions, including any prespecified
cointerventions, that are likely to affect the
outcome and to have been administered
in this study. Consider whether these
cointerventions are balanced between
intervention groups
Y/PY/PN/N/NI
(4.4) Was the intervention
implemented successfully for
most participants?
Risk of bias will be higher if the intervention
was not implemented as intended by, for
example, the health care professionals
delivering care during the trial. Consider
whether or not implementation of the
intervention was successful for most
participants
Y/PY/PN/N/NI
(4.5) Did study participants
adhere to the assigned
intervention regimen?
Risk of bias will be higher if participants did
not adhere to the intervention as intended.
Lack of adherence includes imperfect
compliance, cessation of intervention,
crossovers to the comparator intervention
and switches to another active intervention.
Consider available information on the
proportion of study participants who
continued with their assigned intervention
throughout follow up, and answer ‘No’ or
‘Probably No’ if this proportion is high enough
to raise concerns. Answer ‘Yes’ for studies of
Y/PY/PN/N/NI
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TABLE 24 Risk-of-bias assessment (cohort-study types) (continued )
Bias domain Signalling questions Elaboration
Response
options
interventions that are administered once, so
that imperfect adherence is not possible. We
distinguish between analyses where follow-up
time after interventions switches (including
cessation of intervention) is assigned to
(1) the new intervention or (2) the original
intervention. (1) is addressed under
time-varying confounding, and should
not be considered further here
If N/PN to 4.3, 4.4 or 4.5
(4.6) Was an appropriate
analysis used to estimate the
effect of starting and
adhering to the intervention?
It is possible to conduct an analysis that
corrects for some types of deviation from
the intended intervention. Examples of
appropriate analysis strategies include inverse
probability weighting or instrumental variable
estimation. It is possible that a paper
reports such an analysis without reporting
information on the deviations from intended
intervention, but it would be hard to judge
such an analysis to be appropriate in the
absence of such information. Specialist advice
may be needed to assess studies that used
these approaches. If everyone in one group
received a cointervention, adjustments cannot
be made to overcome this
NA/Y/PY/PN/N/NI
Risk of bias judgement Low/moderate/
serious/critical/NI
Bias as a result of
missing data
(5.1) Were outcome data
available for all, or nearly all,
participants?
‘Nearly all’ should be interpreted as ‘enough
to be confident of the findings’, and a
suitable proportion depends on the context.
In some situations, availability of data from
95% (or possibly 90%) of the participants
may be sufficient, providing that events of
interest are reasonably common in both
intervention groups. One aspect of this is that
review authors would ideally try to locate an
analysis plan for the study
Y/PY/PN/N/NI
(5.2) Were participants
excluded due to missing data
on intervention status?
Missing intervention status may be a problem.
This requires that the intended study sample
is clear, which it may not be in practice
Y/PY/PN/N/NI
(5.3) Were participants
excluded due to missing data
on other variables needed for
the analysis?
This question relates particularly to
participants excluded from the analysis
because of missing information on
confounders that were controlled for
in the analysis
Y/PY/PN/N/NI
If PN/N to 5.1 or Y/PY to 5.2 or 5.3
(5.4) Are the proportion of
participants and reasons for
missing data similar across
interventions?
This aims to elicit whether either
(1) differential proportion of missing
observations or (2) differences in reasons for
missing observations could substantially
impact on our ability to answer the question
being addressed. ‘Similar’ includes some
minor degree of discrepancy across
intervention groups as expected by chance
NA/Y/PY/PN/N/NI
If PN/N to 5.1 or Y/PY to 5.2 or 5.3
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TABLE 24 Risk-of-bias assessment (cohort-study types) (continued )
Bias domain Signalling questions Elaboration
Response
options
(5.5) Is there evidence that
results were robust to the
presence of missing data?
5.5 Evidence for robustness may come from
how missing data were handled in the
analysis and whether sensitivity analyses were
performed by the investigators, or occasionally
from additional analyses performed by the
systematic reviewers. It is important to assess
whether or not assumptions employed in
analyses are clear and plausible. Both content
knowledge and statistical expertise will often
be required for this. For instance, use of a
statistical method such as multiple imputation
does not guarantee an appropriate answer.
Review authors should seek naive (complete-
case) analyses for comparison, and clear
differences between complete-case and
multiple imputation-based findings should
lead to careful assessment of the validity of
the methods used
NA/Y/PY/PN/N/NI
Risk of bias judgement Low/moderate/
serious/critical/NI
Bias in
measurement of
outcomes
(6.1) Could the outcome
measure have been
influenced by knowledge of
the intervention received?
Some outcome measures involve negligible
assessor judgement, for example all-cause
mortality or non-repeatable automated
laboratory assessments. Risk of bias owing to
measurement of these outcomes would be
expected to be low
Y/PY/PN/N/NI
(6.2) Were outcome assessors
aware of the intervention
received by study
participants?
If outcome assessors were blinded to
intervention status, the answer to this
question would be ‘No’. In other situations,
outcome assessors may be unaware of the
interventions being received by participants,
despite there being no active blinding by
the study investigators; the answer to this
question would then also be ‘No’. In studies
where participants report their outcomes
themselves, for example in a questionnaire,
the outcome assessor is the study participant.
In an observational study, the answer to this
question will usually be ‘Yes’ when the
participants report their outcomes themselves
Y/PY/PN/N/NI
(6.3) Were the methods of
outcome assessment
comparable across
intervention groups?
Comparable assessment methods (i.e. data
collection) would involve the same outcome
detection methods and thresholds, same time
point, same definition, and same measurements
Y/PY/PN/N/NI
(6.4) Were any systematic
errors in measurement of
the outcome related to
intervention received?
This question refers to differential
misclassification of outcomes. Systematic
errors in measuring the outcome, if present,
could cause bias if they are related to the
intervention or to a confounder of the
intervention–outcome relationship. This will
usually be because of either outcome
assessors being aware of the intervention
received or becase of non-comparability of
outcome assessment methods, but there are
examples of differential misclassification
arising despite these controls being in place
Y/PY/PN/N/NI
Risk of bias judgement Low/moderate/
serious/critical/NI
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TABLE 24 Risk-of-bias assessment (cohort-study types) (continued )
Bias domain Signalling questions Elaboration
Response
options
Bias in selection of
the reported result
Is the reported effect estimate likely to be selected, on the basis of the results, from
(7.1) multiple outcome
measurements within the
outcome domain?
For a specified outcome domain, it is possible
to generate multiple effect estimates for
different measurements. If multiple
measurements were made, but only one or a
subset is reported, there is a risk of selective
reporting on the basis of results
Y/PY/PN/N/NI
(7.2) multiple analyses of the
intervention–outcome
relationship?
Because of the limitations of using data from
non-randomised studies for analyses of
effectiveness (need to control confounding,
substantial missing data, etc.), analysts may
implement different analytic methods to
address these limitations. Examples include
unadjusted and adjusted models, use of final
value vs. change from baseline vs. analysis of
covariance, different transformations of
variables, a continuously scaled outcome
converted to categorical data with different
cut-points, different sets of covariates used for
adjustment, and different analytic strategies
for dealing with missing data. Application of
such methods generates multiple estimates
of the effect of the intervention vs. the
comparator on the outcome. If the analyst
does not prespecify the methods to be applied,
and multiple estimates are generated but only
one or a subset is reported, there is a risk of
selective reporting on the basis of results
Y/PY/PN/N/NI
(7.3) different subgroups? Particularly with large cohorts often available
from routine data sources, it is possible to
generate multiple effect estimates for
different subgroups or simply to omit varying
proportions of the original cohort. If multiple
estimates are generated but only one or a
subset is reported, there is a risk of selective
reporting on the basis of results
Y/PY/PN/N/NI
Risk of bias judgement Low/moderate/
serious/critical/NI
Overall bias Low/moderate/
serious/critical/NI
PN, probably no; PY, probably yes; N, No; NA, not applicable; NI, no information; NRSI, non-randomised stidies of
interventions; Y, Yes.
Note
Responses in bold are potential markers for low risk of bias, and responses in italics are potential markers for a risk of bias.
Where questions relate only to sign posts to other questions, no formatting is used.
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Appendix 5 Clinical Practice Research Datalink
product code lists
Appendix 5 is provided as a Microsoft Excel file containing five worksheets (one for each of the five casestudy conditions) (see Report Supplementary Material 1). Within each worksheet the lists of product
codes obtained from the CPRD Research Applications Code Browser Version 3.0.0 that represent the
possible medications that patients may be prescribed for the treatment of one of the five case study
conditions is presented. Table 25 provides a high-level summary of the codes.
TABLE 25 Clinical Practice Research Datalink product code list
Study condition Product code
Glucose control with oral drug therapy in T2DM 2219
7912
16602
26218
41558
Treatment of hypertension in T2DM 2
58
1209
1211
1213
Lipid management in T2DM 65193
63140
55034
51200
7374
Secondary prevention of myocardial infarction 59699
56850
34544
3310
26995
Treatment of depression 2525
48065
4690
8831
873
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Appendix 6 Unit prescription drug cost
calculations
TABLE 26 Unit prescription drug cost calculations
Drug substance
DDD
(mg)
NIC from
PCA (pence)
Quantity
from PCA
Strength from
PCA (mg)
NIC/quantity
(£)
Cost per
daya (£)
Initial glucose control in T2DM
Glibenclamide 7 1,072,539 279,251 5 0.04 0.05
Gliclazide 60 3,322,771 195,041 60 0.17 0.17
Glimepiride 2 2,650,357 685,422 2 0.04 0.04
Glipizide 10 8,679,376 762,384 5 0.11 0.23
Tolbutamide 1500 17,494,096 266,373 500 0.66 1.97
Metformin 2000 531,088,447 111,025,385 500 0.05 0.19
Acarbose 300 108,607 1234 100 0.88 2.64
Alogliptin 25 6,918,604 10,147 25 6.82 6.82
Canagliflozin 200 58,466,442 447,445 100 1.31 2.61
Dapagliflozin 10 191,937,124 1,468,764 10 1.31 1.31
Empagliflozin 17.5 16,291,281 124,666 10 1.31 2.29
Exenatide 1 10,031,280 1470 60 68.24 1.14
Linagliptin 5 271,703,001 2,287,246 5 1.19 1.19
Liraglutide 1.2 337,718,696 86,033 6 39.25 7.85
Lixisenatide 0.02 45,851,757 15,830 0.28 28.97 2.07
Nateglinide 360 631,585 17,827 180 0.35 0.71
Pioglitazone 30 144,198,158 1,125,016 30 1.28 1.28
Repaglinide 4 1,620,508 246,350 2 0.07 0.13
Saxagliptin 5 80,113,342 709,874 5 1.13 1.13
Sitagliptin 100 670,533,026 5,644,766 100 1.19 1.19
Vildagliptin 100 18,582,165 312,012 50 0.60 1.19
Rosiglitazoneb 6 – – – – 2.34
Guar gumb,c 68.5 – – – – 2.34
Dulaglutide 0.16 1,717,714 938 0.75 18.31 3.91
Hypertension in T2DM
Bendroflumethiazide 2.5 115,395,532 38,916,033 2.5 0.03 0.03
Chlortalidone 25 410 70 50 0.06 0.03
Cyclopenthiazideb 0.5 – – – – 1.07
Indapamide 2.5 40,603,410 7,849,048 2.5 0.05 0.05
Xipamide 20 274,581 19,761 20 0.14 0.14
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TABLE 26 Unit prescription drug cost calculations (continued )
Drug substance
DDD
(mg)
NIC from
PCA (pence)
Quantity
from PCA
Strength from
PCA (mg)
NIC/quantity
(£)
Cost per
daya (£)
Chlorothiazide 500 92,160 200 500 4.61 4.61
Hydrochlorothiazide 25 743,206 4701 25 1.58 1.58
Hydroflumethiazideb 25 – – – – 1.07
Candesartan cilexetil 8 27,228,854 6,187,293 8 0.04 0.04
Eprosartan 600 7,848,330 156,629 600 0.50 0.50
Irbesartan 150 15,321,402 2,527,161 150 0.06 0.06
Losartan potassium 50 43,142,921 10,854,773 50 0.04 0.04
Olmesartan medoxomil 20 23,454,180 507,120 20 0.46 0.46
Telmisartan 40 2,105,968 429,294 40 0.05 0.05
Valsartan 80 7,680,126 790,946 80 0.10 0.10
Captopril 50 1,209,326 274,077 50 0.04 0.04
Enalapril maleate 10 8,273,970 2,164,274 10 0.04 0.04
Fosinopril sodium 15 1,717,978 32,658 10 0.53 0.79
Imidapril hydrochloride 10 523,685 20,308 10 0.26 0.26
Lisinopril 10 30,787,577 8,978,102 10 0.03 0.03
Moexipril hydrochloride 15 22,272 896 15 0.25 0.25
Perindopril erbumine 4 25,785,508 604,0253 4 0.04 0.04
Perindopril arginine 4 1,125,376 53,760 5 0.21 0.17
Quinapril 15 2,130,784 69,778 10 0.31 0.46
Ramipril 2.5 75,859,752 18,621,897 2.5 0.04 0.04
Ramipril with felodipine 2.5 456,727 5209 2.5 0.88 0.88
Trandolapril 2 4,668,257 191,955 2 0.24 0.24
Cilazapril 2.5 1,662,225 8985 5 1.85 0.93
Perindopril tosilate 4 11,821 594 5 0.20 0.16
Amlodipine 5 153,321,726 47,137,956 5 0.03 0.03
Diltiazem hydrochloride 240 3,855,905 93,720 240 0.41 0.41
Felodipine 5 63,115,662 4,197,918 5 0.15 0.15
Isradipine 5 4,429,879 13,442 2.5 3.30 6.59
Lacidipine 4 14,646,423 910,750 4 0.16 0.16
Lercanidipine hydrochloride 10 77,973,540 3,825,663 10 0.20 0.20
Nicardipine hydrochloride 90 397,902 35,119 30 0.11 0.34
Nifedipine 30 3,656,530 149,471 30 0.24 0.24
Nisoldipineb 20 – – – – 0.93
Verapamil hydrochloride 240 7,104,750 358,394 240 0.20 0.20
Doxazosin 4 52,769,814 14,187,844 4 0.04 0.04
Indoraminc 4.7 5,674,414 34,4947 20 0.16 0.04
Prazosin 5 74,527 205 5 3.64 3.64
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TABLE 26 Unit prescription drug cost calculations (continued )
Drug substance
DDD
(mg)
NIC from
PCA (pence)
Quantity
from PCA
Strength from
PCA (mg)
NIC/quantity
(£)
Cost per
daya (£)
Terazosin 5 1,372,116 136,216 5 0.10 0.10
Amiloride hydrochloride 10 18,835,995 565,354 5 0.33 0.67
Amiloride hydrochloride
with thiazide
10 868,138 75,026 5 0.12 0.23
Triamterene 100 211,025 1511 50 1.40 2.79
Triamterene with thiazide 100 160,534 4540 50 0.35 0.71
Spironolactone 75 24,174,720 4,339,112 25 0.06 0.17
Atenolol 75 25,567,900 8,522,336 25 0.03 0.09
Hyperlipidaemia in T2DM
Atorvastatin 20 158,989,904 31,324,266 20 0.05 0.05
Fluvastatin 60 1,475,946 163,264 20 0.09 0.27
Pravastatin 30 6,780,883 1,648,896 10 0.04 0.12
Rosuvastatin 10 134,267,696 2,085,108 10 0.64 0.64
Simvastatin 30 15,635,680 5,206,048 10 0.03 0.09
Secondary prevention of myocardial infarction
Captopril 50 1,209,326 274,077 50 0.04 0.04
Enalapril maleate 10 8,273,970 2,164,274 10 0.04 0.04
Fosinopril sodium 15 1,717,978 32,658 10 0.53 0.79
Lisinopril 10 30,787,577 8,978,102 10 0.03 0.03
Perindopril erbumine 4 25,785,508 6,040,253 4 0.04 0.04
Perindopril arginine 4 1,125,376 53,760 5 0.21 0.17
Quinapril 15 728,515 23,878 5 0.31 0.92
Ramipril 2.5 75,859,752 18,621,897 2.5 0.04 0.04
Ramipril with felodipine 2.5 456,727 5209 2.5 0.88 0.88
Trandolapril 2 4,668,257 191,955 2 0.24 0.24
Cilazapril 2.5 1,662,225 8985 5 1.85 0.93
Perindopril tosilate 4 11,821 594 5 0.20 0.16
Acebutolol 400 1,202,284 18,079 400 0.67 0.67
Atenolol 75 25,567,900 8,522,336 25 0.03 0.09
Bisoprolol 10 20,420,456 5,828,018 10 0.04 0.04
Carvedilol 37.5 2,684,299 577,569 6.25 0.05 0.28
Metoprolol tartrate 150 15,398,869 2,318,257 50 0.07 0.20
Aspirinc 127.5 154,533,218 52,719,924 75 0.03 0.05
Clopidogrel 75 129,484,315 19,793,087 75 0.07 0.07
Ticagrelor 180 190,143,810 1,950,196 90 0.97 1.95
Atorvastatin 20 158,989,904 31,324,266 20 0.05 0.05
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TABLE 26 Unit prescription drug cost calculations (continued )
Drug substance
DDD
(mg)
NIC from
PCA (pence)
Quantity
from PCA
Strength from
PCA (mg)
NIC/quantity
(£)
Cost per
daya (£)
Fluvastatin 60 1,475,946 163,264 20 0.09 0.27
Pravastatin 30 6,780,883 1,648,896 10 0.04 0.12
Rosuvastatin 10 134,267,696 2,085,108 10 0.64 0.64
Simvastatin 30 15,635,680 5,206,048 10 0.03 0.09
Candesartan cilexetil 8 27,228,854 6,187,293 8 0.04 0.04
Eprosartan 600 7,848,330 156,629 600 0.50 0.50
Irbesartan 150 15,321,402 2,527,161 150 0.06 0.06
Losartan potassium 50 43,142,921 10,854,773 50 0.04 0.04
Olmesartan medoxomil 20 23,454,180 507,120 20 0.46 0.46
Telmisartan 40 2,105,968 429,294 40 0.05 0.05
Valsartan 80 7,680,126 790,946 80 0.10 0.10
Depression
Amitriptyline hydrochloride 75 42,327,326 12,089,330 25 0.04 0.11
Amoxapine 150 65,772 168 100 3.92 5.87
Clomipramine hydrochloride 100 5,343,700 663,607 50 0.08 0.16
Dosulepin hydrochloride 150 9,835,231 1,582,426 75 0.06 0.12
Doxepind 100 – – 50 0.20 0.41
Imipramine hydrochloride 100 4,075,545 858,036 25 0.05 0.19
Lofepramine 105 39,309,425 1,177,389 70 0.33 0.50
Nortriptyline 75 115,762,972 1,077,134 25 1.07 3.22
Trazodone hydrochloride 300 61,816,624 718,214 150 0.86 1.72
Trimipramine 150 1672 56 50 0.30 0.90
Citalopram 20 86,323,713 23,901,861 20 0.04 0.04
Escitalopram 10 5,540,518 1,121,092 10 0.05 0.05
Fluoxetine 20 87,922,802 23,735,904 20 0.04 0.04
Fluvoxamine maleate 100 4,073,827 55,899 100 0.73 0.73
Paroxetine 20 25,034,806 3,116,825 20 0.08 0.08
Sertraline 50 100,699,567 15,289,272 50 0.07 0.07
Isocarboxazid 15 3,453,630 12,118 10 2.85 4.28
Moclobemide 300 1,057,512 22,678 300 0.47 0.47
Phenelzine 60 2,647,884 117,682 15 0.23 0.90
Tranylcypromine 10 45,505,295 51,406 10 8.85 8.85
Agomelatine 25 8,035,533 74,999 25 1.07 1.07
Duloxetine 60 276,427,017 2,904,742 60 0.95 0.95
Mirtazapine 30 26,199,391 4,793,099 30 0.05 0.05
Reboxetine 8 4,467,383 141,747 4 0.32 0.63
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
114
TABLE 26 Unit prescription drug cost calculations (continued )
Drug substance
DDD
(mg)
NIC from
PCA (pence)
Quantity
from PCA
Strength from
PCA (mg)
NIC/quantity
(£)
Cost per
daya (£)
Tryptophanc 44.6 18,495 566 50 0.33 0.29
Venlafaxine 100 17,440,533 3,256,789 75 0.05 0.07
a Calculated as (NIC/Quantity) × (DDD/Strength from PCA).
b Data not available within the PCA for December 2015; cost per day based on an average of the values for other drugs
within the same class.
c Data for DDD not available; DDD based on an average of the values for other drugs within the same class.
d Data from PCA for December 2015 deemed unreliable; NIC/Quantity derived by dividing cost of 50 mg 28-cap pack
by 28.
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Appendix 7 Search strategy and study selection
details for prescriber time data
Search strategy
Date of search: 8 July 2016.
Databases: Ovid MEDLINE (R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid
MEDLINE (R) Daily and Ovid MEDLINE (R) 1946 to present; EMBASE 1974 to 7 July 2016.
1. general practitioner.ab,hw,kf,kw,ot,ti,xs.
2. GP.ab,hw,kf,kw,ot,ti,xs.
3. physician.ab,hw,kf,kw,ot,ti,xs.
4. clinician.ab,hw,kf,kw,ot,ti,xs.
5. doctor.ab,hw,kf,kw,ot,ti,xs.
6. medic.ab,hw,kf,kw,ot,ti,xs.
7. consultant.ab,hw,kf,kw,ot,ti,xs.
8. medical specialist.ab,hw,kf,kw,ot,ti,xs.
9. physician assistant.ab,hw,kf,kw,ot,ti,xs.
10. physician associate.ab,hw,kf,kw,ot,ti,xs.
11. nurse.ab,hw,kf,kw,ot,ti,xs.
12. pharmacist.ab,hw,kf,kw,ot,ti,xs.
13. healthcare professional.ab,hw,kf,kw,ot,ti,xs.
14. medical professional.ab,hw,kf,kw,ot,ti,xs.
15. medical staff.ab,hw,kf,kw,ot,ti,xs.
16. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17. prescriber time.ab,hw,kf,kw,ot,ti,xs.
18. staff time.ab,hw,kf,kw,ot,ti,xs.
19. time utilization.ab,hw,kf,kw,ot,ti,xs.
20. time utilisation.ab,hw,kf,kw,ot,ti,xs.
21. workload.ab,hw,kf,kw,ot,ti,xs.
22. workflow.ab,hw,kf,kw,ot,ti,xs.
23. work processes.ab,hw,kf,kw,ot,ti,xs.
24. medication management.ab,hw,kf,kw,ot,ti,xs.
25. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
26. time study.ab,hw,kf,kw,ot,ti,xs.
27. time motion study.ab,hw,kf,kw,ot,ti,xs.
28. time-motion study.ab,hw,kf,kw,ot,ti,xs.
29. (time and motion method).ab,hw,kf,kw,ot,ti,xs.
30. time-and-motion method.ab,hw,kf,kw,ot,ti,xs.
31. (time and motion study).ab,hw,kf,kw,ot,ti,xs.
32. time-and-motion study.ab,hw,kf,kw,ot,ti,xs.
33. time motion analysis.ab,hw,kf,kw,ot,ti,xs.
34. time-motion analysis.ab,hw,kf,kw,ot,ti,xs.
35. (before and after study).ab,hw,kf,kw,ot,ti,xs.
36. before-and-after study.ab,hw,kf,kw,ot,ti,xs.
37. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38. 16 and 25 and 37 –
Total hits = 227.
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Study selection details
The targeted literature search identified a total of 227 citations. After titles and abstracts were screened,
216 citations were excluded and 11 citations were reviewed in full-text. Four studies contained relevant
information and the most appropriate evidence was selected from the four studies by prioritising evidence
from larger sample sizes and studies that reported prescriber time for different types of prescriptions
(e.g. new vs. renewals) and/or different types of prescribers (GP vs. nurse).85,100–102 It should be noted that
one of the four studies identified was a systematic review and led to the identification of two additional
studies with relevant information based on their reporting of mean consultation times based on large
sample sizes and in different types of prescribers.103,104
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Appendix 8 Differences in standardised (90-day)
total costs for short and long prescription lengths
TABLE 27 Differences in standardised (90-day) total costs for short and long prescription lengths under various
scenarios (2015 £)
Scenarios
Values tested
Total cost standardised
to 90 days Difference
(cost savings
with ≥ 60 days)< 60 days ≥ 60 days < 60 days ≥ 60 days
Glucose control with oral drug therapy in T2DM
Base case – – 8.85 2.52 (6.33)
No prescriber time cost 0 0 2.59 1.87 (0.72)
50% decrease quantity wasted, days 0.43 2.48 8.41 1.68 (6.73)
50% increase quantity wasted, days 1.29 7.44 9.30 3.36 (5.94)
50% decrease cost of drug per day 0.18 0.14 8.41 1.68 (6.73)
50% increase cost of drug per day 0.55 0.43 9.30 3.36 (5.94)
50% decrease dispensing fee 0.46 0.52 8.01 2.42 (5.59)
50% increase dispensing fee 1.38 1.57 9.70 2.62 (7.08)
50% decrease prescriber time cost 1.70 1.72 5.72 2.20 (3.52)
50% increase prescriber time cost 5.09 5.16 11.99 2.85 (9.14)
Treatment of hypertension in T2DM
Base case – – 8.13 0.75 (7.38)
No prescriber time cost 0 0 1.88 0.63 (1.25)
50% decrease quantity wasted, days 0.62 3.49 7.99 0.46 (7.53)
50% increase quantity wasted, days 1.85 10.47 8.28 1.05 (7.23)
50% decrease cost of drug per day 0.042 0.041 7.99 0.46 (7.53)
50% increase cost of drug per day 0.13 0.12 8.28 1.05 (7.23)
50% decrease dispensing fee 0.45 0.46 7.34 0.74 (6.60)
50% increase dispensing fee 1.35 1.39 8.93 0.77 (8.16)
50% decrease prescriber time cost 1.77 1.77 5.01 0.69 (4.32)
50% increase prescriber time cost 5.30 5.32 11.26 0.82 (10.44)
Lipid management in T2DM
Base case – – 7.21 0.12 (7.09)
No prescriber time cost 0 0 1.75 0.96 (0.79)
50% decrease quantity wasted, days 0.31 8.11 7.12 (0.49) (6.63)
50% increase quantity wasted, days 0.94 24.32 7.30 0.73 (6.57)
50% decrease cost of drug per day 0.052 0.052 7.12 (0.49) (6.63)
50% increase cost of drug per day 0.16 0.15 7.30 0.73 (6.57)
continued
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TABLE 27 Differences in standardised (90-day) total costs for short and long prescription lengths under various
scenarios (2015 £) (continued )
Scenarios
Values tested
Total cost standardised
to 90 days Difference
(cost savings
with ≥ 60 days)< 60 days ≥ 60 days < 60 days ≥ 60 days
50% decrease dispensing fee 0.45 0.50 6.42 0.25 (6.17)
50% increase dispensing fee 1.35 1.50 7.99 (0.013) (8.00)
50% decrease prescriber time cost 1.56 1.57 4.48 0.54 3.94
50% increase prescriber time cost 4.68 4.72 9.93 (0.30) (10.23)
Secondary prevention of myocardial infarction
Base case – – 8.89 (0.18) (9.07)
No prescriber time cost 0 0 1.88 0.28 (1.6)
50% decrease quantity wasted, days 0.48 3.28 8.79 (0.37) (9.16)
50% increase quantity wasted, days 1.43 9.84 8.99 0.019 (8.97)
50% decrease cost of drug per day 0.037 0.034 8.79 (0.37) (9.16)
50% increase cost of drug per day 0.11 0.10 8.99 0.019 (8.97)
50% decrease dispensing fee 0.45 0.48 8.05 (0.12) (8.17)
50% increase dispensing fee 1.35 1.45 9.73 (0.24) (9.97)
50% decrease prescriber time cost 1.88 1.89 5.38 0.049 (5.33)
50% increase prescriber time cost 5.63 5.66 12.39 (0.40) (11.59)
Depression
Base case – – 10.26 2.00 (8.26)
No prescriber time cost 0 0 2.89 0.77 (2.12)
50% decrease quantity wasted, days 0.93 1.35 9.84 1.79 (8.05)
50% increase quantity wasted, days 2.80 4.04 10.67 2.20 (8.47)
50% decrease cost of drug per day 0.068 0.054 9.84 1.79 (8.05)
50% increase cost of drug per day 0.20 0.16 10.67 2.20 (8.47)
50% decrease dispensing fee 0.45 0.48 9.23 1.81 (7.42)
50% increase dispensing fee 1.36 1.44 11.29 2.18 (9.11)
50% decrease prescriber time cost 1.61 1.59 6.58 1.39 (5.19)
50% increase prescriber time cost 4.84 4.78 13.94 2.61 (11.33)
Notes
Over a period of 90 days, the TUC for shorter prescriptions ranged from £7.21 to £10.26. For longer prescriptions, the TUC
ranged from –£0.18 to £2.52 over a 90-day period. Note that some of the TUC for longer prescriptions are negative. This is
a statistical artefact owing to some prescriptions (lipid management and secondary prevention of myocardial infarction)
already being routinely prescribed for longer than 90 days. The negative number indicates that prescriptions of longer
duration than 90 days may be associated with lower unnecessary costs than 90-day prescriptions. This does not affect the
comparability of differences in TUC between short and long prescriptions (see Table 13, row 1, columns 6 and 8).
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Appendix 9 Additional tables for decision
modelling case study 2
TABLE 28 Case study 2: health consequence parameters
Base
case
Range
(95% CI) Source
Clinical outcomes
Acute treatment period
Absolute risk of dropout (placebo) 0.193 NA CG90 systematic review of clinical
evidence for escitalopram vs.
placebo (table 70, CG90)95
Relative risk of dropout (escitalopram) 1.11 0.95 to 1.29
Maintenance treatment period
Absolute risk of non-remission (placebo) 0.686 NA
Relative risk of non-remission (escitalopram) 0.88 0.82 to 0.94
Probability of spontaneous remission for patients who
drop out of initial treatment
0.20 0.10 to 0.30 Expert opinion cited in CG9095
Follow-up period
Absolute risk of relapse (placebo) 0.602 NA
Relative risk of non-remission (escitalopram) 0.81 0.75 to 0.88
Probability of relapse for patients who discontinue
initial treatment and in remission
0.67 NA CG90 systematic review of clinical
evidence for escitalopram vs.
placebo (table 70, CG90)95
Murphy et al.105 cited in CG90
evidence review95
Quality-of-life weights
Moderate depression 0.33 0.29 to 0.37 Same as CG90 decision model93
Severe depression 0.15 0.08 to 0.22
Response with remission 0.85 0.83 to 0.87
Response without remission 0.72 0.65 to 0.79
No response 0.58 0.60 to 0.66
NA, not applicable.
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TABLE 29 Case study 2: unit costs and resource use
Unit costs Resource use
Per unit Source
Moderate depression Severe depression
90-day 28-day 90-day 28-day
Patients who continue treatment, remission and no relapse
Escitalopram (20 mg/day), 9-month treatment phase £0.90 per day BNF: £25.20 per 28-tab pack106 £246.38 £246.38 £246.38 £246.38
Patient monitoring
Moderate depression: seven GP consultations over
9-month treatment phase
£34.00 per GP consultation Curtis, 2009107 £238.00 £238.00 £577.50 £577.50
Severe depression: seven consultations over
9-month treatment phase (on average 50% mental
health outpatient and 50% GP consultation)
£130 per outpatient
consultation
Total cost £487.08 £492.48 £826.58 £831.98
Patients who discontinue treatment
Escitalopram (20mg/day), assumed take medication for
1 month only
£0.90 per day BNF: £25.20 per 28-tab pack106 £82.13 £27.38 £82.13 £27.38
Dispensing fees £0.90 per prescription NHS Drug Tariff: Part IIIA –
Professional Fees (Pharmacy
Contractors) July 2016108
£0.90 £0.90 £0.90 £0.90
Patient monitoring
Moderate depression: two GP consultations during
first month
£34.00 per GP consultation Curtis, 2009107 £68.00 £68.00 £165.00 £165.00
Severe depression: two consultations during first
month (on average 50% mental health outpatient
and 50% GP consultation)
£130 per outpatient
consultation
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Unit costs Resource use
Per unit Source
Moderate depression Severe depression
90-day 28-day 90-day 28-day
Subsequent treatment: monthly mental health care for
remainder of the 15 months, for 65% of patients who
remain in contact with health services
Monthly cost of subsequent
health care: £165
NICE guidance95 £1583.40 £1583.40 £1583.40 £1583.40
Total cost £1734.43 £1679.68 £1831.43 £1776.68
Non-remission patients
Escitalopram (20 mg/day), assumed take medication for
3 months
£0.90 per day BNF: £25.20 per 28-tab pack106 £82.13 £82.13 £82.13 £82.13
Dispensing fees £0.90 per prescription NHS Drug Tariff: Part IIIA –
Professional Fees (Pharmacy
Contractors) July 2016108
£0.90 £2.70 £0.90 £2.70
Patient monitoring:
Moderate depression: four GP consultations during
acute treatment
£34.00 per GP consultation Curtis, 2009107 £136.00 £136.00 £330.00 £330.00
Severe depression: four consultations during
acute treatment (on average 50% mental health
outpatient and 50% GP consultation)
£130 per outpatient
consultation
Subsequent treatment: monthly mental health care, for
65% of patients who remain in contact with health
services
Monthly cost of subsequent
health care: £165
NICE guidance95 £2088.00 £2088.00 £2088.00 £2088.00
Total cost £2307.03 £2308.83 £2501.03 £2502.83
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TABLE 29 Case study 2: unit costs and resource use (continued )
Unit costs Resource use
Per unit Source
Moderate depression Severe depression
90-day 28-day 90-day 28-day
Relapse patients
Escitalopram (20 mg/day), assumed take medication for
7 months
£0.90 per day BNF: £25.20 per 28-tab pack106 £382.38 £327.63 £576.38 £521.63
Dispensing fees £0.90 per prescription NHS Drug Tariff: Part IIIA –
Professional Fees (Pharmacy
Contractors) July 2016108
£2.70 £6.30 £2.70 £6.30
Patient monitoring
Moderate depression: two GP consultations during
first month
£34.00 per GP consultation Curtis, 2009107 £68.00 £68.00 £165.00 £165.00
Severe depression: two consultations during first
month (on average 50% mental health outpatient
and 50% GP consultation)
£130 per outpatient
consultation
Subsequent treatment: monthly mental health care for
remainder of the 15 months, for 65% of patients who
remain in contact with health services
Monthly cost of subsequent
health care: £165
NICE guidance95 £1392.00 £1392.00 £1392.00 £1392.00
Total cost £1845.08 £1793.93 £2136.08 £2084.93
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Death
Well:
event free
Myocardial
infarction
Unstable
angina
Stroke
Heart
failure
Diabetes
FIGURE 12 Case study 3: schematic representation of Markov model. Arrows represent the possible transitions
between each of the health states. Copyright © NGC. Reproduced with permission.91
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Appendix 10 Additional tables for decision
modelling case study 3
TABLE 30 Case study 3: relative treatment effects used in the source model and adapted model
Medication/condition
Source model Adapted model
Meta analysis –
table 87, NICE91
Adapted based on
Taitel et al.45 study
(RR= 0.85)
Adapted based on
Hermes et al.35
study (RR= 0.92)
ACEIs/ARBs
Unstable angina 0.98 0.98 0.98
MI 0.81 0.84 0.82
Diabetes 0.70 0.75 0.73
Stroke 0.74 0.78 0.76
Heart failure 0.63 0.68 0.66
Death 0.91 0.93 0.92
Beta-blockers
Unstable angina 0.98 0.99 0.98
MI 0.85 0.88 0.87
Diabetes 1.14 1.12 1.13
Stroke 0.85 0.87 0.86
Heart failure 0.76 0.80 0.78
Death 0.94 0.95 0.94
Calcium channel blockers
Unstable angina 0.88 0.90 0.89
MI 0.80 0.83 0.81
Diabetes 0.81 0.84 0.82
Stroke 0.65 0.71 0.68
Heart failure 0.73 0.77 0.75
Death 0.88 0.90 0.89
Thiazide-type diuretics
Unstable angina 0.89 0.91 0.90
MI 0.78 0.81 0.80
Diabetes 0.98 0.99 0.99
Stroke 0.69 0.74 0.71
Heart failure 0.53 0.60 0.57
Death 0.91 0.92 0.92
MI, myocardial infarction.
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TABLE 31 Case study 3: ‘no treatment’ and ‘typical treatment’ comparators
Intervention
No
treatment ACEIs/ARBs Beta-blockers
Calcium-channel
blockers
Thiazide-type
diuretics
Typical
treatmenta
Cost (£) 4689 4011 4548 4033 3911 4127
QALYs 9.57 10.21 9.89 10.28 10.22 10.16
Incremental costs (£) NA –678 –141 –656 –778 –562
Incremental QALYs NA 0.64 0.32 0.71 0.65 0.59
Simple dominance NA Intervention dominant
ICER (£) NA –1059 –441 –924 –1197 –960
NA, not applicable.
a The ‘typical treatment’ comparator is a weighted average of the costs and QALYs associated with each of the four
groups of antihypertensive medications based on PCA figures published by NHS England, which show the total number
of items dispensed in the community (the data were for 2014, the most recent available data). The proportions
calculated were: ACEIs/ARBs (0.410), beta blockers (0.228), calcium-channel blockers (0.243), thiazide-type
diuretics (0.119).
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